



Isth JULY 18-21
SSC 2018 ♦
DUBLIN
Education, Innovation, Collaboration



PROGRAM

DUBLIN



isth
MELBOURNE



JULY 6-10
RESEARCH
DISCOVERY
OUTCOMES

ISTH2019.ORG



**PLAN
TO
ATTEND**

The International Society on Thrombosis and Haemostasis (ISTH) invites you to join thousands of the world's leading experts at the 27th ISTH Congress and 65th Annual Scientific and Standardization Committee (SSC) Meeting in Melbourne, Australia from **July 6-10, 2019.**

Join us in 2019!

isth2019.org | #ISTH2019

Table of Contents

5 Welcome

- 6 Welcome Message from the ISTH SSC 2018 Meeting President

- 7 Message from the ISTH President

- 8 Message from the SSC Chair

9 Committees

- 9 ISTH SSC 2018 Local Organizing Committee

- 9 ISTH SSC Committees

- 10 Council of the International Society on Thrombosis and Haemostasis (ISTH)

- 11 ISTH SSC 2018 Abstract Reviewers

12 Awards & Grants

- 12 ISTH Young Investigator Awards

- 13 ISTH Reach-the-World Travel Awards

- 14 ISTH SSC 2014 Milwaukee Awards

15 About the ISTH

- 15 ISTH Membership Benefits

- 16 SSC Subcommittees

- 17 SSC Activities and Programs

20 Convention Centre Floorplan

21 Program

- 22 Program Overview

- 26 Daily Program Grids

36 Master Classes

37 Program Details by Day

- 39 Wednesday, July 18, 2018

- 49 Thursday, July 19, 2018

- 59 Friday, July 20, 2018

- 78 Saturday, July 21, 2018

81 Poster Sessions

- 82 Posters: Session 1

- 110 Posters: Session 2

- 138 Publication Only

143 General Meeting Information

- 144 Convention Centre Floorplans

- 147 General Meeting Information

155 Exhibits & Supported Symposia

- 158 ISTH SSC 2018 Supporters

- 159 Supported Symposia

- 159 Wednesday, July 18, 2018

- 161 Thursday, July 19, 2018

- 163 Friday, July 20, 2018

- 166 Exhibition Floorplan

- 167 Exhibitor List

- 168 Exhibitor Profiles

- 186 Corporate Meeting Suites

188 Conflict of Interest Disclosure Information

190 Notes

rpth

research and practice
in thrombosis and haemostasis™



 @RPTHjournal

ISTH™
International Society on
Thrombosis and Haemostasis

Join the Conversation!



isth.org

The ISTH is a global not-for-profit organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

Submit your work for publication in the open access journal of the ISTH



Mary Cushman, M.D., M.Sc.
Editor-in-Chief

Research and Practice in Thrombosis and Haemostasis (RPTH) is the open access journal from the International Society on Thrombosis and Haemostasis (ISTH) dedicated to innovative science and discourse among researchers, clinicians and patients in the global thrombosis and hematology community. In an ever-changing environment, *RPTH* offers an exciting medium for rigorous yet rapid peer review and immediate dissemination of research.

The journal publishes basic, translational, clinical, population and implementation research in thrombosis, hemostasis, vascular disease and related areas with an aim to advance the treatment of patients.

Paper types covered by RPTH: original science, review articles on recent advances, debates, synthesis articles on research translation to practice and compelling case reports.

Visit RPTH.ISTH.ORG to get started today!

Questions? Contact us at +1 919 929 3807



JULY 18-21
ISTH 2018 ♦
SSC DUBLIN
Education, Innovation, Collaboration

WELCOME

Welcome Messages
Committees
Awards & Grants
About the ISTH

WELCOME

**Welcome Message
from the
ISTH SSC 2018 Meeting
President**



Dermot Cox, BSc, PhD
President, ISTH SSC 2018

*A chairde,
Céad míle fáilte go dtí SSC 2018.*

On behalf of the Local Organizing Committee, it gives me great pleasure to welcome you to the 64th Annual Scientific and Standardization Committee (SSC) Meeting of the ISTH in exciting Dublin, Ireland.

The SSC meeting is an annual meeting and every second year it is held in conjunction with the ISTH Congress. This year's meeting is very significant as it will be the last stand-alone SSC meeting. In 2019, we transition to an annual congress with an embedded SSC meeting. With this in mind, with your attendance and engagement, we will make it the biggest and best SSC meeting ever.

The SSC 2018 meeting will highlight the work of the SSC through symposia, poster presentations and an education program that will cover both basic and clinical research in the area of haemostasis. This year the plenary session will be on big data analytics and its role in thrombosis research.

The ISTH encourages student and young investigator participation in the SSC meeting and this is further facilitated by the trainee sessions on the final day of the meeting where they can meet their peers. On the other hand, the masterclasses will provide them with the opportunity to meet world-renowned senior investigators and develop insight into their specialist areas.

In closing, I'd like to thank each of you for attending the 64th SSC Meeting. I hope that you get to renew old friendships and to make new friends in Dublin. These personal relationships are critical to establishing future collaborations. Hopefully you will also have some time to visit the sights of Dublin before you return home.

Slán go fóill!

A handwritten signature in black ink that reads "D Cox". The signature is stylized and written in a cursive-like font.

Dermot Cox, BSc, PhD
President, ISTH SSC 2018



**Message from the
ISTH President**



Ingrid Pabinger, MD
ISTH President

Dear colleagues and friends,

On behalf of the Council of the International Society on Thrombosis and Haemostasis (ISTH), I am pleased to welcome you to Dublin to the 64th Annual Meeting of the Scientific and Standardization Committee (SSC) of the ISTH. We are happy you have joined us.

Through its subcommittees, the SSC conducts some of the ISTH's most important activities, including setting standards and establishing nomenclature, as well as educating and providing guidance on emerging clinical and laboratory matters. It has done so for 64 years and as a result, the activities of the SSC have profoundly shaped our field and will continue to do so well into the future.

While the activities of the SSC are an integral component of the ISTH, they are by no means the only activities that make ISTH the leading and most impactful organization in the field of thrombosis and hemostasis.

The ISTH continues to develop exciting new offerings and programs, among them include the Society's scientific publications, the *Journal of Thrombosis and Haemostasis (JTH)* and the open access journal *Research and Practice in Thrombosis and Haemostasis (RPTH)* which was proudly launched in 2017. Additionally, the ISTH offers a plethora of live and online education programs, important capacity programs in developing countries and the World Thrombosis Day awareness campaign. In addition to the numerous activities in creating guidance documents, ISTH has recently decided to also develop globally applicable practice guidelines.

The underpinning of all these efforts is a growing and dedicated membership that forms a global community, the "ISTH family". On behalf of ISTH leadership, I would like to express our sincere appreciation to all who supports the Society and its activities and who works diligently on behalf of the ISTH, regularly giving their time freely to advance the field and our Society.

On this occasion I would like to recognize ISTH SSC 2018 Meeting President Dermot Cox, PhD, and his Local Organizing Committee, as well as Walter Ageno, MD, and all SSC Subcommittee Chairs, Co-Chairs, and members for creating an exciting program and what certainly will be a memorable meeting.

While this is the last year of the traditional ISTH SSC stand-alone meeting, we look forward to a new era starting in 2019 in Melbourne when the SSC subcommittee sessions will be fully integrated in a new – and from now on annual – ISTH congress program format. We continue to consider the evolution of ISTH congresses and how to best benefit our global community and continue to advance the field and we are excited to start a new chapter.

I am confident that you will benefit from the scientific and cultural experiences here in Dublin and encourage you to also become involved in the many other activities of our organization!

Thank you again for participating in ISTH SSC 2018. Enjoy the science, take advantage of the networking opportunities and – enjoy your time in Dublin!

Ingrid Pabinger, MD
ISTH President

WELCOME

Message from the SSC Chair



Walter Ageno, MD
ISTH SSC Chairman

Dear colleagues and friends,

On behalf of the ISTH SSC, I welcome you to the 64th Annual Meeting of the Scientific and Standardization Committee (SSC) of the ISTH.

Following the success of the ISTH 2017 Congress in Berlin, we are excited to host an ISTH meeting for the first time in Ireland in exciting Dublin. SSC 2018 Meeting President Dermot Cox, PhD, along with the Local Organizing Committee, and the SSC Chairmen have created an exciting educational program for you, full of the latest science.

Each ISTH SSC Subcommittee is led by international experts in the field of thrombosis and hemostasis. The subcommittees work year-round to standardize nomenclature, create standards, and provide guidance on challenging clinical issues. The expert Chairmen and Co-Chairmen collaborate across borders to address key research questions.

The format of the ISTH SSC meeting is designed to favor an active exchange of new, important information and topics of research, and to stimulate cross-disciplinary collaborations. The format of the meeting provides engaging education sessions and in-depth subcommittee sessions.

The educational sessions have been structured with the aim to attract basic and clinical scientists with state-of-the-art as well as “hands on” lectures. Subcommittee sessions will provide new insights into the most challenging practical issues in thrombosis and hemostasis, offering an expert view on the standardization of basic and clinical research methods, nomenclature, preparation of reference reagents, and evaluation of new tests and new drugs. Participants will hear about the ongoing research leading to tomorrow’s new developments.

I would like to take this opportunity to thank Dr. Cox, the local organizers and subcommittee leadership that developed this stimulating and informative program. I strongly encourage you to attend the subcommittee sessions and get involved in the ongoing work of the SSC. The scientific work of the Society would not happen without its dedicated membership, and the SSC is always looking for new contributors.

The SSC subcommittee work offers the easiest way to get involved in the Society while also furthering your own work. ISTH members have the opportunity to collaborate on SSC projects that relate to their interest or propose a new project. Use your time wisely in between sessions and bring your ideas to the leadership of the subcommittees.

I hope you enjoy the science and take advantage of the many networking opportunities here in Dublin!

Kind regards,

A handwritten signature in black ink that reads "Walter Ageno". The signature is fluid and cursive, written in a professional style.

Walter Ageno, MD
ISTH SSC Chairman



ISTH SSC 2018 Local Organizing Committee

President

Dermot Cox, *Ireland*

Executive Committee

Patricia Maguire, *Ireland*

Niamh O'Connell, *Ireland*

James O'Donnell, *Ireland*

Advisory Board

Marian Brennan, *Ireland*

Olwen Foley, *Ireland*

Dermot Kenny, *Ireland*

Steven Kerrigan, *Ireland*

Michelle Lavin, *Ireland*

Niamh Moran, *Ireland*

Fionnuala Ní Áinle, *Ireland*

Beatrice Nolan, *Ireland*

Brian O'Mahony, *Ireland*

Roger Preston, *Ireland*

Albert Smolenski, *Ireland*

Tony McHale, *Ireland*

Rebecca Watkin, *Ireland*

ISTH SSC Committees

SSC Executive Committee

Walter Ageno, *Italy*

SSC Chairman

Nicola Mutch, *United Kingdom*

SSC Secretary/Chairman-elect

Sabine Eichinger, *Austria*

SSC Immediate Past Chairman and Special Assistant to the Chairman

Dermot Cox, *Ireland*

ex-officio: President of ISTH SSC 2018

Standing Committee Chairmen

Anthony Hubbard, *United Kingdom*

Coagulation Standards Standing Committee

Peter Lenting, *France*

WHO-ISTH Standards Liaison Group

Subcommittee Chairmen

Jose A. Diaz, *United States*

Animal, Cellular and Molecular Models of Thrombosis

Pierre Mangin, *France*

Biorheology

Mark Crowther, *Canada*

Control of Anticoagulation

Toshiaki Iba, *Japan*

Disseminated Intravascular Coagulation

COMMITTEES

Guy Young, <i>United States</i>	Factor VIII, Factor IX and Rare Coagulation Disorders
Joost Meijers, <i>the Netherlands</i>	Factor XI and the Contact System
Verena Schroeder, <i>Switzerland</i>	Factor XIII and Fibrinogen
Paul Kim, <i>Canada</i>	Fibrinolysis
Willem H. Ouwehand, <i>United Kingdom</i>	Genomics in Thrombosis and Hemostasis
Marc Carrier, <i>Canada</i>	Hemostasis and Malignancy
Katrien Devreese, <i>Belgium</i>	Lupus Anticoagulant/Antiphospholipid Antibodies
Christoph Male, <i>Austria</i>	Pediatric and Neonatal Hemostasis and Thrombosis
Marc Samama, <i>France</i>	Perioperative and Critical Care Thrombosis and Hemostasis
Jun Teruya, <i>United States</i>	Plasma Coagulation Inhibitors
Donald Arnold, <i>Canada</i>	Platelet Immunology
Paolo Gresele, <i>Italy</i>	Platelet Physiology
John-Bjarne Hansen, <i>Norway</i>	Predictive and Diagnostic Variables in Thrombotic Disease
Chris Gardiner, <i>United Kingdom</i>	Vascular Biology
Sandra Haberichter, <i>United States</i>	von Willebrand Factor
Maha Othman, <i>Canada</i>	Women's Health Issues in Thrombosis and Hemostasis

Council of the International Society on Thrombosis and Haemostasis (ISTH)

Officers

Ingrid Pabinger, <i>Austria</i>	President of the Society
Claire McLintock, <i>New Zealand</i>	President-Elect of the Society
Björn Dahlbäck, <i>Sweden</i>	Treasurer
J. Evan Sadler, <i>United States</i>	Secretary General

Class Members

2018	2020	2022
Peter Lenting, <i>France</i>	Anna Falanga, <i>Italy</i>	Pantep Angchaisuksiri, <i>Thailand</i>
Claire McLintock, <i>New Zealand</i>	David Lillicrap, <i>Canada</i>	Michael Makris, <i>United Kingdom</i>
Jim Morrissey, <i>United States</i>	José López, <i>United States</i>	Flora Peyvandi, <i>Italy</i>
Ingrid Pabinger, <i>Austria</i>	Suely Rezende, <i>Brazil</i>	Sam Schulman, <i>Canada</i>
Jeff Weitz, <i>Canada</i>	Steve Watson, <i>United Kingdom</i>	Alisa Wolberg, <i>United States</i>



Ex-Officio Council Members

Voting

Walter Ageno, <i>Italy</i>	SSC Chairman
Nigel Key, <i>United States</i>	Immediate Past President of the Society

Non-Voting

Mary Cushman, <i>United States</i>	Editor in Chief, <i>RPTH</i>
Robert Medcalf, <i>Australia</i>	President, XXVII ISTH Congress
Johannes Oldenburg, <i>Germany</i>	Past Congress Chair
Pieter Reitsma, <i>the Netherlands</i>	Co-Editor in Chief, <i>JTH</i>
Frits Rosendaal, <i>the Netherlands</i>	Co-Editor in Chief, <i>JTH</i>

ISTH SSC 2018 Abstract Reviewers

Walter Ageno, <i>Italy</i>	Julia Anderson, <i>United Kingdom</i>
Tamam Bakchoul, <i>Germany</i>	Marc Carrier, <i>Canada</i>
Giancarlo Castaman, <i>Italy</i>	Marco Cattaneo, <i>Italy</i>
Chatree Chai-Adisaksopha, <i>Canada</i>	Benilde Cosmi, <i>Italy</i>
Dermot Cox, <i>Ireland</i>	James Douketis, <i>Canada</i>
Gili Kenet, <i>Israel</i>	Sandra Haberichter, <i>United States</i>
John-Bjarne Hansen, <i>Norway</i>	Alfonso Iorio, <i>Canada</i>
Paula James, <i>Canada</i>	Dermot Kenny, <i>Ireland</i>
Steven Kerrigan, <i>Ireland</i>	Paul Kim, <i>Canada</i>
Paul Kyrle, <i>Austria</i>	Michelle Lavin, <i>Ireland</i>
Jerrold Levy, <i>United States</i>	Kellie Machlus, <i>United States</i>
Patricia Maguire, <i>Ireland</i>	Joost Meijers, <i>the Netherlands</i>
Juan Melero-Martin, <i>United States</i>	Niamh Moran, <i>Ireland</i>
Nicola Mutch, <i>United Kingdom</i>	Fionnuala Ní Áinle, <i>Ireland</i>
Beatrice Nolan, <i>Ireland</i>	Niamh O'Connell, <i>Ireland</i>
Flora Peyvandi, <i>Italy</i>	Helen Philippou, <i>United Kingdom</i>
Marlien Pieters, <i>South Africa</i>	Roger Preston, <i>Ireland</i>
Ingmar Schoen, <i>Ireland</i>	Verena Schroeder, <i>Switzerland</i>
David Smadja, <i>France</i>	Albert Smolenski, <i>Ireland</i>
Alex Spyropoulos, <i>United States</i>	Jun Teruya, <i>United States</i>
Tetsumei Urano, <i>Japan</i>	Tine Wyseure, <i>United States</i>
Guy Young, <i>United States</i>	

AWARDS & GRANTS

ISTH Young Investigator Awards

The Young Investigator Awards were provided in the form of travel grants to medical trainees and young scientists (under 40 years of age as of July 17, 2018) who submitted highly rated abstracts.

Recipients of an ISTH SSC 2018 Young Investigator Travel Award

Maria Abbattista, *Italy*

Abrar Ahmad, *Sweden*

Saurabh Bhargava, *India*

Jenny Chia, *Australia*

Chantal Clark, *the Netherlands*

Katarina D. Kovacevic, *Austria*

Delphine Douillet, *France*

Galit Frydman, *United States*

Kristine Jimenez, *Austria*

Xin Li, *China*

Fraser Macrae, *United Kingdom*

Mailin Manke, *Germany*

Davide Matino, *Italy*

Samantha J. Montague, *Australia*

Nadia Alice Vieira Motta, *Brazil*

Banne Nemeth, *the Netherlands*

Zsuzsanna Z. Orosz, *Hungary*

Sameer Parpia, *Canada*

Orla Rawley, *Canada*

Nicoletta Riva, *Malta*

Claudia Schoenichen, *Germany*

Laura L Swystun, *Canada*

Lisa N. van der Vorm, *the Netherlands*

Alexander Witte, *Germany*

Jameel Abdulrehman, *Canada*

Alessandro Aliotta, *Switzerland*

Robert Campbell, *United States*

Tiffany Chu, *United States*

Daniëlle M. Coenen, *the Netherlands*

Mason Dixon, *United States*

Geoffrey Foulon, *France*

Zonne L M Hofman, *the Netherlands*

Georges Jourdi, *France*

Derek Little, *Canada*

Cheryl Maier, *United States*

Georgi Manukjan, *Germany*

Alison Michels, *Canada*

Iraklis C. Moschonas, *Greece*

Zoltan Nagy, *United Kingdom*

Anh Ngo, *United States*

Navaneeth K R Pandian, *United States*

Siavash Piran, *Canada*

Stephanie Elena Reitsma, *United States*

Alba Rodriguez-Rius, *Spain*

Soundarya Nivedita Selvam, *Canada*

Ann-Kathrin Urbanowitz, *Germany*

Matthew Wanat, *United States*

Suzanne Zwaveling, *the Netherlands*



ISTH Reach-the-World Travel Awards

The Reach-the-World Travel Awards are provided in the form of travel grants to clinicians and scientists from Reach-the-World countries to enable participation from all areas of the world at the ISTH SSC 2018 Meeting.

Recipients of an ISTH SSC 2018 Reach-the-World Travel Award

Samuel Abegunde, *Nigeria*
Roza Aisina, *Russian Federation*
Nida Anwar, *Pakistan*
Alicia Noemi Blanco, *Argentina*
Munira Borhany, *Pakistan*
Desiree Coen Herak, *Croatia*
Célia Dos Santos, *Argentina*
Almottesembellah Gaiz, *Iraq*
Beatriz Grand, *Argentina*
Jawad Hassan, *Pakistan*
Salman Hussain, *India*
Xi Jia, *China*
Farheen Karim, *Pakistan*
Ekaterina Koltsova, *Russian Federation*
Letícia Lemos Jardim, *Brazil*
Qiuya Lu, *China*
Ram L. Mallick, *Nepal*
Alexey Martyanov, *Russian Federation*
Daria Morozova, *Russian Federation*
Samina Naz Mukry, *Pakistan*
Theresa Nwagha, *Nigeria*
Ifeyinwa Maryann Okafor, *Nigeria*
Nadezhda Podoplelova, *Russian Federation*
Ramesh Prasad, *India*
Julija Samonikov Tosevska, *Macedonia*
Aimwipa Sasakul, *Thailand*
Gabriela Sciuccati, *Argentina*
Juan Serrano, *Venezuela*
Rashi Singhal, *India*
Deepti Suri, *India*
Ke Xu, *China*
Paula Romina Zubiry, *Argentina*

Irshad Ahmad, *India*
Sidra Asad Ali, *Pakistan*
Anna Balandina, *Russian Federation*
Jose Bonorino, *Argentina*
Ricardo Camelo, *Brazil*
Tomaz Crochemore, *Brazil*
Cassia Ferreira, *Brazil*
Evgene Gluhanyuk, *Russian Federation*
Irina Gribkova, *Russian Federation*
María De Lourdes Herrera, *Argentina*
Anastasia Ignatova, *Russian Federation*
Ons Kaabia, *Tunisia*
Sehar Khaliq, *Pakistan*
Anna Kuprash, *Russian Federation*
Marina Loguinova, *Russian Federation*
Laura Magalhães, *Brazil*
Maria Auxiliadora Parreiras Martins, *Brazil*
Hebe Agustina Mena, *Argentina*
Liliya Mukhametova, *Russian Federation*
Elena Neporada, *Russian Federation*
Sergei Obydennyi, *Russian Federation*
Anupama Patil, *India*
Viola Maria Popov, *Romania*
Ikhwan Rinaldi, *Indonesia*
Marcelo Larami Santoro, *Brazil*
Ecaterina Scarlatescu, *Romania*
Prosenjit Sen, *India*
Wenhong Shen, *China*
Mariia Sorokina, *Russian Federation*
Elif Umit, *Turkey*
Yiming Zhao, *China*
Luciana Werneck Zuccherato, *Brazil*

AWARDS & GRANTS

ISTH SSC 2014 Milwaukee Awards

The ISTH SSC 2014 Meeting President's Fund awarded an additional 12 awards at the ISTH SSC 2018 Meeting. The Milwaukee SSC President's Award was given to the top four overall scored abstracts. The Milwaukee SSC Award was awarded to the top eight overall scored abstracts submitted by those from Reach-the-World countries. This funding is in addition to any funding they would have received from an ISTH SSC 2018 Travel Award.

Milwaukee SSC President's Award

Geoffrey Foulon, *France*

Zonne L M Hofman, *the Netherlands*

Fraser Macrae, *United Kingdom*

Orla Rawley, *Canada*

Milwaukee SSC Award

Samuel Abegunde, *Nigeria*

Irshad Ahmad, *India*

Jose Bonorino, *Argentina*



Ekaterina Koltsova, *Russian Federation*

Nadezhda Podoplelova, *Russian Federation*

Ramesh Prasad, *India*

Ecaterina Scarlatescu, *Romania*

Wenhong Shen, *China*





About the ISTH

The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

The Society is dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals wherever they may live.

At the ISTH, we introduce and promote education and outreach initiatives, research activities, scientific meetings, peer-reviewed publications, expert committees and the development of standards allowing a common language and approach to basic and clinical science all over the world.

Through its mission of building community and advancing knowledge, the Society also offers a complete portfolio of publications. They include the *Journal of Thrombosis and Haemostasis (JTH)* and the new open-access journal *Research and Practice in Thrombosis and Haemostasis (RPTH)*.

The Society also leads World Thrombosis Day, a year-long program that culminates on 13 October each year to focus attention on the often overlooked and misunderstood condition of thrombosis.

Today, the ISTH is the leading thrombosis and hemostasis professional organization in the world, boasting more than 5,000 members in 98 countries.

A highly-regarded Society poised on the leading edge of science, the ISTH offers a comprehensive membership that includes the following benefits:

ISTH membership benefits:

- Subscription and exclusive discounts on open access article submissions to the official ISTH publications: *Journal of Thrombosis and Haemostasis (JTH)* and *Research and Practice in Thrombosis and Haemostasis (RPTH)*
- Priority registration and significantly discounted fees for ISTH meetings and congresses
- Full access to the online ISTH Academy webinars, webcasts and courses with Continuing Medical Education (CME) at academy.isth.org
- Access to ISTH member-only resources, including an increasing array of educational materials
- Eligibility to apply for travel grants, fellowships and awards
- Access to the ISTH Career Center and exclusive discounts to post job openings
- Opportunity to hold elected and/or appointed offices, nominate and vote on Society matters

ABOUT THE ISTH

For more information or to join the ISTH, please contact:

ISTH Headquarters

610 Jones Ferry Road,
Suite 205
Carrboro, NC 27510
USA

T: +1 919-929-3807

F: +1 919-929-3935

E: membership@isth.org

W: www.isth.org

Join the conversation online!

Use #ISTHSSC18

www.facebook.com/internationalsocietythrombosisandhaemostasis

www.facebook.com/worldthrombosisday

www.twitter.com/isth

www.twitter.com/jthjournal

www.twitter.com/rpthjournal

www.twitter.com/thrombosisday

www.linkedin.com/company/2253026/

www.linkedin.com/groups/7025460

www.instagram.com/isthofficeteam/

www.instagram.com/worldthrombosisday/

www.youtube.com/user/IntISocThrombHemo

SSC Subcommittees

The Scientific and Standardization Committee (SSC) is made of of 20 subcommittees in addition to two standing committees and the executive committee. The SSC responds to and addresses a variety of challenges in the field of thrombosis and hemostasis, including:

- Animal, Cellular and Molecular Models of Thrombosis
- Biorheology
- Control of Anticoagulation
- Disseminated Intravascular Coagulation
- Factor VIII, Factor IX and Rare Coagulation Disorders
- Factor XI and the Contact System
- Factor XIII and Fibrinogen
- Fibrinolysis
- Genomics in Thrombosis and Hemostasis
- Hemostasis and Malignancy
- Lupus Anticoagulant/Antiphospholipid Antibodies
- Pediatric and Neonatal Thrombosis and Hemostasis
- Perioperative and Critical Care Thrombosis and Hemostasis
- Plasma Coagulation Inhibitors



- Platelet Immunology
- Platelet Physiology
- Predictive and Diagnostic Variables in Thrombotic Disease
- Vascular Biology
- von Willebrand Factor
- Women's Health Issues in Thrombosis and Hemostasis

SSC Activities and Programs

The SSC supports the ISTH's mission of advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. It holds annual public meetings to discuss and gain consensus around key issues and offers opportunities to present work and publish the results of collaborative research. The SSC facilitates networking with other experts in the field, supports numerous registries and databases where information is collected, updated and shared with the scientific community, issues guidance and expert opinion documents and liaises with the World Health Organization (WHO) as a Nongovernmental Organization (NGO) Affiliate, providing expert opinions and other requested advice.

Why wait? Become involved in the SSC of the ISTH today!





jth
journal of
thrombosis and haemostasis™

Editors-in-Chief:

Pieter Reitsma and
Frits Rosendaal

Impact Factor: **5.287**

ISI Journal Citation Reports®

Ranking: 2016:

8/63 (Peripheral Vascular Disease);

13/70 (Hematology)

The mission of the *Journal of Thrombosis and Haemostasis (JTH)* is to advance science related to the important medical problems of thrombosis, bleeding disorders and vascular biology through the diffusion and exchange of information and ideas within the international research community. Editors invite both fundamental and clinical contributions.

Benefits of publishing in *JTH*

Speed: Submissions are quick and easy with our online system. Papers receive rapid peer review by *JTH's* international editorial board and are published online within days of acceptance through Accepted Articles.

Impact: Your research will be read widely around the world, including exposure to the membership of the International Society on Thrombosis and Haemostasis. Our author tools provide you with extensive opportunities to drive your impact through social and online activity.

Reputation: For more than 13 years, *JTH* has provided a home for high quality research in the field of thrombosis and hemostasis. In conjunction with its prominent editors-in-chief, editorial board and associate editors, *JTH* has published some of the best authors in the field.

Submit online at jth.isth.org


WILEY



isth JULY 18-21
2018 ◆
SSC DUBLIN
Education, Innovation, Collaboration

**CONVENTION CENTER
FLOORPLAN**

CONVENTION CENTRE FLOORPLAN



Levels 3-5

Auditorium

- Plenary Session
- SSC Sessions
- Educations Sessions
- Internet Stations
- Partner Resource Center

Level 2

Wicklow Rooms

- SSC Sessions
- Supported Symposia
- Speaker Ready Room
- Poster Pick-Up Booth
- Corporate Meeting Suites

Level 1

Liffey Rooms

- Poster Sessions
- SSC Sessions
- Supported Symposia
- Master Classes
- Education Sessions
- Trainee Sessions
- ISTH Booth
- Ancillary Meeting Rooms

Ground Level

Forum Rooms

- Registration
- Exhibition Hall
- Main Entrance
- Charging Lockers
- Lost and Found

More detailed floorplans available on page 146 and in the ISTD SSC 2018 App.



JULY 18-21
isth 2018 ♦
SSC DUBLIN
Education, Innovation, Collaboration

PROGRAM


PROGRAM OVERVIEW



Tuesday
July 17, 2018

Wednesday
July 18, 2018

Thursday
July 19, 2018






PROGRAM OVERVIEW

Thursday July 19, 2018		Friday July 20, 2018				Saturday July 21, 2018	
07:00 – 12:00 Poster Session 1	07:00 – 08:00 Master Classes	06:30 – 18:00 Registration	09:45 – 15:15 Exhibition	07:00 – 07:45 Supported Symposium	07:00 – 12:00 Poster Session 2	07:00 – 08:00 Master Classes	07:00 – 08:00 Master Classes
	08:00 – 10:00 SSC Sessions			08:00 – 10:00 Education Sessions			
13:15 – 17:00 Poster Session 2	17:00 – 18:30 Poster Networking - Poster Session 2	09:45 – 15:15 Exhibition	10:00 – 10:30 Coffee Break	10:30 – 12:30 SSC Sessions	06:30 – 14:00 Registration	12:30 – 13:00 Trainee Network Reception	10:00 – 10:30 Coffee Break
			12:30 – 13:15 Lunch	12:30 – 13:00 Trainee Network Reception			
			13:15 – 14:30 Supported Symposia	13:00 – 12:30 Education Sessions		13:00 – 17:00 Trainee Sessions	
			14:30 – 15:00 Coffee Break	15:00 – 17:00 SSC Sessions			
			17:15 – 19:15 SSC Sessions				
					20:00 – 23:00 Networking Evening		

PROGRAM OVERVIEW

Publishing truly innovative papers




Thrombosis and Haemostasis

Editors-in-Chief:
Christian Weber
Gregory Y.H. Lip

12 issues p.a.
ISSN 0340-6245

*Indexed
in JCR**

Subscribe at www.thieme.com/th



TH Open


Editor:
Elinor Switzer

2 issues p.a.
ISSN 2512-9465

**OPEN
ACCESS**

Submit via
<https://mc.manuscriptcentral.com/thopen>

Stay up-to-date in thrombosis and hemostasis



Seminars in Thrombosis & Hemostasis


Editor-in-Chief:
Emmanuel J. Favaloro

8 issues p.a.
ISSN 0094-6176

*Indexed
in JCR**

20% OFF
for new
subscribers

Subscribe at www.thieme.com/sth



Hämostaseologie

Editor-in-Chief:
R. E. Scharf

4 issues p.a.
ISSN 0720-9355

*Indexed
in JCR**

Subscribe at www.thieme.com/hamo

Institutional Subscribers esales@thieme.com

Individual Subscribers www.thieme.com

@thiemepublishers

@ThiemeNY

@thieme-group

@thieme.ny

Special introductory rates are only valid for new individual subscribers and are limited to the first year of subscription. Orders from individuals must include the recipient's name and private address, and be paid by private funds. Only qualified professionals and students are eligible for individual subscriptions.

*JCR stands for Journal Citation Reports

Thieme



isth JULY 18-21
2018 ♦
SSC DUBLIN
Education, Innovation, Collaboration











PROGRAM

DAILY PROGRAM GRIDS

DAILY PROGRAM GRID

 **Wednesday, July 18, 2018**

	06:00	07:00	08:00	09:00	10:00	11:00	12:00	
Forum Foyer	06:00 – 18:00 Registration							
The Forum					09:45 – 15:15 Exhibition			
Auditorium			08:00 – 10:00 Big Data and Its Influence on Research		10:00 – 10:30 Coffee Break – The Forum	10:30 – 12:30 von Willebrand Factor, Part I		12:30 – 13:15 Lunch – The Forum
Liffey A						10:30 – 12:30 Perioperative and Critical Care Thrombosis and Hemostasis		
Liffey Hall 1						10:30 – 12:30 Fibrinolysis		
Liffey Hall 2						10:30 – 12:30 Pediatric and Neonatal Hemostasis and Thrombosis		
Wicklow Hall 1						10:30 – 12:30 Disseminated Intravascular Coagulation		
Wicklow Hall 2						10:30 – 12:30 Lupus Anticoagulant/ Antiphospholipid Antibodies		
Liffey B								

Event Key			
	SSC Sessions		Supported Symposia
	Plenary Session		Master Classes
	Education Sessions		Registration
	Trainee Session		Exhibition
	Poster Session		Networking Event



DAILY PROGRAM GRID

									WEDNESDAY
13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00		
									PROGRAM
		14:30 – 15:00 Coffee Break – The Forum	15:00 – 17:00 von Willebrand Factor, Part I						
13:15 – 14:30 Supported Symposium			15:00 – 17:00 Perioperative and Critical Care Thrombosis and Hemostasis						
			15:00 – 17:00 Fibrinolysis						
13:15 – 14:30 Supported Symposium			15:00 – 17:00 Pediatric and Neonatal Hemostasis and Thrombosis						
13:15 – 14:30 Supported Symposium			15:00 – 17:00 Disseminated Intravascular Coagulation						
13:15 – 14:30 Supported Symposium			15:00 – 17:00 Lupus Anticoagulant/ Antiphospholipid Antibodies						
13:15 – 17:00 Poster Session 1				17:00 – 18:30 Poster Networking – Poster Session 1					

DAILY PROGRAM GRID

 **Thursday, July 19, 2018**

	06:00	07:00	08:00	09:00	10:00	11:00	12:00	
Forum Foyer	06:30 – 18:00 Registration							
The Forum				09:45 – 15:15 Exhibition				
Auditorium			08:00 – 10:00 von Willebrand Factor, Part II	10:00 – 10:30 Coffee Break – The Forum		10:30 – 12:30 von Willebrand Factor, Part II	12:30 – 13:15 Lunch – The Forum	
Liffey A			08:00 – 10:00 Platelet Physiology			10:30 – 12:30 Platelet Physiology		
Liffey Hall 1			08:00 – 10:00 Plasma Coagulation Inhibitors			10:30 – 12:30 Plasma Coagulation Inhibitors		
Liffey Hall 2			08:00 – 10:00 Predictive and Diagnostic Variables in Thrombotic Disease			10:30 – 12:30 Predictive and Diagnostic Variables in Thrombotic Disease		
Wicklow Hall 1								
Wicklow Hall 2			08:00 – 10:00 Hemostasis and Malignancy			10:30 – 12:30 Hemostasis and Malignancy		
Liffey B			07:00 – 12:00 Poster Session 1					
Liffey Meeting Room 2A	07:00 – 08:00 Master Class		Patricia Maguire - Platelet Releasate as a Diagnostic Tool					
Liffey Meeting Room 2B	07:00 – 08:00 Master Class		Michelle Lavin - Clinical Challenges in VWD Diagnosis					
Liffey Meeting Room 3A	07:00 – 08:00 Master Class		Jan Beyer Westendorf - DOACS and Bleeding					
Liffey Meeting Room 3B	07:00 – 08:00 Master Class		Erik Klok - Diagnosis of VTE					



DAILY PROGRAM GRID

	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00		
		14:30 – 15:00 Coffee Break – The Forum	13:15 – 14:30 Supported Symposium	15:00 – 17:00 Personalized Treatment in Hemophilia					THURSDAY PROGRAM	
			13:15 – 14:30 Supported Symposium	15:00 – 17:00 How to Manage Antithrombotic Drugs in Patients Undergoing Invasive Procedures						
			13:15 – 14:30 Supported Symposium							
			13:15 – 14:30 Supported Symposium							
			13:15 – 14:30 Supported Symposium							
			13:15 – 14:30 Supported Symposium							
	13:15 – 17:00 Poster Session 2				17:00 – 18:30 Poster Networking - Poster Session 2					
			Event Key							
	SSC Sessions						Supported Symposia			
	Plenary Session						Master Classes			
	Education Sessions						Registration			
	Trainee Session						Exhibition			
	Poster Session						Networking Event			

DAILY PROGRAM GRID

 **Friday, July 20, 2018**

	06:00	07:00	08:00	09:00	10:00	11:00	12:00	
Forum Foyer	06:30 – 18:00 Registration							
The Forum				09:45 – 15:15 Exhibition				
Auditorium			08:00 – 10:00 Factor VIII, Factor IX and Rare Coagulation Disorders, Part I	10:00 – 10:30 Coffee Break – The Forum		10:30 – 12:30 Factor VIII, Factor IX and Rare Coagulation Disorders, Part I	12:30 – 13:15 Lunch – The Forum	
Liffey A			08:00 – 10:00 Control of Anticoagulation, Part I			10:30 – 12:30 Control of Anticoagulation, Part I		
Liffey Hall 1			08:00 – 10:00 Vascular Biology			10:30 – 12:30 Vascular Biology		
Liffey Hall 2			08:00 – 10:00 Animal, Cellular and Molecular Models of Thrombosis			10:30 – 12:30 Animal, Cellular and Molecular Models of Thrombosis		
Wicklow Hall 1	07:00 – 07:45 Supported Symposium					08:00 – 10:00 Factor XI and the Contact System		10:30 – 12:30 Factor XI and the Contact System
Wicklow Hall 2			08:00 – 10:00 Genomics in Thrombosis and Hemostasis			10:30 – 12:30 Genomics in Thrombosis and Hemostasis		
Liffey B	07:00 – 12:00 Poster Session 2							
Liffey Meeting Room 2A	07:00 – 08:00 Master Class		Roger Preston - Protein C					
Liffey Meeting Room 2B	07:00 – 08:00 Master Class		Suzanne Cannegieter - Prevention of VTE in High Risk Situations					
Liffey Meeting Room 3A	07:00 – 08:00 Master Class		Leslie Skeith - Diagnosis and Treatment of PE in Pregnancy					
Liffey Meeting Room 3B	07:00 – 08:00 Master Class		Colin Longstaff - Fibrinolysis					
Networking Location								

DAILY PROGRAM GRID

 **Saturday, 21 July, 2018**

	06:00	07:00	08:00	09:00	10:00	11:00	12:00
Forum Foyer	06:30 – 14:00 Registration						
Liffey A			08:00 – 10:00 Coagulation and Sepsis		10:00 – 10:30 Coffee Break – Liffey Foyer, Level 1	10:30 – 12:30 Platelets (ITP)	
Liffey Hall 1							12:30 – 13:00 Trainee Networking Reception
Liffey B			08:00 – 10:00 Thrombo-Inflammatory Diseases: Evidence for a Direct Role of the Contact System			10:30 – 12:30 Are the Direct Oral Anticoagulants Changing the Landscape in the Management of Venous Thromboembolism?	
Liffey Meeting Room 2A		07:00 – 08:00 Master Class	Steven Kerrigan - Endothelial Cell Involvement During Sepsis				
Liffey Meeting Room 2B		07:00 – 08:00 Master Class	Marie Lordkipanidzé - Platelet Function Testing				
Liffey Meeting Room 3A		07:00 – 08:00 Master Class	Dermot Cox - Anti-Platelet Agents – Past, Present and Future				
Liffey Meeting Room 3B		07:00 – 08:00 Master Class	Leonardo Brandão - Pediatric Thrombosis				



DAILY PROGRAM GRID

	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00																							
									SATURDAY																						
	13:00 – 17:00 Trainee Session																														
<table border="1"> <thead> <tr> <th colspan="2">Event Key</th> </tr> </thead> <tbody> <tr> <td>■</td> <td>SSC Sessions</td> <td>■</td> <td>Supported Symposia</td> </tr> <tr> <td>■</td> <td>Plenary Session</td> <td>■</td> <td>Master Classes</td> </tr> <tr> <td>■</td> <td>Education Sessions</td> <td>■</td> <td>Registration</td> </tr> <tr> <td>■</td> <td>Trainee Session</td> <td>■</td> <td>Exhibition</td> </tr> <tr> <td>■</td> <td>Poster Session</td> <td>■</td> <td>Networking Event</td> </tr> </tbody> </table>										Event Key		■	SSC Sessions	■	Supported Symposia	■	Plenary Session	■	Master Classes	■	Education Sessions	■	Registration	■	Trainee Session	■	Exhibition	■	Poster Session	■	Networking Event
Event Key																															
■	SSC Sessions	■	Supported Symposia																												
■	Plenary Session	■	Master Classes																												
■	Education Sessions	■	Registration																												
■	Trainee Session	■	Exhibition																												
■	Poster Session	■	Networking Event																												

PROGRAM



JOIN OUR GLOBAL MOVEMENT TO STOP BLOOD CLOTS & SAVE LIVES

Join us as a partner, supporter,
community mobilizer!
More than 1,500 groups already
have. Will you?

WORLDTHROMBOSISDAY.ORG

**CELEBRATE THE
5TH ANNIVERSARY OF THE
WORLD THROMBOSIS DAY
CAMPAIGN!**

STAY CONNECTED



#WorldThrombosisDay #KnowThrombosis #KeepLifeFlowing



Special thanks to our corporate supporters.

ISTH Headquarters 610 Jones Ferry Road, Suite 205, Carrboro, NC 27510 USA Phone: +1 919 929-3807 www.isth.org
©2018 International Society on Thrombosis and Haemostasis, Inc. All rights reserved.



ISTH JULY 18-21
2018 ♦
SSC DUBLIN
Education, Innovation, Collaboration

PROGRAM

MASTER CLASSES

These are ticketed events. Please be sure to arrive on-time as to not to disrupt the session. There will be no admittance to the room after 07:20. If you have not arrived to the session 10 minutes after the start, your seat may be given up to those on the wait list.

MASTER CLASSES

Thursday, July 19, 2018		07:00 – 08:00
Platelet Releasate as a Diagnostic Tool Patricia Maguire, <i>Ireland</i>		Liffey Meeting Room 2A
Clinical Challenges in VWD Diagnosis Michelle Lavin, <i>Ireland</i>		Liffey Meeting Room 2B
DOACS and Bleeding Jan Beyer-Westendorf, <i>Germany</i>		Liffey Meeting Room 3A
Diagnosis of VTE Frederikus Klok, <i>the Netherlands</i>		Liffey Meeting Room 3B
Friday, July 20, 2018		07:00 – 08:00
Protein C Roger Preston, <i>Ireland</i>		Liffey Meeting Room 2A
Prevention of VTE in High Risk Situations Suzanne Cannegieter, <i>the Netherlands</i>		Liffey Meeting Room 2B
Diagnosis and Treatment of PE in Pregnancy Leslie Skeith, <i>Canada</i>		Liffey Meeting Room 3A
Fibrinolysis Colin Longstaff, <i>United Kingdom</i>		Liffey Meeting Room 3B
Saturday, July 21, 2018		07:00 – 08:00
Endothelial Cell Involvement During Sepsis Steven Kerrigan, <i>Ireland</i>		Liffey Meeting Room 2A
Platelet Function Testing Marie Lordkipanidzé, <i>Canada</i>		Liffey Meeting Room 2B
Anti-Platelet Agents: Past, Present and Future Dermot Cox, <i>Ireland</i>		Liffey Meeting Room 3A
Pediatric Thrombosis Leonardo Brandão, <i>Canada</i>		Liffey Meeting Room 3B



isth JULY 18-21
2018 ◆
SSC DUBLIN
Education, Innovation, Collaboration

PROGRAM

PROGRAM DETAILS BY DAY

The background features a complex abstract design. On the left, a cluster of light blue circles of varying sizes fades out towards the center. On the right, a series of dark blue circles of varying sizes are arranged in a pattern that suggests a globe or a network. A large, sweeping, light blue shape curves across the top and right side. In the lower right, a series of dark blue lines form a dense, curved pattern that resembles a stylized leaf or a fan. The overall color palette is shades of blue on a white background.

PROGRAM

WEDNESDAY
JULY 18, 2018



Wednesday, July 18, 2018



08:00 – 10:00

Auditorium (Level 3)

Plenary Session: **Big Data and Its Influence on Research**

Chair: Dermot Cox, *Ireland*

- 08:00 – 08:45 **Mining Personal, Dense, Dynamic, Data Clouds to Optimize Health and Drive Discovery**
Nathan Price, *United States*
- 08:45 – 09:10 **Bioinformatic and Experimental Strategies for Modulating Platelet Function With Peptides Originating From Platelet Proteins**
Denis Shields, *Ireland*
- 09:10 – 09:35 **New Generation Opportunities From Genomic Approaches**
Gianpiero Cavalleri, *Ireland*
- 09:35 – 10:00 **Quantitative Approaches for Identifying Genic and Regulatory Variants Responsible For Rare Bleeding and Platelet Disorders**
Ernest Turro, *United Kingdom*

10:00 – 10:30

The Forum (Ground Level)

Coffee Break in Exhibition Hall

10:30 – 12:30

Auditorium (Level 3)

SSC Session: **von Willebrand Factor, Part I**

Chairman: Sandra Haberichter, *United States*

Co-Chairmen: Ross I. Baker, *Australia*, Simon de Meyer, *Belgium*, Veronica Flood, *United States*, Frank W. Leebeek, *the Netherlands*, James O'Donnell, *Ireland*, Analia Sancheze-Luceros, *Argentina*

Moderators: Sandra Haberichter, *United States*, James O'Donnell, *Ireland*

- 10:30 – 10:45 **Top Abstract Presentation: Patients with Aortic Stenosis Have von Willebrand Factor Abnormalities and Aberrant Angiogenesis in BOEC**
Soundarya Nivedita Selvam, *Canada*
- 10:45 – 11:15 **VWF Clearance and Clinical Implications**
David Lillicrap, *Canada*

Updates on ADAMTS13 and Acquired VWD

- 11:15 – 11:35 **ADAMTS13 Levels in WiN Cohort**
Johan Boender, *the Netherlands*

PROGRAM DETAILS BY DAY

- 11:35 – 11:55** **Standardization and Challenges of ADAMTS13 Activity and Antibody Testing in the Asia Pacific Region**
Ross I. Baker, *Australia*
- 11:55 – 12:10** **The Interactive Registry of Acquired von Willebrand Syndrome (INTREAVWS)**
Augusto B. Federici, *Italy*
- 12:10 – 12:20** **Update on 3Winters-Ips Project**
Augusto B. Federici, *Italy*
- 12:20 – 12:30** **Research Discussion**

10:30 – 12:30

Liffey A (Level 1)

SSC Session: **Perioperative and Critical Care Thrombosis and Hemostasis**

Chairman: Marc C. Samama, *France*

Co-Chairmen: Pierre Albaladejo, *Italy*, James Douketis, *Canada*, Andreas Greinacher, *Germany*, Beverley Hunt, *United Kingdom*, Jerrold H. Levy, *United States*, Alex C. Spyropoulos, *United States*

- 10:30 – 10:45** **Top Abstract Presentation: Development of a New Point-of-care Test for the Detection of Direct Oral Anticoagulants (DOACs)**
Galit Frydman, *United States*

Tranexamic Acid

- 10:45 – 11:15** **TXA in the Prevention of Surgical Bleeding**
Jerrold Levy, *United States*
- 11:15 – 11:45** **TXA in the Management of Bleeding**
Beverley Hunt, *United Kingdom*

Anticoagulants

- 11:45 – 12:30** **New Evidence for Perioperative Management of Oral Anticoagulants**
Pierre Albaladejo, *France*, James Douketis, *Canada*, Alex Spyropoulos, *United States*, Thomas Thiele, *Germany*

10:30 – 12:30

Liffey Hall 1 (Level 1)

SSC Session: **Fibrinolysis**

Chairman: Paul Y. Kim, *Canada*

Co-Chairmen: Krasimir Kolev, *Hungary*, Colin Longstaff, *United Kingdom*, Nicola Mutch, *United Kingdom*, Victoria Ploplis, *United States*, Guy Reed, *United States*, Tetsumei Urano, *Japan*

- 10:30 – 10:45** **Top Abstract Presentation: Polyphosphate Nanoparticles Slow Down the Clotting of Fibrinogen and Increase the Lytic Stability of Fibrin**
Miklós Lovas, *Hungary*
- 10:45 – 11:00** **Update on WHO International Standards Projects**
Colin Longstaff, *United Kingdom*



11:00 – 11:30 **DIC in Trauma and Terminology Standardization**

Satoshi Gando, *Japan*

11:30 – 12:00 **Fibrinolysis Shutdown – Old Dog: Can We Treat It with New Trick?**

Hunter Moore, *United States*

12:00 – 12:30 **Role of Platelet Function on TIC**

Mark Walsh, *United States*

10:30 – 12:30

Liffey Hall 2 (Level 1)

SSC Session: **Pediatric and Neonatal Hemostasis and Thrombosis**

Chairman: Christoph Male, *Austria*

Co-Chairmen: Manuela Albisetti Pedroni, *Switzerland*, Tina Biss, *United Kingdom*, Fiona Newall, *Australia*, Sarah Harvey O'Brien, *United States*, Leslie Raffini, *United States*, Shoshana Revel-Vilk, *Israel*

10:30 – 10:45 **Top Abstract Presentation: Platelet Hyporeactivity Combined with Enhanced Coagulation in Healthy Term and Preterm Newborns During First Days of Life**
Ekaterina Koltsova, *Russian Federation*

10:45 – 11:00 **DIC Survey: Project Update and Future Steps**
Anthony Chan, *Canada*

11:00 – 11:15 **Pediatric Pulmonary Embolism Working Group: Planned Projects**
Madhvi Rajpurkar, *United States*

11:15 – 11:25 **Database and DNA Biorepository for Congenital Antithrombin Deficiency: Status Update**
Riten Kumar, *United States*

Use of DOACs in Children and Adolescents: Is It Time?

11:25 – 11:40 **An Update of DOAC Clinical Trial Data**
Sarah O'Brien, *United States*

11:40 – 11:50 **Debate: Are They Ready for Routine Use? No**
Anthony Chan, *Canada*

11:50 – 12:00 **Debate: Are They Ready for Routine Use? Yes**
Leslie Raffini, *United States*

12:00 – 12:10 **Proposal for Pediatric DOAC Registry: North America**
Leslie Raffini, *United States*

12:10 – 12:20 **Proposal for Pediatric DOAC Registry: Europe**
Susanne Holzhauer, *Germany*

12:20 – 12:30 **Task Force for Pediatric Anticoagulant Drug Development – Update**
Christoph Male, *Austria*

PROGRAM DETAILS BY DAY

10:30 – 12:30

Wicklow Hall 1 (Level 2)

SSC Session: Disseminated Intravascular Coagulation

Chairman: Toshiaki Iba, *Japan*

Co-Chairmen: Bernd Jilma, *Austria*, Alessandro Squizzato, *Italy*, Jecko Thachil, *United Kingdom*, Theodore E. Warkentin, *Canada*, Kazuma Yamakawa, *Japan*, Sacha Zeerleder, *the Netherlands*

10:30 – 10:45 **Top Abstract Presentation: Recombinant A2 Domain of von Willebrand Factor Attenuates Microthrombi Formation, Organ Injuries and D-dimer Levels in a Porcine Model of Methicillin-Resistant Staphylococcus Aureus (MRSA) Sepsis-Induced Disseminated Intravascular Coagulation (DIC)**
Miguel Cruz, *United States*

Pathophysiology of DIC

10:45 – 11:10 **Current Pathological and Laboratory Considerations in Diagnosing DIC**
Cheng-Hock Toh, *United Kingdom*

11:10 – 11:30 **Does Cellular Waste Always Harm? The Role of Cell-Free DNA and Histones in Systemic Inflammation**
Sacha Zeerleder, *the Netherlands*

11:30 – 11:50 **Glycocalyx and Control of Microvascular Perfusion and Capillary Density**
Hans Vink, *the Netherlands*

11:50 – 12:10 **Leukocyte-Derived Extracellular DNA as an Underlying Cause of Extracorporeal Circuit Obstruction**
Takashi Ito, *Japan*

12:10 – 12:30 **Complement-Coagulation Interface in Sepsis DIC**
Florea Lupu, *United States*

10:30 – 12:30

Wicklow Hall 2 (Level 2)

SSC Session: Lupus Anticoagulant/Antiphospholipid Antibodies

Chairman: Katrien Devreese, *Belgium*

Co-Chairmen: Cristina Belizna, *France*, Hannah Cohen, *United Kingdom*, Bas de Laat, *the Netherlands*, Doruk Erkan, *United States*, Masahiro Ieko, *Japan*, Denis G. Wahl, *France*

10:30 – 10:35 **Introduction**
Katrien Devreese, *Belgium*

10:35 – 10:50 **Top Abstract Presentation: Pregnancy Outcomes in Women With Antiphospholipid Antibodies: Interim Results From a Single Centre Cohort Study**
Margreta Frishman, *United Kingdom*

10:50 – 11:00 **Antiphospholipid Antibodies in Lymphoma**



Cristina Belizna, *France*

Thrombin Generation

- 11:00 – 11:20** **Thrombin Generation and APS: Overview, New Results and Efforts for Standardization**
Romy Kremers, *the Netherlands*
- 11:20 – 11:30** **Development of Antidotes for Anti-Xa DOACS to Allow the Use of Routine Coagulation Assays in the Diagnosis of APS**
Hilde Kelchtermans, *the Netherlands*

Lupus Anticoagulant

- 11:30 – 11:45** **Taipan Snake Venom/Ecarin Time for LAC in Anticoagulated Patients: Preliminary Results from a Multicenter Study**
Gary Moore, *United Kingdom*
- 11:45 – 12:00** **LAC Testing During DOAC: Neutralizing the Culprit?**
Julien Favresse, *Belgium*
- 12:00 – 12:10** **Need for Update of the 2009 Recommendations for LAC Detection? Results of a Questionnaire and Panel Discussion**
Hannah Cohen, *United Kingdom*
- 12:10 – 12:30** **Panel Discussion**
Cristina Belizna, *France*, Hannah Cohen, *United Kingdom*, Philip de Groot, *the Netherlands*, Bas de Laat, *the Netherlands*, Katrien Devreese, *Belgium*, Doruk Erkan, *United States*, Masahiro Ieko, *Japan*, Ian Mackie, *United Kingdom*, Thomas Ortel, *United States*, Vittorio Pengo, *Italy*, Jacob Rand, *United States*, Denis Wahl, *France*

12:30 – 13:15

The Forum (Ground Floor)

Lunch in Exhibition Hall

13:15 – 14:30

See Page 159

Supported Symposia

14:30 – 15:00

The Forum (Ground Floor)

Coffee Break in Exhibition Hall

PROGRAM DETAILS BY DAY

15:00 – 17:00

Auditorium (Level 3)

SSC Session: **von Willebrand Factor, Part I**

Chairman: Sandra Haberichter, *United States*

Co-Chairmen: Ross I. Baker, *Australia*, Simon de Meyer, *Belgium*, Veronica Flood, *United States*, Frank W. Leebeek, *the Netherlands*, James O'Donnell, *Ireland*, Analia Sancheze-Luceros, *Argentina*

Clinical Challenges in Diagnosis of VWD

Moderators: Ross Baker, *Australia*, Analia Sanchez Luceros, *Argentina*

- | | |
|---------------|--|
| 15:00 – 15:20 | Removing the Diagnosis of VWD from Patients
Giancarlo Castaman, <i>Italy</i> |
| 15:20 – 15:40 | Clinical Challenges in Low VWF Diagnosis
Michelle Lavin, <i>Ireland</i> |
| 15:40 – 16:00 | Low VWF - Meta Analysis
Alberto Tosetto, <i>Italy</i> |
| 16:00 – 16:20 | Alloantibody Formation in Type 3 Subjects in Zimmerman Program
Pamela Christopherson, <i>United States</i> |
| 16:20 – 17:00 | Discussion of Future Projects |

15:00 – 17:00

Liffey A (Level 1)

SSC Session: **Perioperative and Critical Care Thrombosis and Hemostasis**

Chairman: Marc C. Samama, *France*

Co-Chairmen: Pierre Albaladejo, *Italy*, James Douketis, *Canada*, Andreas Greinacher, *Germany*, Beverley Hunt, *United Kingdom*, Jerrold H. Levy, *United States*, Alex C. Spyropoulos, *United States*

ECMO/VAD

- | | |
|---------------|--|
| 15:00 – 15:20 | Overview of Extracorporeal Devices and Hemostasis
Jun Teruya, <i>United States</i> |
| 15:20 – 15:40 | Impact of VADs and ECMO on Primary Hemostasis and Consequences of Therapeutic Approaches
Barbara Zieger, <i>Germany</i> |
| 15:40 – 16:00 | Anticoagulation and Monitoring for ECMO and VADs: Targets and Drugs
Paul Monagle, <i>Australia</i> |
| 16:00 – 16:20 | Anticoagulation for ECMO and VADs Other than Heparin and Warfarin: Direct Thrombin Inhibitors and Novel Agents
Thomas Renné, <i>Sweden</i> |
| 16:20 – 16:30 | Questions |



SSC Standing Session

16:30 – 17:00 Ongoing SSC Activities: Future Projects, Guidance Papers, Educational Activities

15:00 – 17:00

Liffey Hall 1 (Level 1)

SSC Session: **Fibrinolysis**

Chairman: Paul Y. Kim, *Canada*

Co-Chairmen: Krasimir Kolev, *Hungary*, Colin Longstaff, *United Kingdom*, Nicola Mutch, *United Kingdom*, Victoria Ploplis, *United States*, Guy Reed, *United States*, Tetsumei Urano, *Japan*

15:00 – 15:20 **Use of TEG/ROTEM in Liver Transplantation**

Fuat Saner, *Germany*

15:20 – 15:40 **The Fibrinolytic System and TIC**

Dominik Draxler, *Australia*

15:40 – 16:00 **Modeling of TEG, ROTEM and CCT Algorithms for Trauma Resuscitation**

Kjersti Baksaas-Aasen, *Norway*

16:00 – 16:20 **Disparities Between INR/PTT and TEG**

Ernest Moore, *United States*

16:20 – 16:40 **Clinical Applications of TEG and ROTEM and the Need for Improvement in the Standardization and Validation of These Tests**

Gabriel Dumitrescu, *Sweden*

16:40 – 17:00 **Need of a Standardized Test for the Diagnosis and Quantification of Fibrinolytic Resistance in Sepsis Patients**

Ecaterina Scarlatescu, *Romania*

15:00 – 17:00

Liffey Hall 2 (Level 1)

SSC Session: **Pediatric and Neonatal Hemostasis and Thrombosis**

Chairman: Christoph Male, *Austria*

Co-Chairmen: Manuela Albisetti Pedroni, *Switzerland*, Tina Biss, *United Kingdom*, Fiona Newall, *Australia*, Sarah Harvey O'Brien, *United States*, Leslie Raffini, *United States*, Shoshana Revel-Vilk, *Israel*

15:00 – 15:10 **The Identification of At-Risk Patients and Prevention of Venous Thromboembolism in Pediatric Cancer**

Jay Michael Balagatas, *United States*

15:10 – 15:25 **Incidental VTE Management Recommendation: SSC Working Group Update**

Anjali Sharathkumar, *United States*

15:25 – 15:40 **Systematic Review and Meta-Analysis of the Literature on Pediatric PTS Predictors**

Marisol Betensky, *United States*

PROGRAM DETAILS BY DAY

- 15:40 – 15:55 **Survey on Anticoagulation Management During ECMO**
Meera Chitlur, *United States*
- 15:55 – 16:10 **Setting Standards for Appropriate and Necessary Care for Young Women with Heavy Menstrual Bleeding and Bleeding Disorders – an Update**
Ayesha Zia, *United States*

Quality of Life and Adherence to Anticoagulant Therapy in Children and Adolescents: Proposal for Working Group

- 16:10 – 16:20 **Introduction to the Session and Speakers**
Tina Biss, *United Kingdom*
- 16:20 – 16:30 **Adherence to Anticoagulant Therapy in Pediatrics: Quantitative Study**
Fiona Newall, *Australia*
- 16:30 – 16:40 **QoL and Adherence to Anticoagulant Therapy in Adolescents: Qualitative Study**
Kay Rooney, *United Kingdom*
Ruth Struthers, *United Kingdom*
- 16:40 – 17:00 **International Pediatric Thrombosis Network**
Heleen Van Ommen, *the Netherlands*

15:00 – 17:00

Wicklow Hall 1 (Level 2)

SSC Session: Disseminated Intravascular Coagulation

Chairman: Toshiaki Iba, *Japan*

Co-Chairmen: Bernd Jilma, *Austria*, Alessandro Squizzato, *Italy*, Jecko Thachil, *United Kingdom*, Theodore E. Warkentin, *Canada*, Kazuma Yamakawa, *Japan*, Sacha Zeerleder, *the Netherlands*

Clinical Advances in DIC

- 15:00 – 15:24 **Heparin-Induced Thrombocytopenia (HIT) Versus Non-HIT DIC**
Theodore E. Warkentin, *Canada*
- 15:24 – 15:48 **How to Diagnose Coagulopathy in Sepsis Patients**
Kazuma Yamakawa, *Japan*
- 15:48 – 16:12 **Antithrombin Revisited**
Takashi Tagami, *Japan*
- 16:12 – 16:36 **Predicting Mortality in Patients with DIC After Cardiac Surgery**
Jerrold Levy, *United States*
- 16:36 – 17:00 **International Prospective Registry for the Diagnosis and Management of Sepsis-Associated Disseminated Intravascular Coagulation**
Alessandro Squizzato, *Italy*



15:00 – 17:00

Wicklow Hall 2 (Level 2)

SSC Session: **Lupus Anticoagulant/Antiphospholipid Antibodies**

Chairman: Katrien Devreese, *Belgium*

Co-Chairmen: Cristina Belizna, *France*, Hannah Cohen, *United Kingdom*, Bas de Laat, *the Netherlands*, Doruk Erkan, *United States*, Masahiro Ieko, *Japan*, Denis G. Wahl, *France*

Antiphospholipid Antibodies-Solid Phase Assays

- 15:00 – 15:10 **Antiphosphatidyl Serine/Prothrombine Antibodies: Pro's and Con's to Include in the Diagnostic/Classification Criteria – Pro**
Maria Laura Bertolaccini, *United Kingdom*
- 15:10 – 15:20 **Antiphosphatidyl Serine/Prothrombine Antibodies: Pro's and Con's to Include in the Diagnostic/Classification Criteria – Con**
Vittorio Pengo, *Italy*
- 15:20 – 15:30 **aPS/PT Inclusion in Diagnostic/Classification Criteria: Discussion**
Maria Laura Bertolaccini, *United Kingdom*
Vittorio Pengo, *Italy*
- 15:30 – 15:45 **Role of IgM in APS: Results of the Solid Phase Assays Multicenter Study**
Walid Chayoua, *the Netherlands*
- 15:45 – 16:00 **Anti-Domain I Chemiluminescence Detection in a Prospective Cohort**
Denis Wahl, *France*

Diagnosis of APS

- 16:00 – 16:30 **Update on the New APS Classification Criteria Development Efforts**
Doruk Erkan, *United States*
- 16:30 – 16:50 **New Insights on APS Diagnostics Derived from Imaging APS Immune Complexes**
Jacob Rand, *United States*
- 16:50 – 17:00 **Closing Remarks**
Katrien Devreese, *Belgium*

17:00 – 18:30

Liffey B (Level 1)

Poster Networking – Poster Session 1

Posters will be presented during the entire duration of the meeting in two (2) poster sessions.

Posters being presented during **Poster Session 1** will be displayed from **Wednesday, July 18 at 13:15 – Thursday, July 19 at 12:00**; the authors will be present during a **Poster Networking** held on **Wednesday, July 18 from 17:00 – 18:30**. Posters will need to be dismantled for **Poster Session 1** by **12:00** on **Thursday, July 19**.

NOTE: All posters that have not been taken down by 12:00 will be dismantled and destroyed.

The background features a complex abstract design. On the left, a cluster of light blue circles of varying sizes fades out towards the center. On the right, a series of dark blue circles of varying sizes are arranged in a pattern that suggests a sphere or a similar three-dimensional form. A series of thin, dark blue lines curve and sweep across the right side of the page, creating a sense of motion and depth. The overall color palette is monochromatic, using various shades of blue on a white background.

PROGRAM

THURSDAY
JULY 19, 2018



Thursday, July 19, 2018



08:00 – 10:00

Auditorium (Level 3)

SSC Session: **von Willebrand Factor, Part II**

Chairman: Sandra Haberichter, *United States*

Co-Chairmen: Ross I. Baker, *Australia*, Simon de Meyer, *Belgium*, Veronica Flood, *United States*, Frank W. Leebeek, *the Netherlands*, James O'Donnell, *Ireland*, Analia Sancheze-Luceros, *Argentina*

Diagnosis of VWD and Assays of VWF Activity

Moderator: Simon DeMeyer, *Belgium*

- 08:00 – 08:20** **Diagnostic Algorithm: A Look to Latin America**
Analia Sanchez-Luceros, *Argentina*
- 08:20 – 08:40** **Diagnostic Algorithm - BloodCenter of Wisconsin**
Sandra Haberichter, *United States*
- 08:40 – 09:00** **Calibration of ISTH Lot#5 and Standardization of VWF:GPIbM**
Anthony Hubbard, *United Kingdom*
- 09:00 – 09:20** **Variability in VWF:RCo Results: Data from the UK NEQAS (Blood Coagulation) Proficiency Testing Program**
Ian Jennings, *United Kingdom*
- 09:20 – 09:40** **VWF:GPIbM Assay Assessment of DDAVP Response**
Kenneth Friedman, *United States*
- 09:40 – 10:00** **Discussion of Future Projects**

08:00 – 10:00

Liffey A (Level 1)

SSC Session: **Platelet Physiology**

Chairman: Paolo Gresele, *Italy*

Co-Chairmen: Marie-Christine Alessi, *France*, Marina Camera, *Italy*, Andrew L. Frelinger III, *United States*, Marie Lordkipanidzé, *Canada*, Jose Rivera Pozo, *Spain*, Matthew T. Rondina, *United States*

Moderators: Paolo Gresele, *Italy*, Marie Lordkipanidzé, *Canada*

- 08:00 – 08:15** **Top Abstract Presentation: Platelet Chemokine Receptor CXCR7 Mediates an Anti-Thrombotic and Anti-Thromboinflammatory Effect**
Madhumita Chatterjee, *Germany*
- 08:15 – 08:25** **Overview of the Platelet Physiology SSC – Ongoing and New Projects and Presentation of the Session**
Paolo Gresele, *Italy*

THURSDAY

PROGRAM DETAILS

PROGRAM DETAILS BY DAY

08:25 – 08:45 **Diagnosis and Management of Platelet-Type von Willebrand Disease: Guidance Based on Expert Consensus**
Maha Othman, *Canada*

Unconventional Platelet Functions: Methodological Aspects and Pathophysiologic Implications

08:45 – 09:05 **Platelet Migration**
Steffen Massberg, *Germany*

09:05 – 09:20 **Platelet Chemotaxis: Novel Triggers**
Eleonora Petito, *Italy*

09:20 – 09:40 **Platelet-Mediated Bacterial Killing: In Vitro Studies**
Randall G. Worth, *United States*

09:40 – 10:00 **Platelets and Host Defense against Pulmonary Bacterial Infection: In Vivo Testing**
Simon C. Pitchford, *United Kingdom*

08:00 – 10:00

Liffey Hall 1 (Level 1)

SSC Session: Plasma Coagulation Inhibitors

Chairman: Jun Teruya, *United States*

Co-Chairmen: Herm Jan Brinkman, *the Netherlands*, Cecilia Guillermo, *Uruguay*, Ian Jennings, *United Kingdom*, Richard A. Marlar, *United States*, Eriko Morishita, *Japan*, Hiroko Tsuda, *Japan*

08:00 – 08:15 **Top Abstract Presentation: Effect of Andexanet-Tissue Factor Pathway Inhibitor (TFPI) Interaction on In Vitro Clot Formation and Lysis via Different Coagulation Pathways**
Genmin Lu, *United States*

Tissue Factor Pathway Inhibitor (TFPI)

Moderator: Jun Teruya, *United States*

08:15 – 08:40 **Clinical Significance of TFPI**
Alan Mast, *United States*

08:40 – 09:00 **TFPI: How Amsterdam Found Its Own Factor V**
Saskia Middeldorp, *the Netherlands*

Protein S

Moderator: Hiroko Tsuda, *Japan*

09:00 – 09:20 **Post Veni-Puncture Cleavage of Protein S and the Influence Thereof on Protein S Testing**
Herm Jan Brinkman, *the Netherlands*



09:20 – 09:40 **Investigation into Racial Differences in Genetic Risk Factor for Venous Thromboembolism**

Hiroko Tsuda, *Japan*

09:40 – 10:00 **Prevalence of Protein S Deficiency in Latin America**

Cecilia Guillermo, *Uruguay*

08:00 – 10:00

Liffey Hall 2 (Level 1)

SSC Session: **Predictive and Diagnostic Variables in Thrombotic Disease**

Chairman: John-Bjarne Hansen, *Norway*

Co-Chairmen: Cecilia Becattini, *Italy*, Suzanne Cannegieter, *the Netherlands*, Geert-Jan Geersing, *the Netherlands*, Paul A. Kyrle, *Austria*, Grégoire Le Gal, *Canada*, Marc Righini, *Switzerland*

Updates of SSC Projects

Moderator: Suzanne Cannegieter, *the Netherlands*

08:00 – 08:10 **Introduction**

John-Bjarne Hansen, *Norway*

08:10 – 08:25 **Top Abstract Presentation: Individualized Prediction Model for Risk of First DVT Using Clinical Assessment and D-dimer**

Sameer Parpia, *Canada*

08:25 – 08:50 **Standardized Definition for the Diagnosis of Death from VTE in Clinical Studies**

Noémie Kraaijpoel, *the Netherlands*

08:50 – 09:10 **Definition of Diagnostic Criteria and Classification of Subsegmental Pulmonary Embolism**

Frederikus Klok, *the Netherlands*

Ongoing Projects

Moderator: Paul Kyrle, *Austria*

09:10 – 10:00 **Ongoing Projects Will Be Presented with Various Presenters**

08:00 – 10:00

Wicklow Hall 2 (Level 2)

SSC Session: **Hemostasis and Malignancy**

Chairman: Marc Carrier, *Canada*

Co-Chairmen: Cihan Ay, *Austria*, Christophe Dubois, *France*, Guy Meyer, *France*, Simon Noble, *United Kingdom*, Casey Lee O'connell, *United States*, Jeffrey Zwicker, *United States*

PROGRAM DETAILS BY DAY

08:00 – 08:15 **Top Abstract Presentation: Ir-CPI: An Original Inhibitor of Thrombosis and Thrombosis-associated With Cancer**
Valérie Pireau, *Belgium*

SSC Malignancy and Hemostasis - Clinical Projects

Moderators: Guy Meyer, *France*, Casey O'Connell, *United States*

08:15 – 08:20 **Welcome and Updates on SSC Malignancy & Hemostasis Projects**
Marc Carrier, *Canada*

08:20 – 08:45 **Management of Cancer-Associated Thrombosis in Patients with Thrombocytopenia**
Bethany Samuelson Bannow, *United States*

08:45 – 09:10 **The Use of Direct Oral Anticoagulants for the Management of Cancer-Associated Thrombosis**
Alok Khorana, *United States*

09:10 – 09:35 **Assesment of Quality of Life Among Patients with Cancer-Associated Thrombosis**
Simon Noble, *United Kingdom*
Leslie Padrnos, *United States*

09:35 – 10:00 **Hematological Malignancies: Risk of Thrombosis and Use of Thromboprophylaxis**
Darko Antic, *Serbia*

10:00 – 10:30

The Forum (Ground Floor)

Coffee Break in Exhibition Hall

10:30 – 12:30

Auditorium (Level 3)

SSC Session: von Willebrand Factor, Part II

Chairman: Sandra Haberichter, *United States*

Co-Chairmen: Ross I. Baker, *Australia*, Simon de Meyer, *Belgium*, Veronica Flood, *United States*, Frank W. Leebeek, *the Netherlands*, James O'Donnell, *Ireland*, Analia Sancheze-Luceros, *Argentina*

VWD and Pregnancy

Moderator: Veronica Flood, *United States*

10:30 – 10:50 **von Willebrand Disease and Pregnancy: A Review of Evidence**
Paula James, *Canada*

10:50 – 11:10 **Blood Volume-Based von Willebrand Factor to Prevent Postpartum Hemorrhage in von Willebrand Disease**
Margaret Ragni, *United States*



11:10 – 11:30 **Antifibrinolytic Therapy for Preventing VWD-Related Postpartum Hemorrhage: Indications and Limitations**
Peter Kouides, *United States*

11:30 – 12:00 **Discussion of Future Projects**

10:30 – 12:30

Liffey A (Level 1)

SSC Session: **Platelet Physiology**

Chairman: Paolo Gresele, *Italy*

Co-Chairmen: Marie-Christine Alessi, *France*, Marina Camera, *Italy*, Andrew L. Frelinger III, *United States*, Marie Lordkipanidzé, *Canada*, Jose Rivera Pozo, *Spain*, Matthew T Rondina, *United States*

Moderators: Marina Camera, *Italy*, Matthew Rondina, *United States*

10:30 – 10:40 **Standardization of Flow Cytometry for the Assessment of Platelet Disorders**
Andrew L. Frelinger III, *United States*

10:40 – 10:50 **Standardization of Flow Cytometry for the Assessment of Platelet Disorders**
José Rivera Pozo, *Spain*

10:50 – 11:10 **Multidimensional Platelet Analysis by Mass Cytometry: A New Tool in Platelet Diagnostics**
Thomas A. Blair, *United States*

11:10 – 11:30 **Multiple Flow Cytometry for the Study of Platelets: Methodological Aspects and Open Issues**
Khalid M. Naseem, *United Kingdom*

11:30 – 11:50 **Measurement of MPV: A Standardization Study**
Paul Harrison, *United Kingdom*

11:50 – 12:10 **Methods for the Conservation and Shipment of Platelets: Update and Progress**
Marie Lordkipanidzé, *Canada*

12:10 – 12:30 **Standardization and Interlaboratory Comparison of Platelet Aggregation Reagents: A Multicentric Comparison (Launch of a New Project)**
Marie Christine Alessi, *France*

10:30 – 12:30

Liffey Hall 1 (Level 1)

SSC Session: **Plasma Coagulation Inhibitors**

Chairman: Jun Teruya, *United States*

Co-Chairmen: Herm Jan Brinkman, *the Netherlands*, Cecilia Guillermo, *Uruguay*, Ian Jennings, *United Kingdom*, Richard A. Marlar, *United States*, Eriko Morishita, *Japan*, Hiroko Tsuda, *Japan*

PROGRAM DETAILS BY DAY

Antithrombin

Moderators: Jean Connors, *United States*, Jun Teruya, *United States*

- 10:30 – 10:50 **Molecular Basis and Thrombotic Manifestations of Antithrombin Deficiency in Japanese Patients**
Eriko Morishita, *Japan*
- 10:50 – 11:10 **Debate: Antithrombin Replacement During Heparin Therapy: Pro**
Meera Chitlur, *United States*
- 11:10 – 11:30 **Debate: Antithrombin Replacement During Heparin Therapy: Con**
Paul Monagle, *Australia*
- 11:30 – 11:40 **Debate: Discussion**

Heparin-Like Substance

- 11:40 – 12:00 **Is It Myth or Reality?**
Shiu-ki (Rocky) Hui, *United States*

SSC/ISTH Secondary Coagulation Standard Lot #5

Moderator: Jun Teruya, *United States*

- 12:00 – 12:10 **An Update on the Calibration of Protein S, Protein C and Antithrombin**
Craig Thelwell, *United Kingdom*

SSC Standing Session

- 12:10 – 12:30 **Ongoing SSC Activities/Future Projects**

10:30 – 12:30

Liffey Hall 2 (Level 1)

SSC Session: Predictive and Diagnostic Variables in Thrombotic Disease

Chairman: John-Bjarne Hansen, *Norway*

Co-Chairmen: Cecilia Becattini, *Italy*, Suzanne Cannegieter, *the Netherlands*, Geert-Jan Geersing, *the Netherlands*, Paul A. Kyrle, *Austria*, Grégoire Le Gal, *Canada*, Marc Righini, *Switzerland*

Diagnosis of VTE

Moderator: Grégoire Le Gal, *Canada*

- 10:30 – 10:45 **Why Do We Miss Pulmonary Embolism So Often?**
Geert-Jan Geersing, *the Netherlands*
- 10:45 – 11:00 **Diagnosis of PE: Current Recommendations**
Marc Righini, *Switzerland*



11:00 – 11:15 **Diagnosis of PE in the ER: So You Think You Can Be an Emergency Physician?**

Kerstin de Wit, *Canada*

11:15 – 11:30 **Panel Discussion**

Biomarkers and Risk Prediction of VTE

Moderator: John-Bjarne Hansen, *Norway*

11:30 – 11:50 **D-Dimer Diagnostics: Real Life Implementation Challenges**

Rita Selby, *Canada*

11:50 – 12:10 **Predicting Recurrence in All Patients with a First VTE**

Suzanne Cannegieter, *the Netherlands*

12:10 – 12:30 **Are Risk Prediction Models for VTE Ready for Use?**

Sabine Eichinger, *Austria*

10:30 – 12:30

Wicklow Hall 2 (Level 2)

SSC Session: **Hemostasis and Malignancy**

Chairman: Marc Carrier, *Canada*

Co-Chairmen: Cihan Ay, *Austria*, Christophe Dubois, *France*, Guy Meyer, *France*, Simon Noble, *United Kingdom*, Casey Lee O'connell, *United States*, Jeffrey Zwicker, *United States*

SSC Malignancy and Hemostasis - Basic Science and Open Forum

Moderators: Cihan Ay, *Austria*, Christophe Dubois, *France*

10:30 – 11:00 **IrCPI a New Potent Inhibitor of Thrombosis and Thrombosis Associated with Cancer**

Edmond Godfroid, *Belgium*

11:00 – 11:30 **Update on the HYPERCAN Study**

Anna Falanga, *Italy*

11:30 – 12:00 **Using Biomarkers for VTE Risk Stratification in Patients with Lung Adenocarcinoma**

Grigorios Gerotziafas, *France*

12:00 – 12:30 **Open Forum**

Marc Carrier, *Canada*

12:30 – 13:15

The Forum (Ground Floor)

Lunch in Exhibition Hall

PROGRAM DETAILS BY DAY

13:15 – 14:30

See Page 161

Supported Symposia

14:30 – 15:00

The Forum (Ground Floor)

Coffee Break in Exhibition Hall

15:00 – 17:00

Auditorium (Level 3)

Education Session: Personalized Treatment in Hemophilia

Chairs: Guy Young, *United States*, Michelle Lavin, *Ireland*

-
- | | |
|---------------|---|
| 15:00 – 15:20 | The History of Hemophilia Replacement Therapy: From Samuel Lane to Extended Half-Life Factor Replacement Therapy
Kathelijjn Fischer, <i>the Netherlands</i> |
| 15:20 – 15:35 | Hemophilia A (Case Based Presentation)
Beatrice Nolan, <i>Ireland</i> |
| 15:35 – 15:50 | Hemophilia B (Case Based Presentation)
Johnny Mahlangu, <i>South Africa</i> |
| 15:50 – 16:05 | Hemophilia A With Inhibitors (Case Based Presentation)
Carmen Escuriola-Ettingshausen, <i>Germany</i> |
| 16:05 – 16:20 | Using Electronic Data to Manage Hemophilia
Niamh O'Connell, <i>Ireland</i> |
| 16:20 – 16:45 | Novel Approaches to Pharmacokinetics and Individualized Pharmacologic Dosing of Factor Products
Peter Collins, <i>United Kingdom</i> |
| 16:45 – 17:00 | Panel Discussion |

15:00 – 17:00

Liffey A (Level 1)

Education Session: How to Manage Antithrombotic Drugs in Patients Undergoing Invasive Procedures

Chairs: James Douketis, *Canada*, Fionnuala Ní Áinle, *Ireland*

-
- | | |
|---------------|--|
| 15:00 – 15:20 | Perioperative Mechanisms of Thrombosis
John-Bjarne Hansen, <i>Norway</i> |
|---------------|--|



- 15:20 – 15:35** **The Role for Laboratory Testing Before Urgent Surgery (Case Based Presentation)**
Adam Cuker, United States
- 15:35 – 15:50** **Determinants of Acute Coronary Syndromes in a Perioperative Setting**
Ursula Rauch-Kröhnert, Germany
- 15:50 – 16:05** **Determinants of Bleeding in a Perioperative Setting (Case Based Presentation)**
Charles Marc Samama, France
- 16:05 – 16:20** **Perioperative Prevention of Thromboembolism: An Asian Perspective**
Heng Joo Ng, Singapore
- 16:20 – 16:40** **Why It Is Safe to Continue Antithrombotics for Some Procedures and Not Others?**
Peter Verhamme, Belgium
- 16:40 – 17:00** **Panel Discussion**

17:00 – 18:30

Liffey B (Level 1)

Poster Networking – Poster Session 2

Posters will be presented during the entire duration of the meeting in two (2) poster sessions.

Posters bring presented during Poster Session 2 will be displayed from Thursday, July 19 at 13:15 – Friday, July 20 at 12:00; the authors will be present during a Poster Networking held on Thursday, July 19 from 17:00 – 18:30. The poster area is located in Liffey B. Posters will need to be dismantled for Poster Session 2 by 12:00 on Friday, July 20.

NOTE: All posters that have not been taken down by 12:00 will be dismantled and destroyed.

The background features a complex abstract design. On the left, a cluster of light blue circles of varying sizes fades out towards the center. On the right, a series of dark blue circles of varying sizes are arranged in a pattern that suggests a globe or a network. A large, sweeping, light blue curved shape dominates the upper right quadrant. In the lower right, a series of dark blue curved lines form a fan-like or funnel-like shape. The overall color palette is monochromatic, using various shades of blue on a white background.

PROGRAM

FRIDAY
JULY 20, 2018



Friday, July 20, 2018



07:00 – 07:45

See page 163

Supported Symposia

08:00 – 10:00

Auditorium (Level 3)

SSC Session: **Factor VIII, Factor IX and Rare Coagulation Disorders, Part I**

Chairman: Guy Young, *United States*

Co-Chairmen: Manuel Carcao, *Canada*, Peter Collins, *United Kingdom*, Alfonso Iorio, *Canada*, Gili Kenet, *Israel*, Johnny N. Mahlangu, *South Africa*, Maria Elisa Mancuso, *Italy*

08:00 – 08:10 **Introduction to SSC Sessions**
Guy Young, *United States*

08:10 – 08:25 **Top Abstract Presentation: Enhanced FIX Collagen IV Binding Shows Improved Hemostatic Effects in a Hemophilia B Mouse Model**
Davide Matino, *Italy*

Practical Considerations with the Use of Emicizumab

Moderators: Manuel Carcao, *Canada*, Guy Young, *United States*

08:25 – 08:45 **Treatment of Breakthrough Bleeds**
Peter Collins, *United Kingdom*

08:45 – 09:00 **Management of Surgery**
Maria Elisa Mancuso, *Italy*

09:00 – 09:15 **Laboratory Issues**
Stefan Tiefenbacher, *United States*

09:15 – 09:25 **Surveillance and Monitoring for Adverse Events**
Flora Peyvandi, *Italy*

09:25 – 09:45 **Institute for Clinical and Economic Review of Emicizumab**
David Rind, *United States*

09:45 – 10:00 **Panel Discussion**

08:00 – 10:00

Liffey A (Level 1)

SSC Session: **Control of Anticoagulation, Part I**

Chairman: Mark Crowther, *Canada*

Co-Chairmen: Julia Anderson, *United Kingdom*, Chatree Chai-Adisaksopha, *Canada*, Benilde Cosmi, *Italy*, Adam Cuker, *United States*, Jonathan Douxfils, *Belgium*, Ismail Elalamy, *France*

PROGRAM DETAILS BY DAY

- 08:00 – 08:15** **Welcome and Introductions**
Mark Crowther, *Canada*
- 08:15 – 08:25** **Top Abstract Presentation: Outcomes in Non-Valvular Atrial Fibrillation Patients with Good and Poor INR Control After Switching to Direct Oral Anticoagulants**
Scott Kaatz, *United States*

Session I: Laboratory Measures of Anticoagulation

Moderators: Chatree Chai-Adisaksopha, *Canada*, Adam Cuker, *United States*

- 08:25 – 08:50** **Reference Measurement Procedure for the Manual Tilt Tube Technique: An Update**
Ton van den Besselaar, *the Netherlands*
- 08:50 – 09:15** **Is Common Calibration with Heparin/LMWH Calibrator Good Enough for Orientation About Levels of Anti-Xa DOAC**
Henrik von Horn, *Sweden*
- 09:15 – 09:45** **Is Laboratory Monitoring of DOAC Required in Patients with APS; Insight from the Canadian RAPS Study**
Kim Legault, *Canada*
- 09:45 – 10:00** **Questions**

08:00 – 10:00

Liffey Hall 1 (Level 1)

SSC Session: **Vascular Biology**

Chairman: Chris Gardiner, *United Kingdom*

Co-Chairmen: Alexander Brill, *United Kingdom*, Emma C. Josefsson, *Australia*, Juan Melero-Martin, *United States*, Rienk Nieuwland, *the Netherlands*, David Smadja, *France*, Johannes Thaler, *Austria*

- 08:00 – 08:15** **Top Abstract Presentation: Inhibition of Integrin $\alpha_v\beta_3$ with Cilengitide Prevents Endothelial Injury Induced by Neutrophil Extracellular Traps in Response to Staphylococcus Aureus Infection in a 3D Ex Vivo Model of Sepsis**
Carolina Denis Garcarena, *Ireland*

Extracellular Vesicles

- 08:15 – 08:20** **Introduction**
Chris Gardiner, *United Kingdom*
- 08:20 – 08:30** **Update on ISTH/ISEV/ISAC Working Party on Flow-Cytometry of Extracellular Vesicles**
Rienk Nieuwland, *the Netherlands*
- 08:30 – 08:45** **Mechanisms of VTE in Cancer**
Johannes Thaler, *Austria*



- 08:45 – 09:00** **Prediction of Venous Thromboembolism in Cancer Patients Using a Extracellular Vesicle-Based Clotting Assay**
Rienk Nieuwland, *the Netherlands*
- 09:00 – 09:15** **Overview of Procoagulant Extracellular Vesicle Assays**
Nigel Mackman, *United States*
- 09:15 – 10:00** **Round Table Discussion on Standardisation of Procoagulant Extracellular Vesicle Assays**
Ali Amirkhosravi, *United States*, Françoise Dignat-George, *France*, Nigel Mackman, *United States*, Francois Mullier, *Belgium*, Rienk Nieuwland, *the Netherlands*, Johannes Thaler, *Austria*, Barry Woodhams, *United Kingdom*

08:00 – 10:00

Liffey Hall 2 (Level 1)

SSC Session: **Animal, Cellular and Molecular Models of Thrombosis**

Chairman: Jose A. Diaz, *United States*

Co-Chairmen: Brian C. Cooley, *United States*, Margarethe Geiger, *Austria*, Laura Gutierrez, *Spain*, Nobuo Nagai, *Japan*, Laura Sanchez, *Sweden*, Maxim Shaydakov, *United States*

Animal, in Vitro and Computational Models to Study Thrombosis

- 08:00 – 08:15** **Top Abstract Presentation: von Willebrand Factor Interactions With Platelets and Leukocytes is Critical for Obesity-mediated Venous Thrombosis**
Alison Michels, *Canada*
- 08:15 – 08:30** **Introduction Why We Developed This Program? The SSC Animal, Molecular and Cellular Models**
Jose A. Diaz, *United States*
- 08:30 – 09:00** **What Is New in VT Models? First Consensus in VT Models**
Prakash Saha, *United Kingdom*
- 09:00 – 09:30** **Can We Reproduce Thrombosis Conditions Using in Vitro Assays?**
Jain Abhishek, *United States*
- 09:30 – 10:00** **Can We Reproduce Thrombosis Conditions Using Computational Models?**
Miguel Aguirre-Font, *Spain*

08:00 – 10:00

Wicklow Hall 1 (Level 2)

SSC Session: **Factor XI and the Contact System**

Chairman: Joost Meijers, *the Netherlands*

Co-Chairmen: Edward P. Feener, *United States*, Heiko Herwald, *Sweden*, Coen Maas, *the Netherlands*, Owen J. McCarty, *United States*, Stephanie A. Smith, *United States*, Evi X. Stavrou, *United States*

PROGRAM DETAILS BY DAY

- 08:00 – 08:15** **Top Abstract Presentation: Inhibition of Factor XII is Antithrombotic in a Primate Model of Extracorporeal Membrane Oxygenation**
Michael Wallisch, *United States*
- 08:15 – 08:30** **The Anti-FXIIa Antibody BAY 1213790 Shows Antithrombotic Efficacy Without Increased Bleeding in Rabbit Models**
Anja Buchmuller, *Germany*
- 08:30 – 08:45** **Nanobodies for Detection of Contact Activation**
Zonne Liza Michaëla Hofman, *the Netherlands*
- 08:45 – 09:00** **Cell Receptor Interactions of the Contact System and FXI**
Simon Caulton, *United Kingdom*
- 09:00 – 09:15** **Activation and Inactivation of Contact Proteases**
Tilman Hackeng, *the Netherlands*
- 09:15 – 09:30** **Biochemistry of Contact Activation Initiation**
David Gailani, *United States*
- 09:30 – 10:00** **Nomenclature for the Contact Proteins**
Alvin Schmaier, *United States*

08:00 – 10:00

Wicklow Hall 2 (Level 2)

SSC Session: **Genomics in Thrombosis and Hemostasis**

Chairman: Willem H. Ouwehand, *United Kingdom*

Co-Chairmen: Daniel Bellissimo, *United States*, Paul F. Bray, *United States*, Kathleen Freson, *Belgium*, Anne Goodeve, *United Kingdom*, Michele P. Lambert, *United States*, Pieter Reitsma, *the Netherlands*

- 08:00 – 08:05** **Welcome**
- 08:05 – 08:20** **Top Abstract Presentation: Accumulation of Rare Variants in STAB2 in Type 1 von Willebrand Disease Patients**
Eric Manderstedt, *Sweden*

NGS in Clinical Diagnosis of Inherited Bleeding, Thrombotic and Platelet Disorders (BPD) (PART 1)

- 08:20 – 08:35** **Formation of Alpha Granules in Megakaryocytes and Platelets**
Walter Kahr, *Canada*
- 08:35 – 08:50** **The 100,000 Genomes Project**
Kate Downes, *United Kingdom*
- 08:50 – 09:05** **Diagnostic Challenges in Patients with Suspected Inherited Platelet Disorders**
Juliana Perez Botero, *United States*



09:05 – 09:15

Break

Genome Wide Association Studies, Risk Modifiers and eQTL Studies

- 09:15 – 09:30 **Hemostasis-Related Variants Identified by GWAS in the Caerphilly Prospective Study**
Benjamin Rodriguez, *United States*
- 09:30 – 09:45 **Exome Sequencing Studies Identify STAB2 Deficiency as a Genetic Risk for Venous Thromboembolic Disease**
Karl Desch, *United States*
- 09:45 – 10:00 **Expression QTL Studies in Seven Different Blood Cell Types**
Roman Kreuzhuber, *United Kingdom*

10:00 – 10:30

The Forum (Ground Floor)

Coffee Break in Exhibition Hall

10:30 – 12:30

Auditorium (Level 3)

SSC Session: Factor VIII, Factor IX and Rare Coagulation Disorders, Part I

Chairman: Guy Young, *United States*

Co-Chairmen: Manuel Carcao, *Canada*, Peter Collins, *United Kingdom*, Alfonso Iorio, *Canada*, Gili Kenet, *Israel*, Johnny N. Mahlangu, *South Africa*, Maria Elisa Mancuso, *Italy*

SSC and Other Project Updates

Moderators: Johnny Mahlangu, *South Africa*, Guy Young, *United States*

- 10:30 – 10:42 **Calibration of SSC/ISTH Plasma Standard Lot #5**
Craig Thelwell, *United Kingdom*
- 10:42 – 10:54 **Calibration of WHO International Standard for Factor V**
Anthony Hubbard, *United Kingdom*
- 10:54 – 11:06 **Hemophilia Carriers Nomenclature**
Robert Sidonio, *United States*
- 11:06 – 11:18 **Gene Therapy Clinical Trials**
Alok Srivastava, *India*
- 11:18 – 11:30 **EHC Partners Programme**
Brian O'Mahony, *Belgium*
- 11:30 – 11:40 **Questions**

FRIDAY

PROGRAM DETAILS

PROGRAM DETAILS BY DAY

Rare Bleeding Disorders

Moderator: Manuel Carcao, *Canada*

11:40 – 12:00 **Plasminogen Deficiency**
Charles Nakar, *United States*

12:00 – 12:30 **Diagnosing Rare Platelet Disorders**
Diane Nugent, *United States*

10:30 – 12:30

Liffey A (Level 1)

SSC Session: **Control of Anticoagulation, Part I**

Chairman: Mark Crowther, *Canada*

Co-Chairmen: Julia Anderson, *United Kingdom*, Chatree Chai-Adisaksopha, *Canada*, Benilde Cosmi, *Italy*, Adam Cuker, *United States*, Jonathan Douxfils, *Belgium*, Ismail Elalamy, *France*

Session II: Impact of DOACs on Coagulation Laboratory Testing

Moderators: Julia Anderson, *United Kingdom*, Benilde Cosmi, *Italy*

10:30 – 10:50 **Impact of DOACs on LAC Testing: The Australian Perspective**
Jennifer Curnow, *Australia*

10:50 – 11:10 **Evaluation of the DOAC-Stop[®] Procedure to Overcome the Effect of DOAC on Several Tests for Thrombophilia Screening**
Francois Mullier, *Belgium*

Update on Current Projects

11:10 – 11:20 **Unusual Site Thrombosis Treated with DOACs**
Walter Ageno, *Italy*, Nicoletta Riva, *Malta*

11:20 – 11:30 **CVT Registry**
Francesco Dentali, *Italy*

11:30 – 11:40 **START Events Registry**
Sophie Testa, *Italy*

11:40 – 11:50 **ORTHO-START Registry**
Elvira Grandone, *Italy*

11:50 – 12:00 **DOAC Testing in Ontario: Results from IQMH**
Karen Moffat, *Canada*

12:00 – 12:10 **Venous Stent Registry**
Sam Schulman, *Canada*

12:10 – 12:30 **Questions**



10:30 – 12:30

Liffey Hall 1 (Level 1)

SSC Session: **Vascular Biology**

Chairman: Chris Gardiner, *United Kingdom*

Co-Chairmen: Alexander Brill, *United Kingdom*, Emma C. Josefsson, *Australia*, Juan Melero-Martin, *United States*, Rienk Nieuwland, *the Netherlands*, David Smadja, *France*, Johannes Thaler, *Austria*

Neutrophil Extracellular Traps

10:30 – 10:40 **Proposed Guidelines for Studying NETs**
Alexander Brill, *United Kingdom*

10:40 – 11:20 **Round Table Discussion on Standardisation of Study of NETs**
Alexander Brill, *United Kingdom*, Simon De Meyer, *Belgium*. Paul Harrison, *United Kingdom*. Emma Lefrançois, *France*. Cheng-Hock Toh, *United Kingdom*

Circulating Endothelial Progenitor Cells

11:20 – 11:50 **Preclinical Evaluation and Optimization of a Cell Therapy Using Human Cord Blood-Derived Endothelial Colony-Forming Cells for Ischemic Retinopathies**
Reinhold Medina, *United Kingdom*

11:50 – 12:05 **Endothelial Progenitor Cells as Biomarkers**
Gian Paolo Fadini, *Italy*

12:05 – 12:15 **New Flow Technologies to Quantify EPC and Circulating Stem Cells**
Coralie Guérin, *Luxembourg*

12:15 – 12:30 **Update on Standardisation of CEPCs**
Juan Melero-Martin, *United States*
David Smadja, *France*

10:30 – 12:30

Liffey Hall 2 (Level 1)

SSC Session: **Animal, Cellular and Molecular Models of Thrombosis**

Chairman: Jose A. Diaz, *United States*

Co-Chairmen: Brian C. Cooley, *United States*, Margarethe Geiger, *Austria*, Laura Gutierrez, *Spain*, Nobuo Nagai, *Japan*, Laura Sanchez, *Sweden*, Maxim Shaydakov, *United States*

Can We Explore New Pathways in VT?

10:30 – 11:00 **Insights from Metabolomics**
Sarah Onida, *United Kingdom*

11:00 – 11:30 **Insights from Proteomics**
Laura Sanchez-Rivera, *Sweden*

FRIDAY

PROGRAM DETAILS

PROGRAM DETAILS BY DAY

11:30 – 12:00 **Insights from Genomics**
Chrissta Maracle, *the Netherlands*

12:00 – 12:30 **Panel Discussion: All Presenters: Models (First Session) and Explorative Tools (Second Session)**

10:30 – 12:30

Wicklow Hall 1 (Level 2)

SSC Session: **Factor XI and the Contact System**

Chairman: Joost Meijers, *the Netherlands*

Co-Chairmen: Edward P. Feener, *United States*, Heiko Herwald, *Sweden*, Coen Maas, *the Netherlands*, Owen J. Mccarty, *United States*, Stephanie A. Smith, *United States*, Evi X. Stavrou, *United States*

10:30 – 10:45 **Factor XI and XII Deficiency in Low TF Mice**
Nigel Mackman, *United States*

10:45 – 11:00 **The Contact System and Complement**
Berhane Ghebrehwet, *United States*

11:00 – 11:15 **The Contact System in Lung Disease**
Malgorzata Wygrecka, *Germany*

11:15 – 11:30 **Novel Functions of the Contact System in Innate Immunity**
Yi Wu, *United States*

11:30 – 11:45 **The Contact System in Alzheimer Disease**
Sidney Strickland, *United States*

11:45 – 11:55 **Clinical Role of FXII, PK and HK in Thrombosis**
Nigel Key, *United States*

11:55 – 12:05 **Contribution of FXII, PK and HK to Thrombosis – Pro**
Thomas Renné, *Sweden*

12:05 – 12:15 **Contribution of FXII, PK and HK to Thrombosis – Con**
James H. Morrissey, *United States*

12:15 – 12:30 **Debate Discussion**

10:30 – 12:30

Wicklow Hall 2 (Level 2)

SSC Session: **Genomics in Thrombosis and Hemostasis**

Chairman: Willem H. Ouwehand, *United Kingdom*

Co-Chairmen: Daniel Bellissimo, *United States*, Paul F. Bray, *United States*, Kathleen Freson, *Belgium*, Anne Goodeve, *United Kingdom*, Michele P. Lambert, *United States*, Pieter Reitsma, *the Netherlands*



NGS in Clinical Diagnosis of Inherited Bleeding, Thrombotic and Platelet Disorders (BPD) (PART 2)

10:30 – 10:50 **The Implementation of a Panel-Based next Generation Sequencing Approach in the Diagnosis of Inherited Platelet Disorders**
Harald Schulze, *Germany*

10:50 – 11:10 **Whole-Exome Sequencing in Evaluation of Patients with Venous Thromboembolism**
Alfred Lee, *United States*

11:10 – 11:30 **Carrier Detection of Inherited Bleeding Disorders in Women; An Irish Experience**
Catriona Keenan, *Ireland*

11:30 – 11:45

Break

Variant Interpretation & Data Sharing

11:45 – 12:00 **Variant Interpretation: When Is a Negative Result Negative?**
Karyn Megy, *United Kingdom*

12:00 – 12:15 **Data Sharing: DECIPHER and MatchMaker**
Kathleen Freson, *Belgium*

12:15 – 12:30 **A Decade of Genomics in Thrombosis and Haemostasis – What Next?**
Willem H. Ouwehand, *United Kingdom*

12:30 – 13:15

The Forum (Ground Floor)

Lunch in Exhibition Hall

13:15 – 14:30

See page 163

Supported Symposia

14:30 – 15:00

The Forum (Ground Floor)

Coffee Break in Exhibition Hall

15:00 – 17:00

Auditorium (Level 3)

SSC Session: **Factor VIII, Factor IX and Rare Coagulation Disorders, Part II**

Chairman: Guy Young, *United States*

Co-Chairmen: Manuel Carcao, *Canada*, Peter Collins, *United Kingdom*, Alfonso Iorio, *Canada*, Gili Kenet, *Israel*, Johnny N. Mahlangu, *South Africa*, Maria Elisa Mancuso, *Italy*

PROGRAM DETAILS BY DAY

New Frontiers in Immune Tolerance Induction

Moderators: Johnny Mahlangu, *South Africa*, Maria Elisa Mancuso, *Italy*

- 15:00 – 15:30** **Novel Approaches for Immune Tolerance Induction**
David Lillicrap, *Canada*
- 15:30 – 15:45** **Extended Half-Life Products and ITI**
Manuel Carcao, *Canada*
- 15:45 – 16:00** **Prophylaxis with ITI**
Carmen Escuriola-Ettingshausen, *Germany*
- 16:00 – 16:20** **Debate: ITI in the Era of Efficizumab – Yes**
Ri Liesner, *United Kingdom*
- 16:20 – 16:40** **Debate: ITI in the Era of Efficizumab – No**
Beatrice Nolan, *Ireland*
- 16:40 – 17:00** **Panel Discussion**

15:00 – 17:00

Liffey A (Level 1)

SSC Session: Control of Anticoagulation, Part II

Chairman: Mark Crowther, *Canada*

Co-Chairmen: Julia Anderson, *United Kingdom*, Chatree Chai-Adisaksopha, *Canada*, Benilde Cosmi, *Italy*, Adam Cuker, *United States*, Jonathan Douxfils, *Belgium*, Ismail Elalamy, *France*

Practical Issues with DOACs In “Real Life”

Moderators: Jonathan Douxfils, *France*, Ismail Elalamy, *France*

- 15:00 – 15:15** **Welcome and Introductions**
Mark Crowther, *Canada*
- 15:15 – 15:45** **DOACs Measurements and Clinical Events: Recent Evidences from the Literature and the Presentation of the “MAS – Measure and See” Study**
Sophie Testa, *Italy*
- 15:45 – 16:15** **The SAFIR Registry: Rivaroxaban Use in the Very Elderly**
Olivier Hanon, *France*
- 16:15 – 16:45** **Management and Outcome of Life-Threatening Emergency Situations in Patients Treated with DOAC or VKA – Results of the RADOA-Registry**
Edelgard Lindhoff-Last, *Germany*
- 16:45 – 17:00** **Questions**



15:00 – 17:00

Liffey Hall 1 (Level 1)

SSC Session: **Factor XIII and Fibrinogen**

Chairman: Verena Schroeder, *Switzerland*

Co-Chairmen: Zsuzsa Bagoly, *Hungary*, Matthew J. Flick, *United States*, Martin Guthold, *United States*, Marlien Pieters, *South Africa*, Sanj Raut, *United Kingdom*, Anetta Undas, *Poland*

15:00 – 15:20 **Top Abstract Presentation: Binding of Coagulation factor XIII Zymogen to Activated Platelet Subpopulations: Roles of Integrin $\alpha\text{IIb}\beta\text{3}$ and Fibrinogen**
Nadezhda Podoplelova, *Russian Federation*

Standardization Topics

15:20 – 15:40 **SSC/ISTH Secondary Coagulation Standard Lot #5: An Update on the Calibration of Factor XIII and Fibrinogen**
Craig Thelwell, *United Kingdom*

15:40 – 16:00 **Update on Value Assignment of FXIII-B to the WHO 1st IS for FXIII Plasma**
Sanj Raut, *United Kingdom*

16:00 – 16:20 **Update on the Standardization of the Fibrin Clot Turbidity and Lysis Assays**
Marlien Pieters, *South Africa*

16:20 – 16:40 **Strategies for Diagnosis of Fibrinogen Disorders**
Alessandro Casini, *Switzerland*

16:40 – 17:00 **Nomenclature of Genetic Variants of FXIII**
Verena Schroeder, *Switzerland*

15:00 – 17:00

Liffey Hall 2 (Level 1)

SSC Session: **Platelet Immunology**

Chairman: Donald Arnold, *Canada*

Co-Chairmen: Tamam Bakchoul, *Germany*, Philip Y. Choi, *Australia*, Brian Curtis, *United States*, Shigeki Miyata, *Japan*, François Mullier, *Belgium*, Rachel Petermann, *France*

15:00 – 15:15 **Top Abstract Presentation: Type I Interferons Upregulate IFITM3 in Human Platelets and Megakaryocytes to Control Viral Infectivity**
Robert Campbell, *United States*

Introduction

15:15 – 15:25 **Overview of Platelet Immunology SSC Activities**
Donald Arnold, *Canada*

15:25 – 15:35 **Thrombocytopenia Learning E-Module**
Tamam Bakchoul, *Germany*

PROGRAM DETAILS BY DAY

Autoimmune Thrombocytopenia

Moderator: Tamam Bakchoul, *Germany*

- 15:35 – 15:55** **H. Pylori Testing in ITP SSC Project: An International Survey**
Prakash Vishnu, *United States*
- 15:55 – 16:15** **ITP Virtual Biobank – Proposal**
Donald Arnold, *Canada*
- 16:15 – 16:35** **Platelet Microparticles in HIT and ITP**
Francois Mullier, *Belgium*

Alloimmune/ Drug-Induced Thrombocytopenia

Moderator: Donald Arnold, *Canada*

- 16:35 – 16:55** **Standardization of NAIT Testing - SSC Communication**
Rachel Petermann, *France*
- 16:55 – 17:00** **Questions**

15:00 – 17:00

Wicklow Hall 1 (Level 2)

SSC Session: **Biorheology**

Chairman: Pierre Mangin, *France*

Co-Chairmen: Judith Cosemans, *the Netherlands*, Elizabeth E. Gardiner, *Australia*, Wilbur Lam, *United States*, Keith Neeves, *United States*, Warwick Scott Nesbitt, *Australia*, Mikhail A. Panteleev, *Russian Federation*

SSC Project Update

- 15:00 – 15:15** **Update on Multicenter Flow Based Assay Study**
Keith Neeves, *United States*

Biomechanical Aspects of Proplatelet Formation and Platelet Release from Megakaryocytes: Implication for in Vitro Platelet Production

Moderators: Elizabeth Gardiner, *Australia*, Wilbur Lam, *United States*

- 15:15 – 15:40** **In Vivo Proplatelet Formation: Importance of Hemodynamics**
Catherine Léon, *France*
- 15:40 – 16:05** **Platelet Biogenesis: We Make Platelets**
Jorge Valdez, *United States*
- 16:05 – 16:30** **Microfluidic Study of Platelet Production in Dynamic Conditions**
Anne Le Goff, *France*



16:30 – 17:00 **3D Bone Marrow Models for Platelet Production**
Alessandra Balduini, *Italy*

15:00 – 17:00

Wicklow Hall 2 (Level 2)

SSC Session: **Women's Health Issues in Thrombosis and Hemostasis**

Chairman: Maha Othman, *Canada*

Co-Chairmen: Rezan Abdul-Kadir, *United Kingdom*, Patricia L. Casais, *Argentina*, Emmanuel Favaloro, *Australia*, Ian A. Greer, *United Kingdom*, Susan Halimeh, *Germany*, Predrag Miljic, *Serbia*

15:00 – 15:10 **Welcome, Outline of the Women's SSC and Overview of Activities**
Maha Othman, *Canada*

15:10 – 15:25 **Top Abstract Presentation: The Joint Effect Between Different Types of Combined Oral Contraceptives and Genetic Risk Factors on Venous Thrombosis Risk: Results from the MEGA Case-control Study**
Deeksha Khialani, *the Netherlands*

Hot Topics

Moderators: Rezan Abdul-Kadir, *United Kingdom*, Ian Greer, *United Kingdom*, Maha Othman, *Canada*

15:25 – 15:40 **Point of Care Monitoring of Haemostasis During Postpartum Haemorrhage**
Peter Collins, *United Kingdom*

15:40 – 15:55 **Point of Care Testing and Fibrinogen Therapy During Postpartum Hemorrhage: Clinical Applications**
Rachel Collis, *United Kingdom*

15:55 – 16:10 **Classic and Global Hemostasis Testing in Pregnancy and During Pregnancy Complications**
Ekaterina Koltsova, *Russian Federation*

16:10 – 16:25 **Management of Women with Type 2B VWD During Pregnancy and Postpartum**
Predrag Miljic, *Serbia*

16:25 – 16:50 **A Woman's Life-Long Bleeding Condition and Expert Opinion- Panel Discussion**
Anne Goodeve, *United Kingdom*, Paolo Gesele, *Italy*, Maha Othman, *Canada*, Analia Sanchez-Luceros, *Argentina*, Julie Venne, *Canada*

16:50 – 17:00 **Discussion**

17:00 – 17:15

Break

FRIDAY

PROGRAM DETAILS

PROGRAM DETAILS BY DAY

17:15 – 19:15

Auditorium (Level 3)

SSC Session: **Factor VIII, Factor IX and Rare Coagulation Disorders, Part II**

Chairman: Guy Young, *United States*

Co-Chairmen: Manuel Carcao, *Canada*, Peter Collins, *United Kingdom*, Alfonso Iorio, *Canada*, Gili Kenet, *Israel*, Johnny N. Mahlangu, *South Africa*, Maria Elisa Mancuso, *Italy*

Critical Appraisal of Novel Inhibitory Therapies for Hemophilia

Moderators: Peter Collins, *United Kingdom*, Alfonso Iorio, *Canada*

- 17:15 – 17:30 **Antithrombin**
Craig Benson, *United States*
- 17:30 – 17:45 **Tissue Factor Pathway Inhibitor**
Patrick Fogarty, *United States*
- 17:45 – 18:00 **Protein C**
James Huntington, *United Kingdom*
- 18:00 – 18:20 **Expert Commentary**
Peter Lenting, *France*
- 18:20 – 18:40 **Expert Commentary**
Steven Pipe, *United States*
- 18:40 – 19:00 **Panel Discussion**
- 19:00 – 19:15 **Closing**
Guy Young, *United States*

17:15 – 19:15

Liffey A (Level 1)

SSC Session: **Control of Anticoagulation, Part II**

Chairman: Mark Crowther, *Canada*

Co-Chairmen: Julia Anderson, *United Kingdom*, Chatree Chai-Adisaksopha, *Canada*, Benilde Cosmi, *Italy*, Adam Cuker, *United States*, Jonathan Douxfils, *Belgium*, Ismail Elalamy, *France*

Practical Issues with DOACs In “Real Life”

Moderators: Jonathan Douxfils, *France*, Ismail Elalamy, *France*

- 17:15 – 17:45 **Recommendations of the International Council for Standardization in Hematology (ICSH) for Laboratory Measurement of Direct Oral Anticoagulants (DOAC)**
Robert Gosselin, *United States*



17:45 – 18:15 **The DaXa Inhibition Test: A Concept for a Universal and Easily Available aXa Test That Measures the Direct Inhibitory Effect of All Anti-Xa Drugs**
Joost van Pelt, *the Netherlands*

18:15 – 18:45 **Reversal and Biological Strategies in French GIHP-NACO Registry: Need for Guidance**
Pierre Albaladejo, *France*

18:45 – 19:15 **Questions**

17:15 – 19:15

Liffey Hall 1 (Level 1)

SSC Session: **Factor XIII and Fibrinogen**

Chairman: Verena Schroeder, *Switzerland*

Co-Chairmen: Zsuzsa Bagoly, *Hungary*, Matthew J. Flick, *United States*, Martin Guthold, *United States*, Marlien Pieters, *South Africa*, Sanj Raut, *United Kingdom*, Anetta Undas, *Poland*

Scientific Topics

17:15 – 17:35 **Four Autoimmune Coagulation Factor Deficiencies (F13, F8, F5, and vWF) as the Designated Intractable Diseases of Japanese Ministry for Health, Labor and Welfare**
Akitada Ichinose, *Japan*

17:35 – 17:55 **Investigating Fibrinogen and Factor XIIIa Deficiencies in the Zebrafish**
Richard Fish, *Switzerland*

17:55 – 18:15 **The Effect of Activated Factor XIII on Human Vascular Smooth Muscle Cells**
László Muszbek, *Hungary*

18:15 – 18:35 **The Fibrin Network in Diabetes: Mechanisms and Therapeutic Implications**
Ramzi Ajjan, *United Kingdom*

18:35 – 18:55 **Fibrin Clot Properties as Predictors of Thromboembolic Events and Bleeding**
Anetta Undas, *Poland*

18:55 – 19:15 **The Role of Fibrin Crosslinking by FXIIIa in Clot Embolization**
Robert A.S. Ariëns, *United Kingdom*

17:15 – 19:15

Liffey Hall 2 (Level 1)

SSC Session: **Platelet Immunology**

Chairman: Donald Arnold, *Canada*

Co-Chairmen: Tamam Bakchoul, *Germany*, Philip Y. Choi, *Australia*, Brian Curtis, *United States*, Shigeki Miyata, *Japan*, François Mullier, *Belgium*, Rachel Petermann, *France*

PROGRAM DETAILS BY DAY

Alloimmune/ Drug-Induced Thrombocytopenia

Moderator: Donald Arnold, *Canada*

- 17:15 – 17:35** **Autoimmune TCP Post Alemtuzimab - Proposal**
Philip Y. Choi, *Australia*
- 17:35 – 17:55** **Priority Areas in Drug-Induced Immune Thrombocytopenia**
Tamam Bakchoul, *Germany*

Heparin-Induced Thrombocytopenia

Moderator: François Mullier, *Belgium*

- 17:55 – 18:15** **Prediction Rule for the Diagnosis of HIT: A Cohort Study**
Michael Nagler, *Switzerland*
- 18:15 – 18:35** **HIT Functional Testing Workshop- Proposal**
Ishac Nazy, *Canada*
- 18:35 – 18:55** **Heparin-Independent Platelet Activation in HIT Functional Assays**
Tamam Bakchoul, *Germany*

Concluding Remarks

- 18:55 – 19:15** **Future Directions, Collaborations, Education**
Donald Arnold, *Canada*

17:15 – 19:15

Wicklow Hall 1 (Level 2)

SSC Session: **Biorheology**

Chairman: Pierre Mangin, *France*

Co-Chairmen: Judith Cosemans, *the Netherlands*, Elizabeth E. Gardiner, *Australia*, Wilbur Lam, *United States*, Keith Neeves, *United States*, Warwick Scott Nesbitt, *Australia*, Mikhail A. Panteleev, *Russian Federation*

Moderator: Judith Cosemans, *the Netherlands*

- 17:15 – 17:30** **Top Abstract Presentation: Shear Enhances Fibrin-induced GPVI Shedding and Platelet ADAM10 Function**
Samantha J. Montague, *Australia*

Contribution of Biorheology to Platelet/Cell Aggregates

Moderators: Warwick Nesbitt, *Australia*, Mikhail Panteleev, *Russian Federation*

- 17:30 – 17:55** **Platelet 'Priming' via VWF Potentiates Novel Neutrophil Interaction and Mediates NETosis Under Flow**
Kevin Woollard, *Australia*



- 17:55 – 18:20** **The Importance of Using More Physiological Shear-Based Methods for Identifying Hidden Interactions Following Infection of the Bloodstream**
Steven Kerrigan, *Ireland*
- 18:20 – 18:45** **Platelet Count and Cancer Metastasis**
Owen McCarty, *United States*
- 18:45 – 19:15** **von Willebrand Factor at Platelet-Endothelial Cell Junction Under Aberrant Blood Flow**
JingFei Dong, *United States*

17:15 – 19:15

Wicklow Hall 2 (Level 2)

SSC Session: **Women's Health Issues in Thrombosis and Hemostasis**

Chairman: Maha Othman, *Canada*

Co-Chairmen: Rezan Abdul-Kadir, *United Kingdom*, Patricia L. Casais, *Argentina*, Emmanuel Favaloro, *Australia*, Ian A. Greer, *United Kingdom*, Susan Halimeh, *Germany*, Predrag Miljic, *Serbia*

Update on Ongoing/Complete SSC Projects

Moderator: Predrag Miljic, *Serbia*

- 17:15 – 17:25** **Artemis Study – Diagnostic Management Study in Pregnant Women with Clinically Suspected PE**
Frederikus Klok, *the Netherlands*
- 17:25 – 17:35** **Hematologic Alterations in Patients Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization: A Prospective Observational Pilot Study**
Maria T. DeSancho, *United States*
- 17:35 – 17:40** **Discussion**

Update on International Registries

Moderator: Patricia Casais, *Argentina*

- 17:40 – 17:50** **Registry of Pregnancy in Patients Exposed to Direct Oral Anticoagulants (DOACs)**
Saskia Middeldorp, *the Netherlands*
- 17:50 – 18:00** **WiTEAM: International Registry on Women with Placenta-Mediated Complications and Thrombophilia**
Amparo Santamaría Ortiz, *Spain*
- 18:00 – 18:10** **DIC in Pregnancy: Nomenclature, Scoring and a Global Registry**
Offer Erez, *Israel*
- 18:10 – 18:15** **Discussion**

PROGRAM DETAILS BY DAY

Update on New SSC Projects

Moderators: Ian Greer, *United Kingdom*, Susan Halimeh, *Germany*

- 18:15 – 18:25** **Hemophilia Carrier Nomenclature: Proposed Terminology to Improve Communication**
Robert Francis Sidonio, Jr, *United States*
- 18:25 – 18:35** **Obstetrics and Gynaecological Outcomes of Women with Platelet Function Disorders**
Deborah Obeng-Tuudah, *United Kingdom*
- 18:35 – 18:45** **Registry for Invasive Treatments for Massive Pulmonary Embolism in Pregnancy and Postpartum Period**
Marc Blondon, *Switzerland*
- 18:45 – 18:55** **Setting Standards for Appropriate and Necessary Care for Young Women with Heavy Menstrual Bleeding and Bleeding Disorders: An International Panel Survey**
Ayesha Zia, *United States*
- 18:55 – 19:05** **The TEAM-VTE Study: Risk, Predictors, Impact and Outcome of Anticoagulation-Associated Abnormal Menstrual Bleeding in Patients with VTE**
Frederikus Klok, *the Netherlands*
- 19:05 – 19:10** **Briefing, Recommendations, Announcements**
Maha Othman, *Canada*
- 19:10 – 19:15** **Discussion**

The background features a complex abstract design. On the left, a cluster of light blue circles of varying sizes fades into the white background. On the right, a series of dark blue circles are arranged in a grid-like pattern, with thin lines connecting them to form a mesh. A large, sweeping, light blue curved shape dominates the center, overlapping with other elements. The overall aesthetic is clean, modern, and geometric.

PROGRAM

SATURDAY
JULY 21, 2018

PROGRAM DETAILS BY DAY

Saturday, July 21, 2018



08:00 – 10:00

Liffey A (Level 1)

Education Session: **Coagulation and Sepsis**

Chairs: Jecko Thachil, *United Kingdom*, Steven Kerrigan, *Ireland*

- 08:00 – 08:20 **Sepsis: A Disorder of Coagulation or Platelets?**
Dermot Cox, *Ireland*
- 08:20 – 08:35 **A Hemostasis Perspective on How to Mitigate Sepsis Mortality**
Toshiaki Iba, *Japan*
- 08:35 – 08:50 **Sepsis: A Critical Care Physician Perspective**
Jerry J. Zimmerman, *United States*
- 08:50 – 09:05 **DIC in Sepsis and Obstetrics**
Beverley Hunt, *United Kingdom*
- 09:05 – 09:40 **Sepsis Reconsidered**
Clifford S. Deutschman, *United States*
- 09:40 – 10:00 **Panel Discussion**

08:00 – 10:00

Liffey B (Level 1)

Education Session: **Thrombo-Inflammatory Diseases: Evidence for a Direct Role of the Contact System**

Chairs: Joost C.M. Meijers, *the Netherlands*, Roger Preston, *Ireland*

- 08:00 – 08:25 **Resurrection of the Contact System – What We Now Know and What Remains to Be Determined**
Coen Maas, *the Netherlands*
- 08:25 – 08:45 **Hereditary Angioedema – Examining a Complex Etiology (Case Based Presentation)**
Marcel Levi, *United Kingdom*
- 08:45 – 09:05 **Medical Device Thrombosis – Causes and Prevention (Case Based Presentation)**
Jeffrey I. Weitz, *Canada*
- 09:05 – 09:35 **Targeting the Contact System for Treatment of Thrombo-Inflammatory Diseases**
Thomas Renné, *Sweden*
- 09:35 – 10:00 **Panel Discussion**



10:00 – 10:30

Liffey Foyer (Level 1)

Coffee Break

10:30 – 12:30

Liffey A (Level 1)

Education Session: Platelets (ITP)

Chairs: Paolo Gresele, *Italy*, Patricia Maguire, *Ireland*

10:30 – 10:55 **The Role of Platelets in Vascular Integrity and in the Prevention of Bleeding**
Michael Berndt, *Australia*

10:55 – 11:10 **Immune Platelet Disorders (Case Based Presentation)**
Donald Arnold, *Canada*

11:10 – 11:25 **Abnormal Bleeding in Mild/Moderate ITP: Case Report and the Role of Platelet Dysfunction (Case Based Presentation)**
Andrew L. Frelinger III, *United States*

11:25 – 11:40 **The Measurement of Mean Platelet Volume in the Differential Diagnosis of ITP: Case Report and State of the Art (Case Based Presentation)**
Patrizia Noris, *Italy*

11:40 – 12:05 **Immune Thrombocytopenia: Pathophysiology and Treatment: Future Directions**
Phillip Y. Choi, *Australia*

12:05 – 12:30 **Panel Discussion**

10:30 – 12:30

Liffey B (Level 1)

Education Session: Are the Direct Oral Anticoagulants Changing the Landscape in the Management of Venous Thromboembolism?

Chairs: Jan Beyer-Westendorf, *Germany*, Niamh O'Connell, *Ireland*

10:30 – 10:55 **Unmet Clinical Needs in the Management of Venous Thromboembolism**
Sabine Eichinger, *Austria*

10:55 – 11:10 **DOACs for the Treatment of Cancer Associated Thrombosis (Case Based Presentation)**
Marc Carrier, *Canada*

11:10 – 11:25 **DOACs for the Treatment of VTE in Unusual Site VTE (Case Based Presentation)**
Walter Ageno, *Italy*

PROGRAM DETAILS BY DAY

- 11:25 – 11:40 **Low Dose DOACs for the Secondary Prevention of VTE (Case Based Presentation)**
Jeffrey I. Weitz, *Canada*
- 11:40 – 12:05 **The Relevance Of “Real World” Data on the DOACs in the Management of VTE**
- 12:05 – 12:30 **Panel Discussion**

12:30 – 13:00

Liffey Hall 1 (Level 1)

Trainee Session Networking Reception

13:00 – 17:00

Liffey Hall 1 (Level 1)

Trainee Session

Chairs: Tony McHale, *Ireland*, Rebecca Louise Watkin, *Ireland*

- 13:00 – 13:30 **Building a Career Path: Clinicians**
Paula James, *Canada*
- 13:30 – 14:00 **Building a Career Path: Research**
Sudipto Das, *Ireland*
- 14:00 – 14:30 **Be Your Own Recruiter**
Sinéad Cullen, *Ireland*

14:30 – 15:00

Break

- 15:00 – 15:30 **Research Ethics and Integrity**
Dermot Cox, *Ireland*
- 15:30 – 16:00 **Writing Papers: How to Get a Paper Published**
Pieter Reitsma, *the Netherlands*
- 16:00 – 16:30 **How to Become a Principle Investigator**
Niamh Moran, *Ireland*
- 16:30 – 17:00 **Intersecting Ideas: The Magic of the Unexpected Connection**
Niamh Nic Daeid, *United Kingdom*



isth JULY 18-21
2018 ♦
SSC DUBLIN
Education, Innovation, Collaboration

POSTER SESSIONS

POSTER SESSION 1

POSTER SESSION 2

PUBLICATION ONLY

Posters will be presented during two (2) poster sessions. Poster Session 1 will take place from Wednesday, July 18 at 13:15 through Thursday, July 19 at 12:00. Poster Session 2 will take place from Thursday, July 19 at 13:15 through Friday, July 20 at 12:00. There will be two official poster networking events, which will take place on Wednesday, July 18 from 17:00 – 18:30 for Poster Session 1 and on Thursday, July 19 from 17:00 – 18:30 for Poster Session 2. The Posters will be located in Liffey B.

Posters for Poster Session 1 can be mounted beginning Wednesday, July 18 at 13:15 and dismantled as of Thursday, July 19 at 12:00. Posters for Poster Session 2 can be mounted beginning Thursday, July 19 at 13:15 and dismantled as of Friday, July 20 at 12:00. Material for mounting your poster is provided at the poster desk.

NOTE: All posters that have not been taken down by 12:00 will be dismantled and destroyed.

Accepted poster presenters were offered the opportunity to have their posters professionally printed and delivered to the meeting at no cost. If you have opted to take advantage of this service, kindly note you can pick up your poster(s) at the Poster Pick-Up Booth located in the Wicklow Foyer on Level 2. Posters that have been submitted will also be made available on the ISTH Academy website at <http://academy.isth.org>.

POSTERS

Poster Sessions 1 & 2

Liffey B (Level 1)

Poster Session 1		Posters PB001 to PB359	
Viewing	13:15 – 17:00	Wednesday, July 18, 2018	
	07:00 – 12:00	Thursday, July 19, 2018	
Mounting	13:15	Wednesday, July 18, 2018	
Poster Networking Event	17:00 – 18:30	Wednesday, July 18, 2018	
Dismounting	12:00	Thursday, July 19, 2018	
Poster Session 2		Posters PB360 to PB716	
Viewing	13:15 – 17:00	Thursday, July 19, 2018	
	07:00 – 12:00	Friday, July 20, 2018	
Mounting	13:15	Thursday, July 19, 2018	
Poster Networking Event	17:00 – 18:30	Thursday, July 19, 2018	
Dismounting	12:00	Friday, July 20, 2018	

POSTERS: SESSION 1

- PB001** **Platelet Chemokine Receptor CXCR7 Mediates an Anti-thrombotic and Anti-thromboinflammatory Effect**
M. Chatterjee, M. Manke, M. Cebo, J. Rheinlaender, A. Witte, T. Schäffer, M. Lämmerhofer, O. Borst, M. Gawaz (Germany)
- PB002** **Ticagrelor Inhibits Platelet-induced Formation of Neutrophil Extracellular Traps**
I.C. Moschonas, K.M. Hansson, D. Stakos, A.D. Tselepis (Greece)
- PB003** **Differential Effects of PDE3 and -5 Inhibitors on Thrombus Formation on Collagen versus Inflamed Endothelium**
D.M. Coenen, H.J. Albers, A.D. van der Meer, J.M.E.M. Cosemans (the Netherlands)
- PB005** **Effects of Aspirin and Rivaroxaban Treatment on Murine Arterial Vessel Wall Remodelling and Thrombus Activity**
M. Karel, T. Mastenbroek, M. Nagy, D. Coenen, W. Chaouyâ, A. Brouns, J. Debets, P. Leenders, H. van Essen, R. van Oerle, S. Heitmeier, H. Spronk, J. Heemskerk, M. Kuijpers, J. Cosemans (the Netherlands)



- PB006 Association of PEAR1 Gene Variant with Platelet Reactivity and Clinical Outcomes in Patients Undergoing Stenting and Treated with Aspirin and Clopidogrel**
K. Xu, N. Chan, F. Wang, L. Yang, H. Zhu, J. Li, J. Zhang, Y. Fan, J. Chen, L. Xu, L. Ying, X. Hu, S. Ye, C. Li (China)
- PB007 Beta-1,4-galactosyltransferase 2 c.909C>T Gene Variant Is Predictive of On-clopidogrel Platelet Reactivity**
T. Belleville-Rolland, N. Pallet, A. Savalle, M. Lejeune, L. Mauge, S. Bertil, M.-A. Lorient, P. Gaussem (France)
- PB008 High On-treatment Platelet Reactivity (HTPR) on Clopidogrel but Not on Novel P2Y12 Antagonists in Patients with ACS Undergoing PCI - Single Centre Study**
J. Staško, R. Šimonová, M. Samoš, J. Sokol, L. Stančiaková, I. Škorňová, T. Simurda, P. Kubisz (Slovakia)
- PB009 Detection of Anthocyanins Effects to Alleviating Thrombotic Risks in Comparison to Aspirin**
A. Gaiz, A. Kundur, S. Mosawy, N. Colson, I. Singh (Iraq)
- PB011 Assessment of Clopidogrel Response in Patients with Prior Atherothrombotic Events**
Z. Kaya, P. Özen, A.P. Nas, H. Batur Çağlayan, G. Aydoğdu Taçoy, B. Nazlıel (Turkey)
- PB013 Assessment of Platelet Reactivity with Multiple Electrode Impedance Aggregometry (MEA) in Patients Receiving Ticagrelor**
D. Dineva, I. Paskaleva (Bulgaria)
- PB014 Results of Platelet Aggregation Testing by Light Transmission Aggregometry using Drug Specific Agonists in Patients Taking Antiplatelet Therapy**
S. Margetić, N. Vrkić, B. Getaldic, D. Ruzic Ferenc, I. Vuga (Croatia)
- PB015 Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Atherosclerotic Carotid Stenosis: A Systematic Review of the Literature**
S. Murphy, R. Naylor, J.-B. Ricco, H. Sillesen, S. Kakkos, A. Halliday, G. de Borst, M. Vega de Ceniga, G. Hamilton, D. McCabe (Ireland)
- PB016 The Original Algorithm for Platelet Functional and Molecular Genetic Analysis to Optimize Antiplatelet Therapy in Outpatients with Peripheral Artery Diseases**
O. Sirotkina, N. Surint, A. Topanova, T. Vavilova (Russian Federation)
- PB017 Impact of Time-to-treatment on Freedom-from-relapse for Steroid-Refractory Immune Thrombocytopenia**
P. Vishnu, W.A. Hammond, E.M. Rodriguez, Z. Li, C.E. Rivera (United States)
- PB018 Guidance on the Diagnosis and Management of PT-VWD: A Project from the Platelet Physiology Subcommittee of the ISTH**
M. Othman, P. Gresele (Canada)
- PB019 PK Simulation of Avatrombopag-induced Increases in Platelet Counts with Redosing in Patients with Thrombocytopenia and Chronic Liver Disease**
S. Hayes, C. Farrell, K. Aggarwal, M. Vredenburg, L.F. Allen (United States)

POSTERS

- PB020** **Exploratory Analyses of the Efficacy of Avatrombopag versus Placebo from 2 Phase 3 Studies Using Alternate Baseline Platelet Count Cohorts and an Alternate Secondary Efficacy Endpoint**
F. Poordad, L. Allen, K. Aggarwal, M. Vredenburg, W. Tian, N. Terrault (United States)
- PB021** **Influence of Preoperative Platelet Activity on Coagulation and Blood Loss in Large Orthopedic Surgery**
I. Antropova, B. Yushkov, I. Shlykov, E. Volokitina (Russian Federation)
- PB022** **Superiority of Avatrombopag to Placebo in Increasing Platelet Counts and Reducing Platelet Transfusions in Patients with Chronic Liver Disease-associated Thrombocytopenia Undergoing Scheduled Procedures - Pooled Analysis of 2 Randomized Phase 3 Studies**
F. Poordad, L.F. Allen, K. Aggarwal, M. Vredenburg, N. Alkhouri (United States)
- PB023** **Atypical Presentations of RUNX1 Associated Familial Platelet Disorder with Predisposition to Myeloid Malignancy (FPDMM)**
C. Ward, M.-C. Morel-Kopp, C. Tang, D. Rabbolini, W. Stevenson (Australia)
- PB024** **Population PK/PD Modeling of Avatrombopag in Patients with Thrombocytopenia and Chronic Liver Disease - Guided Phase 3 Dose Selection**
M. Nomoto, Z. Hussein, K. Aggarwal, M. Vredenburg, L.F. Allen (United States)
- PB025** **Gray Platelet Syndrome Variant: Combined Alpha Granule, Dense Granule, and GPVI Deficiency**
E. Salazar, P. Monroig-Bosque, L. Rice (United States)
- PB026** **Bloody Diarrhea with Thrombocytopenia in Male Children: Think of Wiskott Aldrich Syndrome**
D. Suri, A. Kumar Jindal, Rashmi, J. Kumar Shandilya, P. Vignesh, J. Ahluwalia, A. Gupta, A. Rawat, S. Singh (India)
- PB027** **Pseudothrombocytopenia: Beyond Platelets Aggregates**
A. Carmo, N. Costa e Silva, M. Gomes (Portugal)
- PB028** **Coagulation Abnormalities in Dengue and Dengue Hemorrhagic Fever Patients in Pakistan**
J. Hassan, M. Borhany, M. Abid, N. Fatima, T. Shamsi (Pakistan)
- PB030** **Acquired Platelet Function Defect and Moderate Cutaneous Bleeding in a Patient on Treatment with a Leukotriene Receptor Antagonist for Asthma**
M. Marchetti, T. Lerede, M. Testa, S. Brevi, S. Gamba, A. Falanga (Italy)
- PB031** **Pelvic Hematoma Secondary to Glanzmann's Thrombasthenia: A Case Report**
S.L. Hon, J. Sathar, V. Selvaratham, F. Leow, M. Ganesalingam (Malaysia)
- PB032** **Health Related Quality of Life Assessment in Patients with Glanzmann Thrombasthenia from Selected Regions of Pakistan**
M.Y.J. Siddiqi, A. Naz, A. Najmuddin, A. Imran, T.S. Shamsi (Pakistan)



- PB033 Platelet's Disorder in a Case of Chronic Lymphocytic Leukemia**
C. Lodigiani, I. Quaglia, P. Ferrazzi, L. Librè, M. Bacci (Italy)
- PB034 Platelet CXCL14 Regulates Thrombotic Function and Influences Clinical Outcome in Coronary Artery Disease**
A. Witte, D. Rath, M. Gawaz (Germany)
- PB035 Dichotomous Cytosolic Mobilization of Calcium, Sodium and Potassium Ions during Procoagulant COAT Platelet Formation**
A. Aliotta, D. Bertaglia Calderara, L. Alberio (Switzerland)
- PB036 Emerging Value of Platelet Function Testing at Predicting the Risk of Recurrent Vascular Events and Outcomes after TIA/Ischemic Stroke: A Systematic Review of the Literature**
S.T. Lim, S. Murphy, I. Fernandez-Cadenas, J. Montaner, V. Thijs, L. Marquardt, P. Kelly, P. Bath, G. Ford, B. Norrving, D. Cox, D. McCabe, OATS-I (Ireland)
- PB037 Lysis of Blood Cells by Arachidonic Acid Cause ADP-dependent Platelet Activation Responses in Platelet Function Tests using Whole Blood**
S. Ramstrom (Sweden)
- PB038 Assessment of Platelet Count Standardization in Platelet-rich Plasma for Platelet Function Testing by Light Transmission Aggregometry**
M. Dixon, J. Kotha, L.K. Jennings (United States)
- PB039 Kinetic Application of Flow Cytometry for Patients with Unknown Bleeding Disorders: The Underestimated Value of Mepacrine**
G. Manukjan, O. Andres, H. Schulze (Germany)
- PB040 The Gp1ba-Cre Transgenic Mouse: A New Model to Delineate Platelet and Leukocyte Functions**
Z. Nagy, T. Vögtle, M.J. Geer, S. Heising, G. Di Nunzio, J. Mori, R. Gareus, G. Desanti, A. Mazharian, Y.A. Senis (United Kingdom)
- PB041 The Fluidity of Platelet Membrane an Important Parameter for Platelet Function in Chronic Myeloproliferative Neoplasms Patients**
V.M. Popov, H. Bumbea, I. Dumitru, B.M. Matei, C. Oktaviani Matei, M. Omer, M. Andreescu, O. Patrinoiu, F. Mihai, T. Savopol, A.M. Vladareanu, E. Kovacs, M.G. Moisescu (Romania)
- PB042 The Effect of FXa on Platelet Activation, in vitro**
S. Papadaki, A. Tselepis (Greece)
- PB043 Functional Validation of microRNA-126-3p as a Platelet Reactivity Regulator using Human Progenitor Cells**
A. Garcia, S. Dunoyer-Geindre, V. Zapilko, S. Nolli, J.-L. Reny, P. Fontana (Switzerland)
- PB044 Assessment of Light Transmission Aggregometry on the Routine Coagulation Analyzer Siemens CS-2500 using CE-marked Agonists from Hyphen Biomed**
V.-E. Brett, B. Pougault, A. Guy, S. Castet, Y. Huguenin, A. Ryman, C. James, M. Fiore (France)

POSTERS

- PB045** **Lack of Correlation between Verifynow and TEG-platelet Mapping in Ventricular Assist Device Patients**
E. Salazar (United States)
- PB047** **Influence of Sample Platelet Count on Three Common Platelet Function Tests: A Comparative Study**
N. Boknäs, A.S. Macwan, A.L. Södergren, S. Ramström (Sweden)
- PB048** **Comparison of PAC-1 and α -fibrinogen Antibody Binding to Platelet Subpopulations**
A.L. Södergren, S. Ramström (Sweden)
- PB049** **Assessment of Neonatal Platelet Granule Trafficking and Shear-induced Platelet Activation in Neonatal Peripheral and Cord Blood**
A. Ngo, J. Sheriff, K. Jones, A. Rocheleau, A. Mitrugno, J. Aslan, S. Worthington, A. Cox, M. Recht, M. Nieman, L. Malone, A. Zigomalas, W. Bahou, D. Bluestein, O. McCarty, K. Haley (United States)
- PB051** **On the Potential Use of Morphometrics as a Biomarker for Platelet Contractility**
S. Lickert, M. Kenny, V. Vogel, I. Schoen (Ireland)
- PB052** **Impact of Cigarette Smoking on Platelet Count, Mean Platelet Volume, Platelet Aggregability and Platelet Distribution Width of Male Cigarette Smokers in Calabar, Cross River State, Nigeria**
I.M. Okafor, I. Ngusha, U. Udo (Nigeria)
- PB053** **Platelets Role in the Plasma Clotting is Not Limited to Providing a Lipid Surface**
A. Balandina, N. Petrunina, E. Koltsova, F. Ataulakhanov (Russian Federation)
- PB054** **Stability of Platelet Function in Healthy Individuals over a One-year Period**
D. Huskens, J. Konings, Y. Sang, B. de Laat, M. Roest, H. Kelchtermans (the Netherlands)
- PB055** **The Canine Platelet Secretome (CAPS): Proteomic Analysis of Thrombin-stimulated Release**
S.E. Cremer, J.L. Catalfamo, A.T. Kristensen, R.A.N. Goggs, M.B. Brooks (Denmark)
- PB056** **Immunofluorescence Analysis on a Blood Smear - Validation of Stability of Blood Smears during Storage**
K. Althaus, L. Lex, J. Wesche, A. Greinacher (Germany)
- PB057** **Mean Platelet Volume Positively Correlates with Uterine Volume after Menopause, Except Myomas Presence**
B. Bajteková, S. Wimmerová, V. Rusnáková (Slovakia)
- PB058** **Clinical Experience Evaluating Platelet Function by Whole Blood Impedance Lumi-Aggregometry in a Pediatric Population**
A. Obstfeld, B. Doshi, M.P. Lambert (United States)



- PB059** **Functional Activity of Platelets in Patients with Kasabach-Merritt Syndrome**
E. Gluhanyuk, A. Ignatova, A. Fedotov, A. Karelin, D. Nikolaeva, E. Orekhova, L. Khachatryan, M. Panteleev (Russian Federation)
- PB060** **Characterisation of a Haemocompatible Dual in-line Reciprocating Micropump and Mixer for on-chip Assessment of Experimental Anti-platelet Agents**
R. Brazilek, C. Szydzik, F. Akbaridoust, M. Knoerzer, I. Marusic, H. Nandurkar, A. Mitchell, J. Hamilton, W. Nesbitt (Australia)
- PB061** **Flow Cytometric Analysis of Platelet Function in Patients on Antiplatelet Therapy and Suspected Thrombocytopenia**
D. Huskens, M. Roest, L. Florin, B. de Laat, K. Devreese (the Netherlands)
- PB062** **Characterization of Platelet Function with Flow Cytometry for Bleeding Risk Evaluation in Hematological Disorders**
A. Ignatova, E. Suntsova, D. Polokhov, V. Ptushkin, E. Nikitin, P. Zharkov, D. Fedorova, A. Maschan, G. Novichkova, M. Panteleev (Russian Federation)
- PB063** **Study of Leukocyte-platelet Aggregates by Flow Cytometry in Patients with Coronary Artery Disease**
A. Ermakov, O. Sirotkina, T. Vavilova, L. Gaykovaya (Russian Federation)
- PB064** **Evaluation of a New Range of Platelet Agonists for the Diagnosis of Inherited or Acquired Platelet Dysfunctions**
M.-C. Alessi, O. Georgelin, M. Ibrahim, S. Harvel, S. Beaufils, E. Maurer, P. Ohlmann (France)
- PB065** **Usefulness of Optical Aggregometry and Flow Cytometric Studies as a Complementary Tools in Patients with Acquired Platelet Defects (APD)**
M.F. Alberto, M. Asensio, E.I. Bermejo, M. Agazzoni, L. Romero, A. Sanchez-Luceros (Argentina)
- PB066** **Platelet Function in Polycythemia Vera and Primary Myelofibrosis Using Multiple Electrode Aggregometry**
N.S. Nytofte, O.B. Pedersen, H.C. Hasselbalch (Denmark)
- PB067** **Platelet to Lymphocyte Ratio was Significantly Lower for Slovak Postmenopausal Women Born from November to April, Except those with Leiomyoma**
B. Bajteková, S. Wimmerová, V. Rusnáková (Slovakia)
- PB068** **Mild Thrombocytopenia and Bleeding Diathesis in Mice Lacking the PLT/MPV-associated F-BAR Protein PACSIN2**
N. Eaton, C. Drew, J. Wieser, W. Kahr, M. Plomann, H. Falet (United States)
- PB069** **A Novel Role of LASSBio-788 in Inhibiting NF- κ B Mediated Signaling in Platelet of Hypercholesterolemic Rats: Would Be New Antiplatelet Agent?**
N.A.V. Motta, G.F. Lima, E. Barreiro, A. Kümmerle, F.C.F. Brito, Laboratório de Farmacologia Experimental (LAFE) (Brazil)

POSTERS

- PB070** **New Clinicopathologic Finding in a Patient with Acquired Amegakaryocytic Thrombocytopenia Treated with Thrombopoietin Receptor Agonist Therapy**
R. Smith, S. Zandi, Z. Liederman, M. Xu, G. Lim, H. Ghaffar, H. Ni, M. Sholzberg (Canada)
- PB071** **Antibody Mediated Glycan Modification on Platelets and Megakaryocytes: A Potential Role in Platelet Destruction in Autoimmune Thrombocytopenia**
I. Marini, R. Jouni, F. Rigoni, T. Bakchoul (Germany)
- PB072** **ThromboGenomics: High Throughput Sequencing in Patients with Bleeding and Platelet Disorders**
K. Downes, K. Freson, K. Gomez (United Kingdom)
- PB073** **Mitochondria-dependent Necrosis Is Promoted in Wiscott-Aldrich Syndrome Platelets as a Result of the Abnormal Surface-to-Volume Ratio**
S. Obydenyi, E. Artemenko, A. Sveshnikova, A. Ignatova, G. Novichkova, A. Maschan, A. Shcherbina, M. Panteleev (Russian Federation)
- PB074** **Septic Conditions Modulate the Level of miRNAs in Platelets and Megakaryocytes via Altered Dicer Level**
Z. Fejes, B. Szilágyi, T. Orosz, Z. Zimmerman, S. Póliska, G. Nagy, J. Kappelmayer, B. Nagy Jr. (Hungary)
- PB075** **Evidence of a Dominant Negative Effect of Gain-of-Function ITGB3 Mutations over Loss-of Function Mutations in Variant Glanzmann Thrombasthenia**
L. Bury, E. Zetterberg, E. Leinoe, E. Falcinelli, A. Marturano, G. Manni, A.T. Nurden, P. Gresele (Italy)
- PB076** **Bleeding Diathesis Associated with Severe Acquired Platelet Dysfunction and Overproduction of Cyclic AMP in Two Patients with Hematologic Malignancies**
A. Lecchi, E.A. Femia, S. La Marca, A. Artoni, F. Onida, F. Peyvandi, M. Cattaneo (Italy)
- PB077** **In-silico Prediction of Molecular Mass Distance Dependent Changes in Binding Energies between von Willebrand Factor and Platelet Membrane Glycoprotein (GP) Iba in Wild Type and G233V Mutant**
S. Goto, N. Tamura, K. Ayabe, H. Yabushita, H. Oka, S. Goto (Japan)
- PB078** **Molecular Diagnosis of Inherited Platelet Disorders by Analysis of the MYH9 and the Genes Encoding the GB1b-IX-V Complex in an Irish Cohort**
R. Campbell, S. Mc Namara, L. Dempsey, M. Byrne, K. Ryan, B. White, N.M. O'Connell, C. Keenan (Ireland)
- PB079** **Investigation of Polymorphic Variations in Glutathione S Transferase Genes among Immune Thrombocytopenia Patients in Pakistan**
S.N. Mukry, A. Arshad, A. Shahni, T.S. Shamsi (Pakistan)
- PB081** **CD8 T Cell-mediated Platelet Clearance Does Not Occur via Traditional Cytotoxic Protein Killing**
C. Maier, S. Patel, A. Bennett, S. Stowell (United States)



- PB082** **Human Platelets Labeled at Multiple Biotin Densities: A Promising Approach for Monitoring in vivo Platelet Survival in Clinical Trials**
C. Ravanat, V. Heim, A. Pong  rard, A. Dupuis, C. Gachet (France)
- PB083** **Quantitative Alteration of Vesicle Associated miRs and RISC Complex Reflect Platelet Concentrate Molecular Pattern during Storage as Platelets Activity Model**
V. Kishenko, K. Kondratov, A. Fedorov, O. Sirotkina (Russian Federation)
- PB084** **Improving Transfusion Safety by Implementing Platelet Bacterial Screening in a Resource-limited Country**
F. Karim, B. Moiz (Pakistan)
- PB089** **Compensatory Effect of Fibrinogen in Patient with Bone Marrow Aplasia, Septic Shock and Severe Thrombocytopenia Guided by Thromboelastometry: A Case Report**
T. Crochemore, F. Savioli, C. Pessoa, A. Resende, E. Casaroto, L. Bernz, R. Narciso, F. Souto (Brazil)
- PB090** **A Novel Murine Model of Immune Thrombocytopenia Induced by Immunized CD41 Knockout Mice**
X. Li, S. Wang, X. Zuo, M. Hou, J. Peng (China)
- PB091** **Polyphosphate Is Concentrated in the Core of Platelet Aggregates**
C. Clark, S. de Maat, A. Barendrecht, C. Maas (the Netherlands)
- PB092** **Effects of Bothrops jararaca Venom on Platelet Aggregation, Secretion and Protein synthesis**
J.G. Rosa, M.L. Santoro (Brazil)
- PB093** **Effect of Anorexigenic Peptide Obestatin on Platelet Aggregation at White Rat with Overweight in vitro Experiments**
M. Golubeva, E. Khirazova (Russian Federation)
- PB095** **Janus Kinase 3 (JAK3)-dependent Signaling Is Critical to Ca²⁺-dependent Platelet Activation and Thrombus Formation**
M. Manke, S. Geue, P. M  nzer, B. Walker-Allgaier, D. Eib  ler, F. Lang, M. Gawaz, O. Borst (Germany)
- PB096** **An Intermediate State of Integrin α IIb β 3 Mediates Platelet Aggregation under Disturbed Flow**
Y. Chen, L. Ju, S. Jackson, C. Zhu (United States)
- PB097** **In vivo Imaging Reveals the Regulation of Thrombus Formation by ERK and PKA Activity**
T. Hiratsuka, T. Sano, M. Matsuda (Japan)
- PB098** **Role of Protease-activated Receptor 4 in Regulating Platelet Dense Granule Release**
T. Chu, R. Rigg, L. Healy, A. Ngo, A. Mitrugno, J. Aslan, A. Gruber, C. Lindsley, M. Duvernay, H. Hamm, O. McCarty (United States)
- PB099** **Modulation of Smooth Muscle Cell Phenotype by Platelet Adhesion to Endothelial Cells in Type 2 Diabetes Mellitus**
M. Luo, M. Zeng, Y. Lin, D. Fang, J. Wu (China)

POSTERS

- PB100** **New Regulatory Mechanisms of RhoA in Platelets**
S. Comer, Z. Nagy, S. Gambaryan, U. Walter, R. Zahedi, K. Jurk, A. Smolenski (Ireland)
- PB101** **Platelet CLEC-2 Ligation Offers Critical Enhancement for ADP and Thrombin-induced Activation via Synergy between Intracellular Signalling Pathways of CLEC-2 and G-protein Coupled Receptors**
A. Martyanov, M. Pantelev, A. Sveshnikova (Russian Federation)
- PB102** **Identification of Platelet Intracellular Signaling Pathways Controlling the Reversible and Irreversible Platelet Aggregation**
D. Morozova, A. Demianova, M. Canault, M. Pantelev, M.C. Alessi, A. Sveshnikova (Russian Federation)
- PB103** **S100A9 Activates Platelets via RAGE**
S. von Ungern-Sternberg, K. Posavec, D. Heinzmann, M. Gramlich, M. Gawaz, P. Seizer (Germany)
- PB104** **Antidepressant Suppresses Platelet Activation via Collagen Receptor**
N. Sugita, H. Hirakata, T. Murai (Japan)
- PB105** **Induced Apoptosis-like Changes Caused by Sirtinol, a Pharmacologic Inhibitor of Sirt1/2, in Human Platelets**
R.L. Mallick, S. Kumari, S.N. Chaurasia, D. Dash (Nepal)
- PB106** **Tumor Necrosis Factor Receptor Associated Factor 6 (TRAF6) in the Pathogenesis of Immune Thrombocytopenia**
V. Asoglu, E. Umit, M. Demir (Turkey)
- PB107** **Patients with Aortic Stenosis Have von Willebrand Factor Abnormalities and Aberrant Angiogenesis in BOEC**
S.N. Selvam, M. Bowman, M. Inglis, J. Grabell, L. Casey, L. Thibeault, A.M. Johri, P. James (Canada)
- PB108** **High-dose Dexamethasone Alters the Increase in IL-16 Level in Adult Immune Thrombocytopenia**
X. Zuo, X. Wang, X. Li, L. Li, M. Hou, J. Peng (China)
- PB109** **Progranulin Facilitates the Increase of Platelet Count in Immune Thrombocytopenia**
X. Zuo, Y. Yu, X. Li, M. Hou, J. Peng (China)
- PB110** **The Aberrant Expression of microRNAs in B Lymphocytes of Patients with Immune Thrombocytopenia**
X. Jia, B. Zuo, Y. He (China)
- PB111** **A Novel Model using Protein C-to-INR Ratio to Predict Short-term Mortality in Cirrhosis**
A. Patil, C. Bihari (India)
- PB112** **Increased Cytotoxic Potential of CD8 T Cells in Patients with Immune Thrombocytopenia**
J.R. Vrbensky, I. Nazy, N. Ivetic, R. Clare, A.M. Jaffer, J.G. Kelton, D.M. Arnold (Canada)



- PB113** **Gene Expression of Vanin-1 (VNN-1) in Egyptian Adults with Immune Thrombocytopenia (ITP): A Single Center Experience**
D. El Demerdash, R.E. Hussein, N. Abo Elsoad, M. Mattar, A. Ayad (Egypt)
- PB115** **Real-life Bleeding Risk of Anti-factor Xa Direct Oral Inhibitors; Does Prothrombin Complex Concentrate Work?**
J. Graham, P. Gupta, R. Sivers, B. Badugama, D. Sutton, D. Chandra (United Kingdom)
- PB116** **A 9 Year National Study of Patients with Acquired Haemophilia A**
D. Thakkar, C. McDermott, C.L. Robertson, R.C. Tait, C. Bagot, J.R. Rodgers, H.G. Watson, M.M. Khan, R. Kerr, J. Ward, J. Craig, J.A.M. Anderson (United Kingdom)
- PB117** **Is the Profile of Patients with Intracranial Hemorrhage Changing?**
S. Reeves, C. Gray, J. Blundell (United Kingdom)
- PB118** **Hospital Admissions due to Bleeding Events under Direct Oral Anticoagulants**
V. Grilo, A.G. Fonseca (Portugal)
- PB120** **Noonan Syndrome and Bleeding Disorders: An Overview of Current Diagnostic Management**
P.E.G. van der Pas, E.J. Huisman, I.H.I.M. Hollink, C.M. Zwaan, C.H. van Ommen, M.H. Cnossen (the Netherlands)
- PB121** **Long-Term Follow-up of Children on Prophylaxis for Severe Factor VII Deficiency in Lebanon**
R.A. Farah, H.Z. Farhat, D. Buthiau, M. Giansily-Blaizot (Lebanon)
- PB122** **Clinical Presentations and Diagnostic Algorithm of Neonatal FXIII-deficiency**
M. Naderi, N. Cohan, G. Miri-Aliabad, M. Karimi (Iran)
- PB123** **Effectiveness of Pediatric Bleeding Questionnaire in Hemorrhagic Disorders**
A.C. Ramirez Cazares, L.M. Nuño Vazquez, J.E. Colunga Pedraza, D. Gomez Gonzalez, M. Quiroga Treviño, L. Villarreal Martinez (Mexico)
- PB124** **Surgical Management of Rare Factor Deficiencies**
N. Eroglu, E. Erduran, A. Bahadır, H. Saruhan (Turkey)
- PB125** **Assesment of Thirty Six Patients with Rare Factor Deficiency:Single-centre Results from Turkey**
M. Söker, H. Uzel, K. Öncel, S. Söker (Turkey)
- PB126** **Anti-fviii igg4 Antibodies in Patients with Hemophilia A without Inhibitors during Factor VIII Replacement: Results from the Hemfil Cohort Study**
L.M. Moura de Oliveira, D. Goncalves Chaves, L. Lemos Jardim, A.C. Simoes e Silva, M.A. Portugal Santana, C. Carm-Deelder, S. Meireles Rezende (Brazil)
- PB127** **Plasma Profile of Platelet Auto-antibodies in Patients with Thrombocytopenia in Pregnancy**
W. Shen, H. Qin (China)

POSTERS

- PB128** **Lifetime Bleeding History with Modified ISTH-BAT Survey in 2,339 Individuals Establishes Population Prevalence Estimates**
M.-H. Chen, B. Rodriguez, C. Song, A. Lachapelle, C. Wallace de Melendez, P. Armstrong, M. Chan, T. Warner, A. Johnson (United States)
- PB129** **A Cohort Study on Women with Congenital Factor XIII Deficiency in Iran**
M. Naderi, M. Karimi, S. Haghpanah, G. Miri-Aliabad, H. Tavoosi (Iran)
- PB130** **First Look at My Life Our Future Carrier Data from a Pilot Site**
J. Puetz, L. Johnson, C. Hugge, P. Buchanan (United States)
- PB131** **Translation and Validation of the Pictorial Blood Loss Assessment Chart (PBAC) in Arabic**
O. Kaabia, F. Letaief, A. Brahim, H. Skouri, M. Bibi (Tunisia)
- PB132** **Diagnosis Value of Screening Tools for Hemostasis Disorders in Women Consulting for Prolonged Menstruation with Normal Pelvic Exam**
O. Kaabia, F. Letaief, H. Abbessi, I. Ghachem, A. Brahim, S. Hadhri, H. Skouri (Tunisia)
- PB133** **Clinical Screening for Underlying Bleeding Disorder in Nigerian Women**
T. Nwagha, E. Ugwu, H. Okoye, A. Ugwu, Bleeding Disorder in Nigerian Women (Nigeria)
- PB134** **Hemostasis Disorders in Tunisian Women with Non Organic Menorrhagia: A Case Control Pilot Study**
O. Kaabia, F. Letaief, H. Abbessi, A. Brahim, I. Ghachem, S. Hadhri, H. Skouri (Tunisia)
- PB135** **Improving the Gynaecological Management of Women with Bleeding or Thrombotic Disorders by Multi-professional Out-patient Care**
K.M. Musgrave, T.T. Biss, J. Speedie, D. Mansour (United Kingdom)
- PB136** **A Woman's Life-long Bleeding Condition: Diagnostic Dilemma and Expert Opinion**
R. Winikoff, M. Othman (Canada)
- PB137** **Thrombocytopenia in Pregnancy: The Role of Hemostasis Laboratory for Diagnosis and Management of Acute Fatty Liver of Pregnancy**
I. Cuomo, M. Scannapieco, G. Rescigno (Italy)
- PB138** **Quantitative Systems Pharmacology (QSP) to Predict Thrombin Generation with Concomitant AT Lowering and Factor Replacement or Bypassing Agents**
G. Sridharan, S. Tsour, K. Qian, J. Liu, Q. Lu, C. Benson, K. Madigan, S. Huang (United States)
- PB139** **Does Hemophilia Slow Down the Development of Liver Fibrosis?**
M.-A. van Dievoet, I. Leclercq, C. Hermans, C. Lambert, Y. Horsmans, M. Jacquemin, S. Eeckhoudt (Belgium)
- PB140** **Geno- and Phenotype Correlate in Porcine Model of von Willebrand Disease Type 1 and Type 3**
H. Allerkamp, S. Lehner, M. Ekhlasi-Hundrieser, C. Detering, C. Wermes, C. Pfarrer, M. von Depka (Germany)



- PB141** **Pharmacokinetics and Safety of Subcutaneous rIX-FP Administration: Results from a Phase 1 Trial**
I. Pabinger, T. Lissitchkov, J. Roberts, W. Seifert, S. Puli, J. Ye, Y. Li (Austria)
- PB142** **Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B**
A. Branchini, M. Ferrarese, M. Pinotti, F. Bernardi, M. Morfini (Italy)
- PB143** **Engineering Regulatory T Cells to Block Inhibitor Formation**
D. Scott, J. Yoon, M. Abdeladhim, K. Parvathanen, A.-H. Zhang, Y. Kim (United States)
- PB144** **Novel Hyperactive FIX Variants and their Potential for Haemophilia B Gene Therapy**
A.-K. Urbanowitz, P. Milanov, P. Quade-Lyssy, D. Abriss, E. Seifried, J. Schütttrumpf, J. Schwäble (Germany)
- PB145** **Population Pharmacokinetic Analysis of Recombinant Fusion Protein Linking Coagulation Factor IX with Recombinant Albumin (rIX-FP) in Adult and Pediatric Patients with Severe Hemophilia B**
Y. Zhang, J. Roberts, T. Yuraszek, W. Seifert, A. Feussner, A. Brainsky, E. Santagostino, J. Sidhu (United States)
- PB146** **Plasma Extracellular Vesicles (EVs) and Their Correlation with Clinical Phenotype in Pediatric Patients with Severe Hemophilia A (SHA)**
M. Rand, S. Israels, H. Wang, E. McMillan-Ward, V. Blanchette, R. Nieuwland (Canada)
- PB147** **Pharmacokinetics of Recombinant Fusion Protein Linking Activated Factor VIIa to Human Albumin (rVIIa-FP) and Eptacog Alfa in Hemophilia Patients with Inhibitors**
J. Roberts, C. Joch, J. Ye, S. Puli, J. Mahlangu, E. Santagostino (Italy)
- PB148** **Circulating Biochemical Markers of Early Joint Bleeding: Validation Study in Humans**
X. Song, C. Enockson, L. Fogg, L. Boggio, M. Simpson, N. Hakobyan (United States)
- PB149** **APTT Reagent-specific Underestimation of N8-GP (Turoctocog Alfa Pegol) Activity Owing to Attenuated Thrombin Activation**
E. Persson, T. Foscolo (Denmark)
- PB150** **Comparison of rFIX Utilization and Bleed Rates in US Hemophilia B Patients on rIX-FP and Their Prior rFIX Drug**
M. Escobar, C. Leissing, S. Yan, G. Maro, G. Krishnarajah (United States)
- PB151** **Identifying Efficacious Thresholds for Bleeding Risk Reduction in Relation to Factor VIII Levels in Hemophilia A Patients Receiving rVIII-SingleChain**
P. Zhang, C. Fossier, J. Roberts, A. Brainsky, Y. Li, W. McKeand, J. Sidhu (United States)
- PB152** **Whole F8 and VWF Gene Sequencing using Next-generation Sequencing for Mutation-negative French and Canadian Hemophilia A Patients**
F. Lassalle, L. Jouan, L. Swystun, J. Gauthier, C. Zawadzki, J. Goudemand, S. Susen, G.-E. Rivard, D. Lillicrap (Canada)

POSTERS

- PB153** **Within-patient Comparison of Treatment Patterns before and after Switching to rFIXFc: A Report from the UK National Haemophilia Database**
M. Scott, H. Xiang, P. Collins, R. Liesner, C. Hay (United Kingdom)
- PB154** **Arthropathy and Joint Replacement Surgery in Patients with Hemophilia A (PwHA) in the US**
A. Patel, E. Yang, N. Engmann, R. Ko, K. Raimundo (United States)
- PB155** **Extended Half-life Factor Concentrate Use for Patients with Moderate and Severe Hemophilia among ATHN-affiliated U.S. Hemophilia Treatment Centers**
S.E. Croteau, D. Cheng, A.J. Cohen, C.E. Holmes, P.A. Kouides, L.J. Raffini, M. Silvey, C. Thornburg, A.P. Wheeler, E.J. Neufeld (United States)
- PB156** **Genetic Polymorphisms Contributing to the Pharmacokinetics of Factor VIII Concentrates**
B. Lunghi, S. Frusconi, S. Linari, G. Marchetti, F. Bernardi, G. Castaman, M. Morfini (Italy)
- PB157** **Real World Data Analysis of US Claims Database on Coagulation Factor VIII Expenditures in Patients with Hemophilia A: Standard Half-life vs. Extended Half-life Products**
D. Spurden, A. Chhabra, B. Tortella, P. Fogarty, E. Rubinstein, S. Harris, A. Pleil, J. Alvir (United States)
- PB158** **Measuring FIX-Activity of Nonacog Beta Pegol (N9-GP) in a One-stage Ellagic Acid Based Clot Assay on the ACL TOP 50 Series Instrument: A Two-site Study**
A. Khan, B. Wilkinson, K. Shishko, M. Hansen, M. Doyle, M. Triscott, M. Ezban (United States)
- PB159** **Phase 1/2 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics and Safety**
C.W. You, H. Levy, M. Lee, J. Park, S.-B. Hong, S. Kim, H.-J. Shin, D.Y. Kim, J.S. Kim, J.W. Han, S.-J. Kim (United States)
- PB160** **A Prospective Observational Study of Prophylaxis, ACTivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated with Antihemophilic Factor (Recombinant) in the US**
B. Konkle, D.V. Quon, L. Raffini, M. Recht, V. Radulescu, S.L. Carpenter, A. Dunn, M. Watt, J. Booth (United States)
- PB161** **Correlation of Factor Levels with Bleeding Phenotype in Non-severe Hemophilia**
J. Rejtő, G. Schuster, C. Feistritzer, P. Quehenberger, S. Hofer, O. Königsbrügge, E. Grilz, F. Posch, J. Gebhart, C. Ay, I. Pabinger (Austria)
- PB162** **The Effect of Inhibitors on Quality of Life and Pain in Adult Patients with Severe Haemophilia in the PROBE Cohort**
D. Noone, C. Chai-Adisaksopha, R. Curtis, N. Frick, M. Nichol, B. O'Mahony, D. Page, J. Stonebraker, A. Iorio, M.W. Skinner, PROBE (Ireland)
- PB163** **Efficacy and Safety of Recombinant Factor IX- Fusion Protein (rIX-FP) in Patients with Hemophilia B: Interim Results from an Ongoing Phase IIIb Extension Study**
E. Santagostino, I. Pabinger, A. Brainsky, Y. Li, W. Seifert (Italy)



- PB164** **Burden of Mild Hemophilia A: Systematic Literature Review**
F. Peyvandi, A. Lawal, M.R. Fasulo, D. Frame, B. Kim, M. Tavakkoli, M.C. Lee, W.Y. Wong (Italy)
- PB165** **Realworld Health Care Expenditure and Dispensation of Extended and Standard Half-life Recombinant Factor IX Products in Hemophilia B Patients**
D. Spurden, A. Chhabra, B. Tortella, P. Fogarty, E. Rubinstein, S. Harris, A. Pleil, J. Alvir (United States)
- PB166** **Expanding Communications on Hemophilia A Outcomes (ECHO) Study: Cross-sectional Analysis of Baseline Data**
C.R.M. Hay, M. Shima, M. Makris, V. Jiménez-Yuste, M.W. Skinner, J. Oldenburg, K. Fischer, E. Santagostino, S. von Mackensen, S. Rauchensteiner, N. Church, P. Mathew, S. Krassova, C.M. Kessler, on behalf of the ECHO Study Investigators (United Kingdom)
- PB167** **Inhibitor Incidence in Hemophilia A under Exclusive Use of a Third-generation Recombinant Factor VIII Concentrate: Results of the HEMFIL Cohort Study**
L. Lemos Jardim, D. Gonçalves Chaves, C. Brommonschenkel, M. Portugal Santana, M. Hermida Cerqueira, A. Prezoti, C. Santos Lorenzato, V. K Franco, J. van der Bom, S. Meireles Rezende (Brazil)
- PB168** **The Effect of Unmeasurable Endogenous Plasma Factor Activity Levels on Factor VIII Dosing in Patients with Severe Hemophilia A**
P. Chelle, A. McEneny King, A. Iorio, A.N. Edginton (Canada)
- PB169** **Pharmacokinetics of Extended Half-life FVIII Products after Recommended Dosing in a Pediatric Hemophilia A Population**
T. Jacobs, P. Barker, A. McEneny-King, E. Neufeld, J. Panetta, U. Reiss (United States)
- PB171** **Are Current Therapeutic Strategies with Conventional Products Sufficient to Manage the Burden of Haemophilia in Italy?**
R.I. Mazzucchelli, P. Kritikou, K.-J. Myren, J. O'Hara (Italy)
- PB172** **Practical Considerations in Choosing a Cost-effective and-Efficient Solution for Prophylaxis in Haemophilia**
M. Serban, E. Ursu, A. Traila, P. Serban, T. Opait-Dugan, M. Dutescu, D. Puiuiescu, L. Ritli, C. Jinca, E. Boeriu, J.M. Patrascu, S. Cerbu, S. Arghirescu (Romania)
- PB173** **rVIII-SingleChain in Surgical Prophylaxis: Efficacy and Safety in 43 Surgeries**
J. Mahlangu, F. Abdul Karim, C. Djambas Khayat, J. Ong, S. P'Ng, J. Oldenburg, A. Brainsky, S. Lucas, I. Pabinger, for the Affinity Study Group (South Africa)
- PB174** **Estimation of Simoctocog Alfa and Octocog Alfa Activity using One-stage and Chromogenic Assays in Routine Laboratory Practice: Results of a Comparative International Field Study**
T. Vicente, J. Verstedden, C. Borgvall, J. Bichler, O. Walter, S. Tiefenbacher, L. Belyanskaya (Switzerland)
- PB175** **Correlation between the Half-life of GlycoPEGylated Recombinant FVIII (N8-GP) and von Willebrand Factor - Results from Phase 3 Clinical Trials**
P. Chowdary, M. Carcao, W.-H.O. Clausen, P.A. Holme, J. Møss, A. Tosetto, A. Wheeler, E. Santagostino (United Kingdom)

POSTERS

- PB176** **Chronic Pain in Adults with Severe Haemophilia A and B**
J. O'Hara, P. Kritikou, A. Willemze, K.-J. Myrén, D. Noone, K. Khair (United Kingdom)
- PB177** **Disease Burden and Remaining Unmet Need in Patients with Hemophilia A Treated with Primary Prophylaxis**
J. O'Hara, F. Castro, S. O'Hara, J. Black, S. Chaplin, L. Ruiz-Casas, R. Hampton, C. Sima (United Kingdom)
- PB178** **Landscape of Intron 1 and Intron 22 Inversions in Severe Hemophilia A Patients and Inhibitor Development**
L.W. Zuccherato, S. Maria Eloi Santos, L.L. Jardim, D.G. Chaves, S.M. Rezende (Brazil)
- PB179** **The Bone Disease in Haemophilia: The Role of von Willebrand Factor, Factor VIII and Thrombin**
S. Lancellotti, M. Sacco, G. Battafarano, F. Berruti, R. De Cristofaro, A. Del Fattore (Italy)
- PB180** **Long Term Safety and Efficacy of rVIII-SingleChain in Previously Treated Patients with Severe Hemophilia A: Intermediate Results of an Extension Study**
J. Mahlangu, F. Abdul Karim, O. Stasyshyn, B. Korczowski, A. Brainsky, S. Lucas, Y. Li, I. Pabinger, for the AFFINITY Investigators (Austria)
- PB181** **Standardized Determination of FVIII Inhibitors with the Improved FVIII INH Kit**
L. Rosenmayr, L. Wagner, N.B. Binder (Austria)
- PB182** **Decrease in Joint Bleeding Rates Compared with Prior Prophylaxis in Patients with Hemophilia A Treated with BAY 94-9027**
M.E. Mancuso, S. Rangarajan, C. Négrier, M. Wang, M. Maas Enriquez (Italy)
- PB183** **Systematic Review of Efficacy and Factor Consumption of Recombinant Factor IX Products for Prophylactic Treatment of Hemophilia B**
E. Santagostino, S. Yan, T. Matsushita, L. Alberio, J. Davis (Italy)
- PB184** **Comparing Projected Consumption and Cost of Recombinant Factor VIII-SingleChain with Other Recombinant Factor VIII Products in the United States**
S. Yan, R. Hutcheson, L. Stern, G. Krishnarajah (United States)
- PB185** **Joint and Functional Assessment Following Secondary and Tertiary Prophylaxis in PWH who were Previously Receiving Episodic on Demand Factor Replacement Infrequently**
A. Dutta, S. Kakati, H. Kaur, S. Kar (India)
- PB186** **Validation of an Instrument for Nursing Consultation to the Person with Hemophilia**
I. Sangi, R. Camelo, I. Costa, N. Costa, F. Lima, T. Guimaraes (Brazil)
- PB187** **Epidemiological Survey and Audit of Socio-demographic Characteristics of Patients with Haemophilia and other Congenital Bleeding Disorders**
T. Nwagha, M. Adediran, H. Okoye (Nigeria)



- PB188** **Development of a FVIII Antigen Assay to Quantify B-domain Deleted FVIII Antigen in Human Plasma**
M. Robinson, C. Tudan, S. Tiefenbacher (United States)
- PB189** **Exploring Regional Variations in the Cross-cultural, International Implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) Study**
C. Chai-Adisaksopha, D. Noone, R. Curtis, N. Frick, M. Nichol, B. O'Mahony, D. Page, J. Stonebraker, A. Iorio, M.W. Skinner, PROBE (Canada)
- PB190** **Expanding Communications on Hemophilia A Outcomes (ECHO) Study: Choice of Patient-reported Outcomes (PROs) and Feasibility Testing**
S. von Mackensen, C.R.M. Hay, M. Shima, M. Makris, V. Jiménez-Yuste, J. Oldenburg, K. Fischer, E. Santagostino, S. Rauchensteiner, N. Church, P. Mathew, C.M. Kessler, M.W. Skinner, on behalf of the ECHO Study Investigators (Germany)
- PB192** **Hemophilia A Subjects with an Intron-22 Inversion Mutation Show Robust T-cell Responses to Epitopes in Both the FVIII Heavy and Light Chain**
D. Gunasekera, A.F. Karim, M.V. Ragni, K.P. Pratt (United States)
- PB193** **Analysis of HLA-class-II (HLA-II) Peptidomes in Response to Several Therapeutic Factor (F) VIII Proteins (tFVIIIs) in Healthy Donors and Hemophilia A (HA) Patients with and without FVIII Inhibitors (FEIs)**
Z. Sauna, V. Diego, M. Almeida, B. Luu, M. Hofmann, J. Hernandez, R. Rajalingam, S. Williams-Blangero, J. Curran, J. Powell, M. Escobar, J. Blangero, E. Maraskovsky, N. Key, T. Howard (United States)
- PB194** **Recombinant Porcine Factor VIII Post-marketing Safety Studies in the European Union (EU) and United States (US)**
R. Crea, O. Mauric, J.-F. Huang, J. Chen (Austria)
- PB195** **Regulatory T Cells in the Modulation of Hemophilia A**
M. Meissner, J. Gotot, T. Albert, J. Oldenburg, C. Kurts (Germany)
- PB196** **Phase 2 Trial of Subcutaneously Administered Novel FVIIa Variant, Marzeptacog Alfa (activated), in Hemophilia A or B with Inhibitors: Pharmacokinetics, Pharmacodynamics, Safety and Efficacy**
H. Levy, G. Iosava, F. Del Greco, A. Hetherington, J. Hillman (United States)
- PB197** **Potential Clinical Trial Validation of Differential EPCR-dependent Activity by Eptacog Beta, a rhFVIIa Variant, in the Treatment of Bleeding in Hemophilia Patients with Inhibitors**
J. Ducore, W.A. Alexander, I. Mitchell, J. Lawrence, J. Grandoni, D. Bonzo (United States)
- PB198** **Immune Tolerance Induction in Patients with Hemophilia A and Inhibitors: Preliminary Results of the Brazilian Immune Tolerance (BrazilIT) Study**
R. Camelo, L. Magalhaes, L. Jardim, L. Werneck, A. Gonçalves, M.R. Roberti, D. Tan, V. Franco, D. Chaves, S. Rezende (Brazil)

POSTERS

- PB199** **Inhibitor Development and Successful Immune Tolerance Induction in a Young Female Carrier of de novo Severe Hemophilia A**
L.W. Zuccherato, M.D.R.F. Roberti, L.L. Jardim, S.M. Rezende (Brazil)
- PB200** **Risk Modeling Inhibitor Development of Haemophilia A Patients in Australia**
S. Parikh, H. Tran, S. McRae (Australia)
- PB201** **Real-world Bleeding Frequency in Inhibitor Patients on Prophylaxis with APCC: Data Readout of the “FEIBA Global Outcomes Study (FEIBA GO)”**
C. Escuriola Ettingshausen, J. Windyga, P.A. Holme, C. Hermans, C. Negrier, A.R. Cid, S. Rangarajan, G.R. Chiu, V. Cano, R. Crea (Switzerland)
- PB202** **Addressing Barriers to the Use of Oral Anticoagulant Reversal Agents: A CME Intervention**
J. Spyropoulos (United States)
- PB203** **Successful Eradication of Factor FVIII Inhibitor by Cyclophosphamide Treatment in a Patient with Acquired Haemophilia A - A Case Report**
S. Margetic, D. Carzavec, N. Vrkic (Croatia)
- PB204** **Clinical Description and Laboratory Characterization of Heparin-like Substance Causing Bleeding**
L. Hensch, V. Kostousov, K. Bruzdoski, M. Losos, S.K. Hui, J. Teruya (United States)
- PB206** **Skeletal and Cardiac Muscle Myosin Exert Procoagulant and Antifibrinolytic Effects**
J. Coleman, H. Deguchi, J. Zilberman-Rudenko, J. Samuels, C. Silliman, A. Banerjee, J. Griffin, E. Moore (United States)
- PB208** **Recombinant VWF D'D3-albumin Fusion Protein Variants with Enhanced Affinity for Coagulation Factor VIII, Increase the Efficiency of FcRn-mediated Recycling of Co-administered FVIII**
J. Chia, I. Glauser, G. Bass, A. Andrews, T. Weimer, M. Wilson, S. Dower, A. Verhagen (Australia)
- PB209** **Improving the FVIII Binding Affinity of a Recombinant VWF D'D3 Albumin Fusion Molecule Translates to Dosing Benefits with respect to the Half-life Extension of Co-administered FVIII**
S. Pestel, E. Raquet, M. Mischnik, P. Claar, M. Wilson, S. Dower, E. Herzog, T. Weimer, A. Andrews (Australia)
- PB210** **Platelet-nanocapsule Hybrids for On-demand, Targeted Delivery of Factor VIII in Hemophilia A Mice**
C.E. Hansen, W.H. Baldwin, G. Batsuli, S.L. Meeks, W.A. Lam (United States)
- PB211** **Annualized Bleeding Rates, the Current Favorite Clinical Endpoint in Hemophilia Trials: Pitfalls and Caveats**
C. Keipert, M. Müller-Olling, F. Gauly, C. Arras-Reiter, A. Hilger (Germany)
- PB212** **Presence of Plasma Platelet Autoantibodies and Response to the Spleen Tyrosine Kinase (Syk) Inhibitor Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP) - Exploratory Analyses from Phase 3 Studies**
J. Bussel, V. Markovtsov, E. Masuda, B. Cadieux, S. Yi, C. Young, A.-M. Duliege (United States)



- PB214** **Tranexamic Acid Reduces Post-surgical Infection Rates via Direct Immune Cell Modulation**
D.F. Draxler, K. Yep, G. Hanafi, A. Winton, M. Daglas, H. Ho, M. Sashindranath, L.M. Wutzlhofer, A. Forbes, I. Goncalves, H. Tran, S. Wallace, M. Plebanski, P.S. Myles, R.L. Medcalf (Australia)
- PB215** **ROTEM® or Conventional Hemostasis Test: Experience in Cardiac Surgery Setting**
J. Valaize, A. Roisné, A. Mansour, J.-P. Verhoye, T. Fest, P. Gueret, I. Gouin-Thibault, E. Flecher, F. Nedelec-Gac (France)
- PB216** **A New, Hand-held, Multifunctional Coagulation Laboratory for Perioperative Monitoring**
S. Nadkarni, D. Tshikudi, A. Wirth, E. van Cott (United States)
- PB217** **Expansion of Surgery Experiences in Children, Adolescents and Adults with the Extended Half-life Molecule N8-GP**
A. Tosetto, A. Neff, S.R. Lentz, E. Santagostino, L. Nemes, J. Sathar, K. Meijer, P. Chowdary, A. Landorph, M. Dutkiewicz, K. Hampton (Italy)
- PB218** **Monitoring Anticoagulation and Hemostasis in Cardiac Surgical Patients with a Drop of Whole Blood**
D.M. Tshikudi, A.G. Wirth, M.N. Andrawes, S.K. Nadkarni (United States)
- PB220** **Protocol for a Prospective, Randomized, Controlled Phase 2 Pilot Study Investigating Hemostatic Efficacy and Safety of Fibrinogen Concentrate and Cryoprecipitate in Patients Undergoing Cytoreductive Surgery for Pseudomyxoma Peritonei: The FORMA-05 Study**
A. Roy, N. Sargant, S. Rangarajan, S. Alves, J. Bell, S. Stanford, C. Solomon, I. Kruzhkova, S. Knaub, F. Mohamed (United Kingdom)
- PB221** **Classification of Surgical Bleeding Situations**
R. Kocharian, J. Koea, P. Hinoul, A. Martella, D. Zeltsman, J. Hagen (United States)
- PB222** **Recombinant Factor VIIa (Novoseven®) Utilization and Safety for Refractory Bleeding After Cardiac Surgery at a Large Academic Medical Center**
K. Marsh, T. Ahuja, V. Raco, D. Green, J. Papadopoulos (United States)
- PB223** **Rotational Thromboelastometry (ROTEM) as an Alternative Method for Evaluation of Septic Coagulopathy - Preliminary Results**
M. Durila, I. Hadacova, M. Solcova, M. Mikesova, Z. Prikrylova, J. Berousek, T. Vymazal (Czech Republic)
- PB224** **Thromboelastometry-guided Therapy for the Treatment of Hemorrhagic Shock in Postoperative of Vascular Surgery: A Case Report**
T. Crochemore, F. Savioli (Brazil)
- PB225** **Analysis of Fresh Frozen Plasma Requirement in Post Cardiopulmonary Bypass Cardiac Surgery Patient Based on Standard Coagulation and Thrombelastography Tests in Hasan Sadikin Hospital, Bandung**
L. Lismayanti, U. Sukorini, B. Mulyono, T. Triyono (Indonesia)

POSTERS

- PB226** **Quality and Accuracy of Testing for von Willebrand Disease by North American Special Coagulation Laboratories from 2010 to 2017**
J. Abdulrehman, P. Hsu, Y.C. Ziemba, E.M. Van Cott, E. Plumhoff, P. Meijer, R. Selby (Canada)
- PB227** **FXI-deficient Patients with Bleeding Phenotype Show a Spatio-temporal Propagation of Blood Coagulation Shorter and Slower than Normal**
D. Bertaglia Calderara, V. Carle, A. Aliotta, C. Heinis, L. Alberio (Switzerland)
- PB228** **The FVIII: C Measurement of Extended Half-life Recombinant Factor VIII FC Fusion in Haemophilia A Patients**
A. Bowyer, F. Shepherd, B. Sampson, S. Kitchen, M. Makris (United Kingdom)
- PB229** **Overassignment of Recombinant Wild Type (rwt) FIX Potency by a One-stage Method Indicated from Comparison with Chromogenic FXIa and TF/FVIIa Based Methods and through Discrepant Activation of rwt FIX and Plasma Derived (pd) FIX by Plasma Kallikrein (PK)**
S. Rosén (Sweden)
- PB230** **Sensitive and Standardized TGA Measurement in Haemophilia Patients Using Ceveron® Alpha TGA**
L. Rosenmayr, L. Wagner, N.B. Binder (Austria)
- PB231** **Differences in FVIII Measurements of Plasma Spiked with AFSTYLA® Generated with One-stage Clotting Assay using Different Commercial APTT Reagents Compared with Chromogenic Method**
I. Vangenechten, M. Maes, M.-B. Maes, A. Gadisseur (Belgium)
- PB232** **Improved Recovery of rVIII-SingleChain and rIX-FP Spiked Plasma Samples in the OS Clotting Assay**
J. Schiebel, C. Mengel, C. Horn (Germany)
- PB233** **Pre-analytical Variables - Sample Rejection in Hemostasis Laboratories**
L. Brown, D. Kitchen, I. Jennings, S. Munroe - Peart, S. Kitchen, T. Woods, I. Walker (United Kingdom)
- PB234** **Thromboelastometry Profile in Critically Ill Patients: A Single-center, Retrospective, Observational Study**
T. Crochemore (Brazil)
- PB235** **Differences in Activity of Plasma Spiked with IDELVION® Generated with One-stage Clotting Assay using Different Commercial APTT Reagents Compared with Chromogenic Method**
I. Vangenechten, M. Maes, M.-B. Maes, A. Gadisseur (Belgium)
- PB236** **Extended Half-life Factor VIII: From Biology to Patients' Management Optimization**
A. Perrier-Cornet, A. Philippe, P. De Boissieu, T. Lambert, R. D'Oiron, A. Rafowicz, C. Lavenu-Bombled, S. Combe, A. Gillibert, V. Proulle (France)
- PB237** **Evaluation of an Automated Chromogenic Assay for Measuring FVIII:C Levels in the Patients Affected by Hemophilia A**
C. Novembrino, M. Boscolo Anzoletti, M.R. Fasulo, F. Peyvandi (Italy)



- PB238 Underassignment of FIX Potency of rFIX-Albumin Fusion Protein (rFIX-HSA) by One Stage Methods Demonstrated in Studies on FXIa and FIXa Generation**
S. Rosén, P. Bryngelhed, G. Siegert, O. Tiebel (Sweden)
- PB239 Correlation of FIX Activity Assays with Thrombin Generation**
L. Florin, V. Mondelaers, A. Vantilborgh, K.M.J. Devreese (Belgium)
- PB240 Performance Evaluation of 10 APTT Reagents in Quantitative Clot Waveform Analysis**
G. Kershaw, V. Chen (Australia)
- PB241 An International, Multi-centre, Blinded Comparative Study Assessing the Activity of N8-GP in Spiked Haemophilia A Plasma Samples**
M. Hansen, S. Tiefenbacher, W.H.O. Clausen, R. Lützhøft, M. Ezban (Denmark)
- PB242 DOAC Dipstick for Determination of Absence or Presence of Direct Oral Anticoagulants and Creatinine in Urine**
J. Harenberg, R. Schreiner, S. Hetjens, R. Krämer, C. Weiss (Germany)
- PB243 One Stage and Chromogenic Assays Discrepancy in the Estimation of Factor IX (FIX) Recovery. What is it that a Single Hemophilia Center Can and Cannot Do?**
Å.S. Persson, N. Mahmoud Hourani Soutari, E.-M. Norberg, J.P. Antovic (Sweden)
- PB244 Comparison of Two One-stage Clotting Assays and One Chromogenic FIX Assay for Monitoring of Idelvion® Replacement Therapy**
L. Florin, K.M.J. Devreese (Belgium)
- PB245 Levels of Coagulation Factors, Coagulation Inhibitors and TAFI Do Not Affect Global Hemostasis and Bleeding Phenotype in Patients with Hemophilia A**
D. Mikovic, I. Pruner, J. Antovic, R. Chaireti (Sweden)
- PB246 Method Comparison of the PT Rec Coagulation Assay with Existing Reference Methodology for Measuring Prothrombin Time (PT)**
U. Geisen, J. Kappelmayer, R. Jones, A. Lowe, G. Miles, G. Rozsnyai, S. Kitchen (United Kingdom)
- PB247 The Effect of DDAVP on Thrombin Generation in Patients with Bleeding Disorders**
A. Agapidou, C. Hamid, E. Fosbury, A. Riddell, P. Chowdary (United Kingdom)
- PB248 Turoctocog Alfa Pegol (N8-GP) Can Be Measured Accurately Using Normal Human Plasma Calibration in a Validated Chromogenic Assay**
W. Pickering, M. Robinson, S. Tiefenbacher, E. Mirella (Denmark)
- PB249 Comparison of Three Thromboplastin Reagents for International Normalized Ratio (INR) Measurement in Patients on Vitamin K Antagonist Therapy**
R. Perez Montes, E. Martin Martin, F. Depasse (France)
- PB250 New Multiplatform von Willebrand Factor Antigen Assay with Extended Stability**
C. Dunois, M. Peyrafitte, V. Villedieu, S. Molton, J. Amiral (France)

POSTERS

- PB251 External Quality Assurance (EQA) for the Rotem Sigma Thromboelastometry Device**
D. Kitchen, S. Munroe-Peart, L. Brown, I. Jennings, S. Kitchen, T. Woods, I. Walker (United Kingdom)
- PB252 Stored Calibration Curves Can Deliver Acceptable Accuracy and Precision on CS5100 Analysers**
A. Sermon-Cadd, J. Smith, A. Bowyer, S. Kitchen (United Kingdom)
- PB253 Measurement of Immunoglobulins Anti VWF in Patients with Probable AVWS with an Enzyme-linked Immunosorbent Assay (ELISA) Using Platelet VWF as an Antigen**
A.C. Kempfer, A.I. Woods, J. Paiva, M.M. Casinelli, A. Sanchez-Luceros, M.A. Lazzari (Argentina)
- PB254 Performance Evaluation of Automated Thrombin Generation Measurement on Ceveron®alpha TGA**
L. Wagner, N.B. Binder (Austria)
- PB255 Calibrations Performed in the Lab Fail to Correct Fibrinogen Quality Control Variability Generated by Different Reactant Batches**
F. Guerrero, F. Dubois, C. Bressans, M. Lebon, A. Ribes, S. Savy, N. Savy (France)
- PB256 System Performance Evaluation of the Cobas t 711 and Cobas t 511 Analysers**
A. Lowe, S. Kitchen, R. Jones, M. P.M. de Maat, M. Nagler, G. Rozsnyai (United Kingdom)
- PB257 Variations in Automated Platelet Counts Occur Depending on the Principle Used for Cell Counting and on the Non-platelet Blood Cell Parameters**
G.K. Viswanathan, R. Shekar, S. Pai (India)
- PB258 Accuracy and Precision of Point-of-Care International Normalized Ratio (INR) in Pediatric and Adult Patients with Liver Disease Pilot Study**
P.S. Kawada, M. Bauman, J. Yap (Canada)
- PB259 Clearance of Mouse VWF Propeptide Is Mediated by Stabilin-2 and Is Regulated by N-linked Glycan Expression**
O. Rawley, C. Brown, C. Dwyer, K. Nesbitt, D. Lillicrap (Canada)
- PB260 Accumulation of Rare Variants in STAB2 in Type 1 von Willebrand Disease Patients**
E. Manderstedt, C. Lind-Halldén, J. Flygare, S. Lethagen, C. Halldén (Sweden)
- PB261 Expression of the SCARA5 Scavenger Receptor in the Human Kidney and Spleen May Regulate Clearance of VWF**
L.L. Swystun, O. Rawley, J.D. Lai, F. Lassalle, A. Michels, K. Ogiwara, C. Notley, C. Dwyer, K. Nesbitt, J. Ojala, K. Tryggvason, D. Lillicrap (Canada)
- PB262 Diverse Inheritance of VWD Found in Type 3 U.S. Families in the Zimmerman Program**
P. Christopherson, D. Bellissimo, G. Humphreys, C. Perry, V. Flood, J. Gill, S. Haberichter, R. Montgomery, Zimmerman Program Investigators (United States)
- PB263 Despite Lower von Willebrand Factor Values, O Blood Type Is Not a Risk Factor for Bleeding Complications Following Tonsillectomy +/- Adenoidectomy**
N. Archer, P. Forbes, J. Dargie, J. Manganella, G. Licameli, M. Kenna, C. Brugnara (United States)



- PB264** **High Molecular Weight von Willebrand Factor Multimers in Cryoprecipitate Exceed that Found in a Commercial Concentrate**
M.E. Colling, K.D. Friedman, W.S. Dzik (United States)
- PB265** **Safety of a High-purity Plasma-derived Factor X (pdFX) Concentrate over up to 4 Years of Treatment in a Variety of Clinical Situations in Adult and Pediatric Patients with Hereditary Factor X Deficiency (FXD)**
G. Auerswald, K. Kavakli, R. Liesner, C. Akanezi, M. Norton, M.A. Escobar (Germany)
- PB266** **Low Immunogenicity of Two Plasma-derived FVIII Products in Previously Untreated Patients with Non-null F8 Mutations**
A. Pavlova, S. Lowndes, L. Belyanskaya, M. Jansen, O. Walter, J. Oldenburg (Germany)
- PB267** **Pharmacodynamics of Recombinant Fusion Protein Linking Activated Factor VIIa to Human Albumin (rVIIa-FP), Eptacog Alfa and Plasma-derived Factor VII in Patients with Congenital FVII Deficiency**
W.L. van Heerde, P.A. Holme, B. Laros-van Gorkom, C. Joch, S. Puli, J. Roberts (the Netherlands)
- PB268** **Examination of the Utility of Self BAT Questionnaire in an Irish Coagulation Setting**
A. O Sullivan, R.C. Jones, A. Patel, B. White, J.S. O'Donnell, M. Lavin, N. O'Connell, K. Ryan (Ireland)
- PB269** **Targeted Re-sequencing of the Common and Rare Bleeding Disorders**
R. Nilsson, E. Manderstedt, C. Lind Halldén, J. Flygare, R. Ljung, C. Halldén (Sweden)
- PB270** **Molecular Analysis and Bleeding Phenotype of Seven Severe FV-deficient Patients from Pakistan**
M. Borhany, A. Ranc, M. Fretigny, G. Moulis, M. Abid, M. Giansily-Blazot (Pakistan)
- PB271** **Rare Bleeding Disorders in Pakistan: An Update**
M. Borhany, N. Fatima, M. Abid, T. Shamsi (Pakistan)
- PB272** **Functional Polymorphisms of the von Willebrand Factor Gene in Patients with Mild to Moderate Bleeding Tendency and Low or Normal von Willebrand Factor Antigen or von Willebrand Factor Ristocetin Cofactor**
S. Hofer, J. Gebhart, J. Rejtö, G. Hörmann, I. Pabinger, R. Sunder-Plassmann (Austria)
- PB273** **Comparison of a von Willebrand Factor Fully-automated Chemiluminescent Assay Panel for von Willebrand Disease Diagnosis to and Historical Classification**
F. Stufano, L. Baronciani, P. Bucciarelli, M. Boscarino, P. Colpani, D. Mane-Padros, S. Faraudo, F. Peyvandi (Italy)
- PB274** **Profile of Mutations Identified in a Cohort of Czech Patients with Type Normandy von Willebrand Disease**
D. Provaznikova, F. Mareček, A. Radovská, M. Šimoníková, V. Geierová, R. Hrdličková, P. Salaj, I. Hrachovinová (Czech Republic)

POSTERS

- PB275** **Correction of Factor XI Deficiency by Liver Transplantation for Secondary Sclerosing Cholangitis**
I. Martin-Toutain, D. Eyraud, V. Planche, M. Kurdi, P. De Mazancourt, C. Frere (France)
- PB276** **Intense Exercise Increases von Willebrand Factor and Factor VIII Levels in Well-trained Athletes**
N. Androulakis, P. Spatharaki, E. Nioti, I. Papadakis, A. Papadopoulou, G. Notas (Greece)
- PB277** **Prevalence of von Willebrand Disease among Nigerian Youths in Ibadan South-Western Nigeria**
K. Shonde-Adebola, M. Adebola, W. Shokunbi (Nigeria)
- PB278** **Impact of Mitral Valve Clip Procedure on Indices of Acquired von Willebrand Syndrome**
J. Blackshear, P. Pollak, D. Chen (United States)
- PB279** **Comparative Study of Single Nucleotide Polymorphisms (SNPs) in the Exon 28 of the VWF between Healthy Donors, VWD2M (with p.E1549K and p.R1374C) and VWD2B Patients (with p.R1308C and p.V1316M) in a Single Center in Argentina. Preliminary Report**
A.I. Woods, J. Paiva, A.C. Kempfer, M.M. Casinelli, A. Sanchez-Luceros, M.A. Lazzari (Argentina)
- PB280** **Genotyping of Five Patients with Severe Inherited Factor X (FX) Deficiency from Pakistan: Identification of Two Novel Mutations**
M. Borhany, D. Buthiau, F. Rousseau, O. Guillot, M. Abid, T. Shamsi, M. Giansily-Blaizot (Pakistan)
- PB282** **Discrepant von Willebrand Factor (VWF) Activity Levels in Two Unrelated von Willebrand Disease (VWD) Patients**
M. Bowman, A. Tinmouth, R. Selby, M. Sholzberg, D. Lillicrap, D. Good, P. James (Canada)
- PB284** **Are Iranian Patients with von Willebrand Disease Type 2N Properly Differentiated from the Ones with Mild/Moderate Hemophilia A and Do They Receive Appropriate Treatment?**
A. Seidi Zadeh, M. Ahmadinejad, B. Amoohossein, S. Homayoun (Iran)
- PB285** **Polyphosphate Nanoparticles Slow Down the Clotting of Fibrinogen and Increase the Lytic Stability of Fibrin**
A. Tanka-Salamon, M. Lovas, I. Voszka, L. Szabó, K. Kolev (Hungary)
- PB286** **Alternative Complement Pathway Inhibits Fibrinolysis in an in-vitro Whole Blood Model**
J. Samuels, E. Moore, J. Coleman, A. Sauaia, C. Silliman, A. Banerjee (United States)
- PB287** **The Activity of XIIa-dependent Fibrinolysis in Disorders of Carbohydrate Metabolism after Treatment with Regulatory Peptides**
T. Shubina (Russian Federation)
- PB288** **Plasma Proteolytic Enzymes Changes in Patients with Urinary Bladder Cancer as a Tool for Studying Progression**
T. Luhovska, O. Savchuk, P. Yakovlev, N. Raksha, L. Ostapchenko (Ukraine)



- PB289** **The Effects of *Elaeagnus angustifolia*, *Corylus avellana* or *Silybum marianum* on the Attenuation of Ischemic Brain Injury**
M. Kamalinejad, H. Alimoradi, M. Soleymankhani, S. Asadi, A. Pourmoghaddam, M. Babaeian (Iran)
- PB290** **Novel Fibrinogen Missense Mutations in Patients with Fibrinogen Defects**
G. Favuzzi, E. Chinni, G. Tiscia, P. Vergura, F. Cappucci, G. Vecchione, R. Bagna, C. Izzi, D. Rizzi, V. De Stefano, E. Grandone (Italy)
- PB291** **Fibrinogen-binding Affimer with Antifibrinolytic Action Presents Potential New Therapeutic Target**
K.J. Kearney, C. Tiede, F. Phoenix, F.L. Macrae, N. Oxley, N. Pechlivani, K.A. Smith, R.A. Ariens, D.C. Tomlinson, R.A. Ajjan (United Kingdom)
- PB292** **The Use of Fibrinogen-binding Affimer Proteins to Modulate Clot Formation and Lysis**
N. Pechlivani, R. King, C. Tiede, K. Kearney, I. Manfield, F. Phoenix, R. Ariens, D. Tomlinson, R. Ajjan (United Kingdom)
- PB293** **Increased Fibrinolysis as a Specific Marker of Poor Outcome after Cardiac Arrest**
M. Schwameis, N. Buchtele, C. Schörghofer, A. Spiel, B. Jilma (Austria)
- PB294** **Fibrinogen Content under Ischemic Stroke with and without Type 2 Diabetes Mellitus**
O. Kravchenko, N. Raksha, M. Tymoshenko, L. Ostapchenko (Ukraine)
- PB295** **Euglobulin Lysis Time (ELT) Behaviour in Patients with Abnormal Clot Solubility Test (CST)**
L. Remotti, M.F. Ingratti, S.H. Grosso, M.P. Vera Morandini, M.L. Romero, M.G. Agazzoni, A. Sánchez-Luceros, A.N. Blanco (Argentina)
- PB296** **Association between Use of Recombinant Tissue Plasminogen Activator and In-hospital Mortality and 30-day Readmission among Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: A Retrospective Cohort Study**
A. Sarayani, T. Youn, J. Brown (United States)
- PB297** **Staphylokinase Potentiates Thrombolytic Effect of Single Chain Pro-urokinase in Plasma Milieu in vitro**
R. Aisina, L. Mukhametova, K. Gerchkovich, E. Ivanova (Russian Federation)
- PB298** **Local Ultrasound-facilitated Thrombolysis in Pulmonary Embolism: First Dutch Experience and Retrospective Comparison with Systemic Thrombolysis**
M.A. de Winter, E.A. Hart, D.A.F. van den Heuvel, A. Moelker, R.J. Lely, H.A.H. Kaasjager, P.R. Stella, S.A.J. Chamuleau, A.O. Kraaijeveld, M. Nijkeuter (the Netherlands)
- PB300** **Endogenous Fibrinolysis in Patients with Acute Coronary Syndrome and Healthy Volunteers**
P. Savvinova, A. Kalinskaya, A. Shpektor, E. Vasilieva (Russian Federation)
- PB302** **Clot Formation Assessment in Septic Patients with Cancer using a Time-based Parameter from the ROTEM Velocity Curves. A Prospective Observational Pilot Study**
E. Scarlatescu, D.R. Tomescu (Romania)

POSTERS

- PB303** **Increase in Plasma Stability and Thrombolytic Efficacy of pro-UK by Chemical Modification of its Arginine Residues**
L. Mukhametova, R. Aisina, K. Gerchkovich (Russian Federation)
- PB304** **Tissue Plasminogen Activator (tPA) - Loaded PLGA Microspheres Administration in Combination with Extracorporeal Shock Wave Thrombolytic Therapy Reduce Thrombus in the Arterial Thromboembolic Occlusion**
H. Mehrad, B. Hajipour, F. Nasirzadegan, A. Keshavarz, A. Arshadi, S. Sarabi, P. Karimi (Iran)
- PB305** **Recombinant Destabilase-lysozyme - Long-term Thrombolytic with the Original Mechanism of Action**
S. Kalabushev, D. Nalobin, D. Akhaev, V. Manuvera, V. Lazarev, I. Baskova (Russian Federation)
- PB306** **Genome Sequence of the Medicinal Leech *Hirudo Medicinalis*. Discovery of Novel Anticoagulant and Fibrinolytic Proteins and Peptides**
V. Lazarev, V. Manuvera, D. Shirokov, O. Podgorny, E. Grafaskaia, D. Kharlampieva, N. Polina, P. Bobrovsky, V. Babenko (Russian Federation)
- PB307** **Gender Differences in TAFI Regulation in Some Disorders**
E. Roitman, M. Tanashyan, A. Shabalina, I. Kolesnikova (Russian Federation)
- PB309** **The Role of Plasminogen Activator Inhibitor-1 (PAI-1) Levels and PAI-1 4G/5G Polymorphism in the Outcome of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients**
I. Szegedi, E.G. Székely, K.R. Czuriga-Kovács, A. Nagy, F. Sarkady, L.I. Láncki, E. Berenyi, L. Csiba, Z. Bagoly (Hungary)
- PB310** **Differentiation of Coagulation Parameters in Patients with Acute Coronary Syndrome**
Y. Tyravska, T. Vovk, N. Raksha, V. Lizogub (Ukraine)
- PB311** **Cell Free Desoxyribonucleic Acids (cfDNA) Levels Remain High after 6 Months Despite Successful PCI in STEMI Patients which Along with High Metalloproteinases MMP9/MMP2 Activity Is Associated with Unfavorable Disease Course**
O. Koval, A. Skoromna (Ukraine)
- PB312** **Low - Level Blue Laser - Mediated Photodynamic Therapy Accompanied by 5- Aminolevulinic Acid Administration Reduce Smooth Muscle Cells Density in the Rabbit Carotid Artery Neointimal Hyperplasia Model**
H. Mehrad, M. Farhoudi, L. Zeinalizad, M. Haji Sagati, M. Jabbardokht, F. Nasirzadegan, A. Foletti (Iran)
- PB313** **Advanced Atherosclerosis Regression using Inertial Cavitation Effect of Pulsed-focused Ultrasound Accompanied by Combined High-dose Atorvastatin Plus HDL-äoaded Microbubbles Administration**
H. Mehrad, S. Sadigh Eteghad, L. Zeinalizad, S. Sarabi, A. Arshadi, Z. Pishezari, K. Mehrvar (Iran)
- PB314** **Different Pattern of Platelet Binding to Monocytes in Healthy Volunteers and in Patients with Coronary Artery Disease**
M. Loguinova, N. Pinegina, A. Shpektor, L. Margolis, E. Vasilieva (Russian Federation)



- PB315** **Pharmacological Actions of Inosine in a Hypercholesterolemic Model: Is It a New Antiatherosclerotic Drug?**
G.F. Lima, N.A.V. Motta, R.O. Lopes, L.J. Autran, I.A. Moraes, F.C.F. Brito, Laboratório de Farmacologia Experimental (LAFE) (Brazil)
- PB316** **Cement Dust Exposure Associated with Anaemia, Increased Platelets, Cardiac Markers and Dyslipidamia among Male Cement Workers in Calabar, Nigeria**
I.E. Bassey, J.O. Akpotuzor, I.M. Okafor, G. Aniekeme, I.K.P. Isong, U.O. Akpan (Nigeria)
- PB317** **Hyperhomocysteinemia and endothelial Dysfunction of the Athletes in the Arctic Region**
N. Vorobyeva, N. Bushueva (Russian Federation)
- PB318** **Folate Deficiency of the Nenets of the Arctic Regions of the Russia**
N. Vorobyeva, N. Belova (Russian Federation)
- PB319** **Inhibition of Integrin α v β 3 with Cilengitide Prevents Endothelial Injury Induced by Neutrophil Extracellular Traps in Response to Staphylococcus aureus Infection in a 3D ex vivo Model of Sepsis**
C. Garciarena, S. Kerrigan (Ireland)
- PB320** **The Role Exosomal Derived miRNAs in Driving a Host's Response to Infection in Sepsis**
G. Fitzpatrick, R. Watkin, S. Kerrigan (Ireland)
- PB322** **Recombinant Human Soluble Thrombomodulin Protects Vascular Endothelial Cells from Radiation-induced DNA Damage**
X. Wang, X. Wang, T. Kawase, G. Honda, H. Ohkawara, T. Ikezoe (Japan)
- PB324** **Ubiquitin-driven p38 Inflammatory Signaling Induced by Protease-activated Receptors**
J. Trejo (United States)
- PB325** **Low - Level Red Laser - Mediated Photobiomodulation Therapy, Improves Endothelial Dysfunction via Increasing Endothelial Nitric Oxide (NO) Synthase in the Rabbit Carotid Artery Injury Model**
H. Mehrad, J. Mahmoudi, A. Rahimkhani, M. Haji Sagati, Z. Pishzari, L. Zeinalizad, M. Moghadaszadeh (Iran)
- PB326** **The Anti-coagulant Vitamin K-dependent Factor, Protein S, Alters Endothelium Functions by Regulating Multiple Vascular Permeability Related Signaling Pathways**
A. Jooussaume, C. Kanthou, F. Dkhissi, O. Benzakour (France)
- PB327** **Simultaneous Assessment of sE-Selectin, Platelet Count and Mean Platelet Volume as Biomarkers for Pre-eclampsia**
H. Hassan, H. Azzam, M. Othman, M. Hassan, T. Salim (Canada)
- PB328** **Endothelial Cell Activation Is Attenuated by Everolimus via Transcriptional and Post-transcriptional Regulatory Mechanisms after Drug-eluting Coronary Stenting**
Z. Fejes, Z. Zimmerer, T. Szük, S. Poliska, A. Horváth, E. Balogh, V. Jeney, G. Balla, I. Édes, J. Kappelmayer, B. Nagy Jr (Hungary)

POSTERS

- PB329** **The Damaging Effect of Neutrophil Extracellular Traps on the Vascular Endothelium during Sepsis**
T. McHale, C. Garciarena, S. Kerrigan (Ireland)
- PB330** **Comparison of Syndecan-1 Levels as a Marker of Endotheliopathy in Thermal Injury and Blunt Trauma**
R. Ball, M. Bravo, K. Brummel-Ziedins, T. Orfeo, K. Freeman, M. McLawhorn, L. Moffatt, J. Shupp (United States)
- PB331** **Endoglin Implications in ECFC Vasculogenic Properties and Vascular Permeability**
E. Rossi, S. Lecourt, N. Névo, F. Saller, C. Goyard, B. Saubamea, B. Planquette, C. Bernabeu, O. Sanchez, R. Bobe, D.M. Smadja (France)
- PB332** **Ceramide 1 Phosphate Protects Human Endothelial Colony Forming Cells from Apoptosis and Increase Their Angiogenic Responses**
H.A. Mena, P.R. Zubiry, M. Schattner, S. Negrotto (Argentina)
- PB333** **Ticagrelor Induces the Expression of the Endothelial Phenotype CD34+ Progenitor Cells in the Presence of ADP via an Adenosine-mediated Mechanism**
S. Sidiropoulou, K.M. Hansson, A.D. Tselepis (Greece)
- PB334** **Coxsackievirus B3 Replicates in Endothelial Colony Forming Cells and Inhibits Angiogenesis**
P.R. Zubiry, H.A. Mena, J. Etulain, M. Schattner, R.M. Gomez, S. Negrotto (Argentina)
- PB335** **Circulating Progenitor and Mature Endothelial Cells in Patients with Venous Thromboembolic Disease**
S. Ranero, G. Silveira, N. Trias, A. Brugnini, I. Rodriguez, L. Díaz, C. Guillermo, S. Grille (Uruguay)
- PB336** **DVT-on-a-Chip: A Microphysiological Model of Human Venous Valve Function and Thrombosis**
N.K.R. Pandian, A. Jain (United States)
- PB337** **PAR-1 Inhibition Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Endotoxemia**
C. Schoergenhofer, M. Schwameis, G. Gelbenegger, N. Buchtele, B. Thaler, M. Mussbacher, G. Schabbauer, J. Wojta, P. Jilma-Stohlawetz, B. Jilma (Austria)
- PB338** **Status System Hemostasis and Microvasculature in Different Periods after Hypothermia in Rats**
N. Lycheva (Russian Federation)
- PB339** **Platelet-neutrophil Crosstalk: Effects of Serotonin on Neutrophil Activation**
C. Schoenichen, M. Mauler, C. Wippel, D. Stallmann, C. Bode, I. Hilgendorf, D. Dürschmied (Germany)
- PB340** **Type I Interferons Upregulate IFITM3 in Human Platelets and Megakaryocytes to Control Viral Infectivity**
R. Campbell, H. Schwertz, E. Hottz, J. Rowley, N. Tolley, G. Zimmerman, P. Bozza, F. Bozza, A. Weyrich, M. Rondina (United States)



- PB341** **Sphingosine 1-phosphate Induces COX-2/PGE2 Expression via PKCalpha-mediated MAPKs and NF-kappaB Cascades in Human Cardiac Fibroblasts**
C.-M. Yang (Taiwan)
- PB342** **Utility of New Red Cell Parameters for Identifying Functional Iron Deficiency and Anemia in Patients with Familial Mediterranean Fever**
D. Yildirim Gezgin, Z. Kaya, Ş. Demir, S. Gönen, S. Bakkaloğlu Ezgü (Turkey)
- PB343** **The Role of Cytokines in the Development of Acquired Aplastic Anemia**
I. Berger, A. Makhmudova (Uzbekistan)
- PB345** **Ticagrelor Mediated Protection during Myocardial Reperfusion is Exponentiated by SSRIs**
M. Mauler, C. Schoenichen, N. Herr, D. Stallmann, C. Bode, K. Ley, I. Hilgendorf, D. Duerschmied (Germany)
- PB346** **Hemoglobin-activated Platelet Regulates Macrophage Polarization under Hemolytic Conditions**
R. Singhal, S. Chawla, D.K. Rathore, A. Ojha, P. Guchhait (India)
- PB347** **Anti-inflammatory Effect of 5- Aminolevulinic Acid-mediated Sonodynamic Therapy Reduce Macrophages-derived Foam Cells in the Rabbit Abdominal Aorta Atherosclerosis Model**
H. Mehrad, A. Foletti, F. Nasirzadegan, A. Keshavarz, H. Beladerang, L. Kazemi, M.M. Hosseinian Zakariya (Iran)
- PB348** **Signalling Effects of Microparticle-derived Tissue Factor and Activated Factor VII in Endothelial Cells**
A. Brandtner, A. Magnutzki, G. Lehner, C. Feistritzer, V. Haller, M. Joannidis (Austria)
- PB349** **Quantification and Characterisation of Plasma Extracellular Vesicles in Early Onset Preeclampsia**
K. Egan, P. Pszklanna, H. O'Connor, C. Monteith, N. Fischer Dooley, C. Davis, L. Weiss, N. McCallion, S. Cooley, F. Malone, P. Maguire, F. Ni Ainle (Ireland)
- PB350** **Circulating Cholesterol Containing, Platelet-derived Microparticles Contribute to the Procoagulant State Observed in Systemic Lupus Erythematosus**
S. Hu, S. Meaney, C. Wynne (Ireland)
- PB351** **Phosphatidylserine-negative Platelet Microvesicles Are Increased in the Acute and Convalescent Phase of Ischemic Stroke and TIA - Specific Subpopulations Predict Prognosis**
A. Lundström, F. Mobarrez, E. Änggårdh-Rooth, C. Thålin, M. von Arbin, P. Henriksson, B. Gigante, A.C. Laska, H. Wallén (Sweden)
- PB352** **Circulating Microparticles Improve Thrombin Generation and Fibrin Formation in Factor VIII Deficiency Plasma**
Y. Zong, F. Mobarrez, N. Soutari, R. Chaireti, J. Antovic (Sweden)
- PB355** **Effect of Plasma Components on Staphylococcus aureus Adhesion to Tissues Used for the Right Ventricular Outflow Tract (RVOT) Revalvulation**
B. Ditkowski, R. Veloso, J. Claes, L. Liesenborghs, S. Van Kerckhoven S., R. Jashari, M. Gewillig, M. Hoylaerts, B. Meyns, R. Heying (Belgium)

POSTERS

- PB356** **Delayed Initiation and Inadequate Anticoagulation as Independent Risk Factors for Development of Post Thrombotic Syndrome (PTS) - An Observational Study from a Tertiary Care Hospital in North India**
V. Suri, P. Dodda, P. Malhotra, U. Gorski, J. Ahluwalia, N. Kumar, G. Prakash, D. Lad, A. Khadwal, S. Kumari, S. Jain, S. Varma, N. Varma (India)
- PB357** **Mitofusin 2 Regulates Mitochondria in Megakaryocytes, and Hemostasis and Thrombosis in Mice**
S.C. Bhatlekar, R.A. Campbell, L. Guo, B.K. Manne, M.T. Rondina, A.S. Weyrich, P.F. Bray, J.W. Rowley (United States)
- PB358** **PDK1 Is Crucial to Pro-platelet Formation and Thrombopoiesis by Regulating MK Actin Polymerization**
S. Geue, B. Walker-Allgaier, P. Münzer, M. Manke, D. Eißler, F. Lang, K. Aurbach, I. Pleines, H. Schulze, M. Gawaz, O. Borst (Germany)
- PB359** **Unique Megakaryocytes from Human Adipose-derived Mesenchymal Stromal/stem Cell Line: Comparison with Hematopoietic Stem Cell-derived Megakaryocytes**
Y. Ono-Uruga, K. Tozawa, M. Yazawa, T. Mori, M. Murata, Y. Ikeda, Y. Matsubara (Japan)

POSTERS: SESSION 2

- PB360** **Nucleic Acid-based Therapeutic Targets for Protein S Deficient Patients**
J. Tiao, A. Rocchi, Q. Hughes, B. Le, R. Veedu, R. Baker (Australia)
- PB361** **Structural Insights during the Recognition of Endothelial Cell Protein C Receptor to the Protein C/activated Protein C in Presence of Phospholipid within EPCR Groove**
R. Prasad, P. Sen (India)
- PB362** **Retrospective Study about using Bridging Therapy with Sodium Bemiparin in our Center**
P. Romero Garcia, E. Morente Constantin, M. Rivas Luque, M.A. Garcia Ruiz, M.D.P. Garrido Collado, G. Salas Camacho, M. Jurado Chacón (Spain)
- PB363** **The Development Heparin Complex with Glutamate with High Anticoagulant Activity**
L. Nikolaeva, L. Lyapina (Russian Federation)
- PB364** **Betrixaban: Impact on Routine and Specific Coagulation Assays - A Practical Laboratory Guide**
R. Siriez, J. Evrard, J.-M. Dogné, L. Pochet, D. Gheldof, B. Chatelain, C. Vancraeynest, P. Devel, M. Guldenpfennig, C. Devroye, F. Mullier, J. Douxfils (Belgium)
- PB365** **Preparation and Characterization of Nanocarriers for Transdermal Delivery of Enoxaparin**
M. Bhargava, S. Bhargava, S. Jain, V. Bhargava, N. Kapoor (India)



- PB366** **Inhibition of Factor XII is Antithrombotic in a Primate Model of Extracorporeal Membrane Oxygenation**
M. Wallisch, C.U. Lorentz, J. Johnson, M.R. Carris, O.J.T. McCarty, M.T. Hinds, A. Gruber, E.I. Tucker (United States)
- PB367** **Effects of SERPINC1, PROC, PROS1 and EPCR Polymorphisms on the Risk of Venous Thromboembolism and Myocardial Infarction in Young Individuals**
T. Miklós, G. Balla, L. Balogh, Z. Boda, Z. Szabó, É. Molnár, R. Gindele, É. Katona, Z. Bereczky (Hungary)
- PB368** **Structural and Functional Study of Naringin Octasulfate (NOS) on Human Antithrombin and Probing its Role in Thrombus Reduction using Rat Model**
I. Ahmad, M. Abid, S. Sharma, M.Z. Ashraf, M.A. Jairajpuri (India)
- PB370** **Development and Characterization of Neutralizing Monoclonal Antibodies Targeting the Direct Oral Anticoagulant Edoxaban**
E. Maurer, S. Crosnier, C. Baltus, M.-C. Viaud-Massuard, P. Ohlmann (France)
- PB371** **The Effect of JNJ-64179375 on Coagulation Tests with Different Coagulation Analyzers**
T.M. Connolly, M. Chintala, G. Peters, L.K. Jennings, J.P. Kotha (United States)
- PB372** **Emicizumab Impact on Factor VIII Inhibitor Determination in Plasma Samples from Persons with Hemophilia A (PwHA) using a New Kit for Modified Nijmegen-Bethesda Assay (MNBA)**
A. Sadeghi-Khomami, M. Boylan, D.C. Chen, J.I. Adamkewicz (Canada)
- PB373** **Profile of Patients with Hemophilia A and Inhibitor Undergoing Immune Tolerance Induction: Preliminary Data from the BrazIT Study**
L. Magalhães, R. Camelo, L. Jardim, A. Oliveira, D. Chaves, S. Rezende (Brazil)
- PB374** **Development of the First Point-of-Care Test Selective of the Direct Oral Anticoagulant Apixaban for Emergency Assessment of Coagulation**
P. Ohlmann, E. Maurer, S. Crosnier, C. Baltus, M.-C. Viaud, E. Oge, N. Hezard, P. Suchon, P.-E. Morange (France)
- PB375** **Data of Real-life Anticoagulant Treatment with Edoxaban In Patients with Atrial Fibrillation and Patients with Secondary Prevention of Deep Vein Thrombosis. Experience of Thirteen Months in our Center**
A. Garcia Ruiz, M. Rivas Luque, P. Romero Garcia, E. Morente Constantín, M.P. Garrido Collado, M. Jurado Chacon (Spain)
- PB376** **Cross-sectional Survey of Minor Bleeding Rates in Children Prescribed Warfarin**
N. Poci, C. Attard, F. Newall (Australia)
- PB377** **Antithrombin Levels in Nigerians with Type2 Diabetes**
O.A. Awodu, I. Ezenwenyi (Nigeria)
- PB378** **Laboratory Algorithm of Diagnostic of Hemorrhagic Diseases in Patients with Isolated Prolonged Activated Partial Thromboplastin Time (APTT)**
V. Krasivska, O. Stasyshyn (Ukraine)

POSTERS

- PB379** **From Tissue Factor to Thrombin to Fibrin under Whole Blood Flow: Thrombin Makes Fibrin but Fibrin Quenches Thrombin**
S. Diamond (United States)
- PB380** **Effect of Andexanet-tissue Factor Pathway Inhibitor (TFPI) Interaction on in vitro Clot Formation and Lysis via Different Coagulation Pathways**
G. Lu, J. Lin, J. Curnutte, P. Conley (United States)
- PB381** **Anti-factor Xa and Anti-thrombin Antibodies Have Differential Effects upon Coagulation and Complement Regulation - The Role of Antithrombin**
T. McDonnell, C. Wincup, V.M. Ripoll, C. Gerveshi, A. Rahman, I. Mackie, M. Botto, I. Giles (United Kingdom)
- PB382** **Molecular Sequencing of Factor VII Variants through Collaborative Advocacy for Families in the United States: 154 Individuals Using Multi-gene Next Generation Panel**
D. Nugent, S. Williams, D. Diaz, J. Hoang, K. Imfeld, V. Rajan, J. Brewer (United States)
- PB383** **Inappropriate Use of Fresh Frozen Plasma in a Tertiary Care Hospital**
S.A. Ali, M. Mirza, W. Noman (Pakistan)
- PB384** **Effects of Thrombin on Complement Activation**
M. Matsushita (Japan)
- PB385** **Clot Waveform Analysis: Determination of Optimal Wavelength to Assess the Fibrin Coagulation Process**
J. Evrard, R. Siriez, C. Bouvy, J. Laloy, F. Mullier, J.-M. Dogné, J. Douxfils (Belgium)
- PB386** **Role of Phospholipids in Modulating Tissue Factor-FactorVIIa Complex Activity**
P. Sen (India)
- PB387** **Coagulation Abnormalities and Risk Assessment in Acute Promyelocytic Leukemia - An Experience fom Resource Constraint Country**
N. Anwar, N. Fatima, J. Hassan, A. Naz, T. Shamsi (Pakistan)
- PB389** **eNOS, ACE AND PAI-1 Gene Polymorphisms in a Sample of General Population of Northern Greece**
A. Papoutsj, M. Koutsounida, A. Pantelios, A. Pehlivanis, N. Antou, H. Gioukaki, E. Karaoulis, M. Mantzafouli, K. Varsamidis (Greece)
- PB390** **Evaluation of the Analytical and Diagnostic Performance of a Fibrinogen and of a D-dimer Assay for the Horiba® Yumizen G1550**
J. Pego, A. Carmo, F. Rodrigues (Portugal)
- PB391** **Association between Factor V Leiden and APCR Values: Data from a Portuguese University Hospital**
A. Carmo, J. Pego, M. Lourenço, M.D.F. Martins, F. Rodrigues (Portugal)



- PB393** **Prevalence of Common Genetic Variants Associated with Thrombophilia in Asymptomatic young Individuals with a Family History of Thrombosis**
A. Papoutsj, A. Pantelios, N. Antou, J. Giouretziklis, C. Michael, A. Kalifatidou, K. Varsamidis, E. Vagdatli (Greece)
- PB394** **Identification and Differentiation of Coagulation Factors in Prothrombin Complex Concentrates (PCC's)**
C. Wilhelm, M. Mandago, S. Kiessig, S. Wittke (Germany)
- PB395** **Water Extract of Artemisia Argyi Inhibit Coagulation Factor Aberrant Activation to Intervene the Blood Clotting in Ischemic Stroke Patients**
S. Wang, H. Xu, S. Cheng, S. Gong, Y. Liu, J. Ge (China)
- PB396** **Human Factor XII Mutation W268R Causes Urticarial Autoinflammatory Syndrome through Intracellular Misprocessing**
Z.L.M. Hofman, K. Krause, A. Nosairi, N.A. Mahnke, J. Scheffel, M. Maurer, G. Pasterkamp, C.E. Hack, S. de Maat, C. Maas (the Netherlands)
- PB397** **The Surface of Activated Platelets Enhance the Activity of FXIa**
S.E. Reitsma, C. Puy, D. Gailani, E. Tucker, A. Gruber, O.J.T. McCarty (United States)
- PB398** **FXIa Binds and Forms a Complex with Plasminogen Activator Inhibitor-1 that Inhibits Its Activity and Induces Internalization and Degradation by Endothelial Cells**
A. Ngo, C. Puy, E. Tucker, D. Gailani, A. Gruber, O. McCarty (United States)
- PB399** **A Critical Role of High-molecular-Weight Kininogen in Host Defense against Gram-negative Bacterial Infection**
A. Yang, Y. Wu (China)
- PB400** **Bombyx Batryticatus Extract Induce Kallikrein-kinin System by Activating Coagulation Factor XII**
H. Xu, S. Wang, C. Deng (China)
- PB401** **Prothrombin Concentrates for Reversal of Bleeding Induced by Supratherapeutic Doses of JNJ-9375 (A Novel Exosite 1 Thrombin Antibody) in a Rat Tail Transection Model**
M. Chintala, Z. Huang Devine, J. Reckless (United States)
- PB402** **Saliva-derived Tissue Factor Induces Thrombin Generation in a Diurnal Rhythm**
L.N. van der Vorm, J.E.I.G. Brouwers, C. Mondria, B. de Laat, P.G. de Groot, J.A. Remijn (the Netherlands)
- PB403** **Activated Factor VII Fused with Transferrin Showed Prolonged Half-life with Safe Toxicity Profile in Animal Models**
I. Song, H. Lee, H. Kim (Korea)
- PB404** **“Real World” Usage of Prothrombin Complex Concentrates (PCCs) to Correct Coagulopathy. A 3 Year Retrospective Review in an Academic Hospital System**
I. Kourouni, N. Pakzad, I. Kejo, M. Friedman, D. Steiger, R. Jean (United States)

POSTERS

- PB405** **Gene Expression of Coagulation Factors after Experimental Snake Envenomation in Mice**
A.T.A. Sachetto, J.R. Jensen, M.L. Santoro (Brazil)
- PB406** **Enhanced FIX Collagen IV Binding Shows Improved Hemostatic Effects in a Hemophilia B Mouse Model**
D. Matino, D. Stafford, A. Iorio, A. Chan (Italy)
- PB408** **Factor XI Level Is a Determinant of Plasma Clot Growth**
C. Kluft, J. Begijeneman, N. Podoplelova, N. Dashkevich, F. Ataulakhanov (the Netherlands)
- PB409** **Robustness of Spatial Thrombin Generation and Fibrin Clot Propagation**
A. Kuprash, A. Shibeko, M. Panteleev, F. Ataulakhanov, A. Balandina (Russian Federation)
- PB410** **The Blood Clot is Covered by a Fibrin Film that Protects against Microbes**
F. Macrae, C. Duval, S. Baker, N. Yuldasheva, K. Kearney, H. McPherson, N. Asquith, J. Konings, A. Casini, J. Degen, S. Connell, H. Philippou, A. Wolberg, R. Ariëns (United Kingdom)
- PB411** **Binding of Coagulation Factor XIII Zymogen to Activated Platelet Subpopulations: Roles of Integrin α IIb β 3 and Fibrinogen**
N. Podoplelova, Y. Kotova, S. Obydenny, E. Kostanova, A. Demyanova, M. Biriukova, M. Rosenfeld, H. Chambost, M. Kumskova, F. Ataulakhanov, M.-C. Alessi, M. Panteleev (Russian Federation)
- PB412** **Presence and Function of Cellular Factor XIII in Human Cornea**
Z.Z. Orosz, A.H. Shemirani, H. Bárdos, B. Nagy, A. Berta, J. Kappelmayer, R. Ádány, A. Facskó, L. Muszbek (Hungary)
- PB413** **The Effect of Factor XIII Levels on the Incorporation of α 2-plasmin Inhibitor into Fibrin Clots: Association with the Therapeutic Outcome of Acute Ischemic Stroke Patients**
Z. Bagoly, B. Baráth, I. Szegedi, R. Kálmándi, L. Csiba, É. Katona (Hungary)
- PB414** **Peptides Pro-Gly-Pro and Pro-Gly-Arg Reduce the Level of Fibrinogen and the Activity of Factor XIII**
T. Obergan, M. Grigorjeva (Russian Federation)
- PB415** **Fibrin Fiber Mechanical and Structural Properties Are Altered in Individuals with Cardiovascular Disease on Low/Medium Dose Aspirin**
M. Guthold (United States)
- PB416** **Factor XIII Concentrate Can Improve Clot Stabilization Guided by Thromboelastometry in Patient with Liver Disease: A Case Report**
T. Crochemore, F. Savioli (Brazil)
- PB417** **Hypofibrinogenemia and Thrombosis: Report of the Experience of a Case**
V. Olaya, J. Castaño, M. Insuasty, M. Pizza, A. Muñoz (Colombia)
- PB418** **Plasma Fibrinogen Concentration As an Acute Marker of Myocardial Infarction**
C.K. Dike, O.I. Ajayi (Nigeria)



- PB419 Apixaban Does Not Generate False-positive dRVVT Interpretations for Lupus Anticoagulants, Even at Peak Levels**
O. Kumano, S. Platton, P. Jones, G. Moore (Japan)
- PB420 Pregnancy Outcomes in Women with Antiphospholipid Antibodies with a History of Late Fetal Loss: Interim Results from a Single Centre Cohort**
M. Frishman, K. Schreiber, K. Breen, M.J. Cuadrado, B.J. Hunt (United Kingdom)
- PB421 Pregnancy Outcomes in Women with Antiphospholipid Antibodies: Interim Results from a Single Centre Cohort Study**
K. Schreiber, M. Frishman, K. Breen, M.J. Cuadrado, B.J. Hunt (United Kingdom)
- PB422 Antiphospholipid Syndrome: Maternal and Perinatal Outcome after Treatment in Next Pregnancy. Retrospective Analysis**
B. Grand, P. Galatti, L. Voto, G. Mainetti (Argentina)
- PB423 Are IgM Antiphospholipid Antibodies Redundant in the Classification Criteria for the Antiphospholipid Syndrome?**
W. Chayoua, H. Kelchtermans, G. Moore, J.-C. Gris, J. Musial, D. Wahl, S. Zuily, A. Tripodi, P. Fontana, J. Remijn, B. de Laat, K.M. Devreese (the Netherlands)
- PB424 A Single-arm Pilot Feasibility Cohort Study of Rivaroxaban in Antiphospholipid Syndrome**
K. Legault, M. Blostein, M. Carrier, S. Khan, S. Schulman, S. Shivakumar, C. Wu, M. Crowther (Canada)
- PB425 Antiphospholipid Antibodies Activate the Mechanistic Target of Rapamycin (mTOR) and Disrupt Lysosomal Degradation with Effects upon Monocyte Autophagy**
V.M. Ripoll, A. Khawaja, I.P. Giles, A. Rahman (United Kingdom)
- PB426 Use of Direct Oral Anticoagulant in Antiphospholipid Syndrome: Systematic Review of Literature**
V. Dufrost, S. Zuily, D. Wahl (France)
- PB428 Pregnancy Outcomes in Women with Antiphospholipid Antibodies in IVF Conceived Pregnancies: Interim Results from a Single Centre Cohort**
M. Frishman, K. Schreiber, K. Breen, M.J. Cuadrado, B.J. Hunt (United Kingdom)
- PB429 New dRVVT Assays for Lupus Anticoagulant (LA) Detection with Improved Specificity and Sensitivity: HEMOCLOT LA-S and LA-C**
C. Dunois, M. Peyrafitte, S. De Muynck, V. Villedieu, J. Amiral (France)
- PB430 Beta 2 Glycoprotein I Domain V Disulfide Bond Reduction Alters its Conformation with Regard to Antiphospholipid Syndrome (APS)**
I. Buchholz, T. McDonnell, P. Nestler, V. Ripoll-Nunez, A. Radziszewska, A. Rahman, M. Delcea (Germany)
- PB431 Evaluation of Lupus Anticoagulant Testing: A Descriptive Single Centre Experience**
S.F. Pinzon Mariño, A.J. Garcia Ortego, M. Villalba Montaner, E. Salvador Ruperez, J.M. Calvo Villas, N. Fernandez Mosteirín, P. Delgado Beltran (Spain)

POSTERS

- PB432 Purified Anti- 2-Glycoprotein I IgG Potentiates Both Direct and Indirect Platelet Activation - Report of 2 Cases**
J. Kappelmayer, G. Szabo, I. Beke Debreceni, P. Soltesz (Hungary)
- PB433 A Comparison between Mixing Test Specific Cut-off and the Index of Circulating Anticoagulant with Multiple APTT and dRVVT in Specificity for Lupus Anticoagulant**
O. Kumano, G. Moore (Japan)
- PB434 Thrombotic Risk Assessment in Antiphospholipid Syndrome**
A. Carmo, J. Pego, A. Mendes, R. Cunha, F. Rodrigues (Portugal)
- PB435 Importance of Evaluation of Different Antiphospholipid Antibodies**
A. Makatsariya, J. Khizroeva, V. Bitsadze, M. Arslanbekova (Russian Federation)
- PB436 Recent Methods for Laboratory Detection of Lupus Anticoagulant in Patients with Antiphospholipid Syndrome**
V. Krasivska, O. Stasyshyn (Ukraine)
- PB437 Anti-β₂-Glycoprotein I Antibody Delays Fibrin and Thrombin Formation but Enhances Thrombin Generation**
G. Szabo, I. Beke Debreceni, P. Soltesz, J. Kappelmayer (Hungary)
- PB438 Preeclampsia and Antiphospholipid Antibodies**
A. Makatsariya, J. Khizroeva, V. Bitsadze, M. Arslanbekova (Russian Federation)
- PB439 Direct Oral Anticoagulants in Venous Thromboembolic Disease; Boon or Bane?**
A. Ang, N. Pandit (Singapore)
- PB440 Outcomes in Non-valvular Atrial Fibrillation Patients with Good and Poor INR Control after Switching to Direct Oral Anticoagulants**
B. Haymart, X. Kong, E. Kline-Rogers, S. Almany, J. Kozlowski, G. Krol, M. Dahu, J.B. Froehlich, G.D. Barnes, S. Kaatz (United States)
- PB441 PK/PD (Thrombinography and Fibrinography) Response Variability to Rivaroxaban in Patients Aged 80 Years and Older with Atrial Fibrillation: Results of the ADAGE Study**
G. Foulon, E. Curis, J. Le Guen, A.-C. Martin, C. Lafuente-Lafuente, E. Puymirat, P. Gaussem, I. Gouin-Thibault, E. Pautas, V. Siguret (France)
- PB442 Health-related Quality of Life after Pharmacomechanical Catheter-directed Thrombolysis for Proximal Deep Vein Thrombosis**
S.R. Kahn, J.A. Julian, C. Kearon, C.-S. Gu, D.J. Cohen, E.A. Magnuson, A.J. Comerota, M.R. Jaff, M.K. Razavi, S.Z. Goldhaber, S. Vedantham, ATTRACT Study Investigators (Canada)
- PB443 DTI/DXI Interferences with Global Coagulation Tests in Daily Care Emergency Admissions – Results of the Prospective DRESDEN NOAC REGISTRY (NCT01588119)**
L. Wunder, L. Tittl, S. Marten, J. Beyer-Westendorf (Germany)



- PB444** **Evaluation of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of the Anti-factor XI Antibody, AB023, in Healthy Adult Volunteers**
C.U. Lorentz, E.I. Tucker, M. Wallisch, N.G. Verbout, B. Markway, M.R. Carris, A. Gruber (United States)
- PB445** **The Indirect Effects of Dabigatran En Rivaroxaban on Fibrinolysis**
S. Zwaveling, S. Bloemen, J. Konings, H. Kelchtermans, C. Hemker, A. Miszta, B. de Laat (the Netherlands)
- PB446** **Risk of Thrombosis and Bleeding in Patients Treated with Warfarin or Apixaban for Non-valvular Atrial Fibrillation: A Large, National, Retrospective Study**
M. Wanat, X. Wang, S. Abughosh, H. Chen, M. Johnson, M. Fleming (United States)
- PB447** **Novel Universal Antidote to Non-Vitamin K Antagonist Anticoagulants**
G. Jourdi, I. Gouin-Thibault, V. Siguret, S. Gandrille, P. Gaussem, B. Le Bonniec (France)
- PB448** **Comparing the Proportions of Patients that Meet Criteria for Extended Prophylaxis with Betrixaban Based on APEX Trial and FDA Indication**
S. Kaatz, A. Conlon, E. McLaughlin, S. Flanders, V. Chopra, D. Paje (United States)
- PB449** **Reversal of Direct Factor Xa Inhibitor-Associated Major Bleeding with Four-factor Prothrombin Complex Concentrate: A Systematic Review and Meta-analysis**
S. Piran, R. Khatib, S. Schulman, A. Majeed, A. Holbrook, D.M. Witt, R. Nieuwlaat (Canada)
- PB450** **Resumption of Anticoagulant Therapy after Anticoagulant-Related Gastrointestinal Bleeding: A Systematic Review and Meta-analysis**
D. Little, C. Chai-Adisaksoha, C. Hillis, D. Witt, M. Monreal, M. Crowther, D. Siegal (Canada)
- PB451** **Development and Characterization of Novel Nanoparticulate Carrier for Oral Delivery of Low Molecular Weight Heparin**
S. Bhargava, V. Bhargava, A. Jain, V. Bhargava (India)
- PB452** **Recurrent Thrombosis in Patients with Antiphospholipid Antibodies Treated with Vitamin K Antagonists or Rivaroxaban**
M. Abbattista, P. Bucciarelli, A. Tripodi, A. Artoni, F. Gianniello, C. Novembrino, F. Peyvandi, I. Martinelli (Italy)
- PB453** **Measurement of Anti-FXa Activity of Edoxaban and its Metabolites in Plasma and Consistency with LC:MS/MS Reference Concentrations**
C. Dunois, M. Peyrafitte, C. Amiral, A. Javillier, J. Amiral (France)
- PB454** **Variable Response in Individuals to Rivaroxaban and Apixaban over Time**
S. Zwaveling, J. Konings, H. Kelchtermans, B. de Laat, C. Hemker, S. Bloemen (the Netherlands)
- PB455** **Effect of Anti-arrhythmic Medication Drug Interactions on Thrombotic and Bleeding Outcomes in Patients with Atrial Fibrillation**
M. Wanat, X. Wang, S. Abughosh, H. Chen, M. Johnson, M. Fleming (United States)

POSTERS

- PB456 Lean Body Weight is the Best Scale for Venous Thromboprophylaxis Algorithm in Severely Obese Patients Undergoing Bariatric Surgery**
B. Gaborit, P.-A. Moulin, T. Bege, S. Boullu, C. Vincentelli, O. Emungania, P.-E. Morange, S. Berdah, A. Dutour, C. Frere (France)
- PB457 Long-term Monitoring of Patients after Stroke on Antiplatelet Agents Allows to Identify the Advantages and Limitations of Impedance Aggregation**
T. Vavilova, O. Rodionova, V. Sorokoumov, L. Isaeva (Russian Federation)
- PB458 Post Analytical External Quality Assessment of Anticoagulant Dosing for Warfarin Therapy**
D. Kitchen, S. Munroe-Peart, L. Brown, I. Jennings, S. Kitchen, T. Woods, I. Walker (United Kingdom)
- PB459 Creation of an Algorithm for Predicting Doses of Warfarin < 17.5mg Using CYP2C9 and VKORC1 Polymorphisms and Non-genetic Factors**
A.O.M. Mourão, K.B.G. Borges, E.A. Reis, R.P. Souza, E.I.F. Campos, D.D. Ribeiro, M.O.C. Rocha, M.A.P. Martins (Brazil)
- PB460 Warfarin Use Increases Bleeding Risk in Hemodialysis Patients with Atrial Fibrillation: Evidence from Meta-analysis Using Real World Data**
S. Hussain, A.N. Siddiqui, H. Baxi, A. Habib, A.K. Najmi (India)
- PB461 Change of Rivaroxaban Anticoagulant Effect during the 24 Hours**
I. Geltcer, O. Smirnova, O. Matvienko, O. Golovina, L. Papayan (Russian Federation)
- PB463 Flow Based Analysis of Heparin Inhibition of VWF Dependant Platelet Capture**
A. Ranger, T. Mckinnon, M. Laffan (United Kingdom)
- PB464 Comparative Safety of Co-prescribed Calcium Channel Blockers and Oral Anticoagulants for Adverse Bleeding Events in Atrial Fibrillation**
P. Pham, S. Schmidt, J. Brown (United States)
- PB465 Real-world Experience of Direct Oral Anticoagulants Use in North Melbourne, Australia**
R. Brook, T. Kitipornchai, P. Ho, H.Y. Lim (Australia)
- PB466 Relationship between Dabigatran Concentrations in Plasma and Results of Routine Coagulation Assays PT, APTT, TT and Fibrinogen**
S. Margetic, A. Bronic, I. Celap, I. Vuga (Croatia)
- PB467 Measuring Anti-factor Xa Levels to Monitor Enoxaparin in Pregnant Women: A Prospective Comparative Study**
F. Aleidan, A. Aldakhil, B. Allehyani, G. Aljarba, M. Yahia, N. Alghtani, A. Alsuhaibani, A. Alaklabi (Saudi Arabia)
- PB468 Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation in Clinical Practice: Outcomes from the First Observational and Prospective Study in Spanish Population**
M. Cerdá Sabater, E. Johansson, F. Martínez García, M. Fernández Caballero, A. Varela Magallón, S. Rodríguez López, F. Bosch Albareda, A. Santamaría Ortiz (Spain)



- PB469 Real-world Compliance Patterns with Direct Oral Anticoagulants with Acute Venous Thromboembolism**
M. Bartlett, D. Bott Kitslaar, E. Vargas, A. Casanegra, D. Froehling, D. Hodge, R. McBane, W. Wysokinski (United States)
- PB470 Multihospital System Implementation of the Anti-Xa for Titration for Monitoring Unfractionated Heparin (UH) Therapy**
P. Lindholm, K. Zmuda, E. Short, R. Sumugod, A. Shah, D. Cooke (United States)
- PB471 Correcting Inappropriate Prescribing of Direct Oral Anticoagulants: A Population Health Approach**
T. Dawson, D. DeCamilo, E. Kline-Rogers, B. Haymart, J. Froehlich, G. Barnes (United States)
- PB472 Impact of Rivaroxban on Platelet Reactivity and von Willebrand Factor Antigen and Activity in Patients with Venous Thrombosis**
N. Schultz, P.A. Holme, C.E. Henriksson, S. Bjørnsen, P.M. Sandset, E.M. Jacobsen (Norway)
- PB473 Weekly Warfarin Maintenance Dose According to Variations in Four Genes Evaluated in Patients Assisted at a Brazilian Anticoagulation Clinic**
E.I.F. Campos, K.B.G. Borges, A.O.M. Mourão, M.O.C. Rocha, D.D. Ribeiro, R.P. de Souza, M.A.P. Martins (Brazil)
- PB474 Spontaneous Rectus Sheath Hematoma in Patients on Anticoagulant Therapy: A Systematic Review**
S. Khaliq (Pakistan)
- PB475 Promising Antithrombotic Peptide Agents**
M. Grigorjeva, L. Lyapina (Russian Federation)
- PB476 Knowledge of, Satisfaction with and Adherence to Oral Anticoagulant Drugs among Patients in Tripoli Medical Center; Tripoli, Libya**
M. Abugrin, A. Ali, E. Sadouh, A. Khaled, H. Ahmed, M. Elhadi, T. Emahbes, A. Elhadi, A. Saeed, T. Khaled, E. Omran (Libyan Arab Jamahiriya)
- PB477 Development, Implementation and Evaluation of Application for Monitoring Oral Anticoagulant Therapy**
J.A.Q. Oliveira, T.Q.V. Sá, J.O.G. Ramos, L.B. Ribeiro, M.A.P. Martins, A.L.P. Ribeiro, M.S. Marcolino (Brazil)
- PB478 Patient Satisfaction Associated with Warfarin Treatment in Different Settings: A Cross-sectional Study**
N. Riva, C. Borg Xuereb, W. Ageno, M. Makris, A. Gatt (Malta)
- PB479 A Multicenter Experience with Idarucizumab “in Real World” as Reversal Anticoagulation of Dabigatran**
M. Villalba Montaner, R. Martínez Fernández, O. Gavin Sevastián, I. Cuesta Gallardo, J.M. Real Campaña, L.I. Sancho Val, A.R. Millán Acero, E. Salvador Rúperez, S.F. Pinzón Mariño, B. Sánchez Quiñones, A.J. Garcia Ortego, G. Ferrer Garrido, N. Fernandez Mosteirín, J.M. Calvo Villas, P. Delgado Beltrán (Spain)

POSTERS

- PB480** **The Effect of Peptide Selank on the Parameters of the Rat Hemostasis System against the Background of Endothelial Dysfunction**
E. Rogozinskaya, L. Lyapina (Russian Federation)
- PB481** **Retrospective Observational Study of Patients Treated with Rivaroxaban in Saudi Arabia**
M. Riazuddin, M. Ahmed, S. Khan, O. Emadi, M. Abufarhaneh, M. Alkasab, H. Alsudairy, K. Alshammari, A. Sheikh, A. Alrashed, I. Butt, A. Alfifi, M. Khan (Saudi Arabia)
- PB482** **Combined Q-Switched-Nd: YAG Laser-mediated Photomechanic Thrombolytic Therapy Plus Tissue Plasminogen Activator (tPA) Administration Reduce Thrombus Content in the Arterial Atherothrombotic Stenosis**
H. Mehrad, S.M. Tabatabaei, M. Bolourian, M.R. Moktari, M.M. Hosseini, A. Mirzakhani, M.H. Daghighi (Iran)
- PB483** **Description and Evaluation of the Comparison of Activated Partial Thromboplastin Time versus Anti-factor Xa Activity for Therapeutic Unfractionated Heparin Monitoring in a Tertiary Academic Medical Center using Three Different Adult Weight-based, Nurse Managed Nomogram Protocols**
L. Talamo, D. Chyn, S. Palkimas, H. Maitland (United States)
- PB484** **Idarucizumab for Reversing Anticoagulation in Patients Treated with Dabigatran: Experience in our Center**
E. Morente Constantin, P. Romero Garcia, M. Rivas Luque, A. Garcia Ruiz, M.D.P. Garrido Collado, M. Jurado Chacon (Spain)
- PB485** **Warfarin Dose Requirements in Patients with Heart Diseases Assisted at an Anticoagulation Clinic in the Southeast Brazil**
E.I.F. Campos, C.M. Bertollo, A.M.M. Reis, I.G. Ferreira, J.C. Sá, M.O.C. Rocha, M.A.P. Martins (Brazil)
- PB486** **Direct-acting Oral Anticoagulant Drug Level Monitoring in Clinical Patient Management**
A. Rottenstreich, N. Zacks, G. Kleinstern, B. Hirsch Raccach, B. Roth, Y. Kalish (Israel)
- PB487** **Establishment of a Centralized Monitoring System for Patients Receiving Anticoagulant Therapy in the Arkhangelsk Region Russia**
N. Vorobyeva, A. Vorobyeva, A. Schapkov (Russian Federation)
- PB488** **Evaluation of Algorithms for Warfarin Dose Prediction**
E.I.F. Campos, K.B.G. Borges, J.M. Costa, M.A.P. Martins (Brazil)
- PB489** **Development of an Educational Intervention Focused on Low-income Population Treated with Warfarin**
J.M. Costa, M.S. Marcolino, H.C. Barbosa, J.A.Q. Oliveira, L.R.A. Campos, E.I.F. Campos, H.C. Torres, M.A.P. Martins (Brazil)
- PB490** **A Novel Factor Va Inhibitory Antibody Prevents Blood Clots without Increasing Bleeding Risk**
J. Wu, R. Li, Y. Yang, N. Chen, Y. Li, J. He, X. Fan (China)
- PB491** **Direct Oral Anticoagulant Use in Obese Patients: Preliminary Results of a Pilot Study**
L. Talamo, S. Palkimas, H. Maitland (United States)



- PB492 Arterial Thrombosis Depends on Shear Rate More Than Shear Rate Gradient**
D. Kim, C. Lauren, D. Ku (United States)
- PB493 Increased Platelet Count and Reticulated Platelets in Recently Symptomatic versus Asymptomatic Carotid Artery Stenosis and in Cerebral Microembolic Signal-negative Patient Subgroups: Results from the HEIST Study**
S. Murphy, S.-T. Lim, J. Kinsella, D. Murphy, H. Enright, D. McCabe, HEIST Study Group (Ireland)
- PB494 The Collagen-induced Platelet Aggregation and Artery Status in Patients with Arterial Hypertension of Very High Risk**
E. Shorikov, D. Shorikova (Ukraine)
- PB495 Significance of Single Nucleotide Polymorphisms (SNPs) within Genes Encoding Platelet Glycoprotein Receptors in Patients with Infective Endocarditis (IE)**
M. Sorokina, A. Andreev, A. Balatskiy, A. Pisaryuk, N. Povalyaev, E. Kotova, Y. Karaulova, A. Milto (Russian Federation)
- PB496 Risk Factors for Brain Vessels's Thrombosis/Stenosis in Young Patients with Ischemic Stroke**
T. Tsvetanov, M. Cholakova, M. Staneva, P. Antova, I. Staykov (Bulgaria)
- PB497 In vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions**
H. Haguet, J. Douxfils, C. Graux, C. Chatelain, F. Mullier, J.-M. Dogné (Belgium)
- PB498 Impaired Fibrinolytic Activity in Nigerian Myocardial Infarction Patients**
O.I. Ajayi, F.S. Ozimede (Nigeria)
- PB499 Shear Enhances Fibrin-induced GPVI Shedding and Platelet ADAM10 Function**
S.J. Montague, S. Hicks, P.Y. Choi, C.S.-M. Lee, X. He, R.K. Andrews, W.M. Lee, E.E. Gardiner (Australia)
- PB500 Resonance Raman Spectroscopy as a Tool to Study Blood Flow in Brain Vessels in vivo**
E.I. Nikelshparg, N.A. Brazhe, K. Thomsen, M. Lønstrup, A.R. Brazhe, G.V. Maksimov, M. Lauritzen, O. Sosnovtseva (Russian Federation)
- PB501 Assessing Three-dimensional Fibrin Polymerization Dynamics during Heparin Administration and Protamine Reversal in Cardiac Surgical Patients**
D.M. Tshikudi, O. Simandoux, D. Kang, D. Yelin, S.K. Nadkarni (United States)
- PB502 Anticoagulation Monitoring of Pediatric Patients on Life Support Systems Using a Microfluidic Device that Mimics Complex Vascular Architecture**
D. Luna, N. Pandian, J. Bui, P. Gadangi, T. Mathur, C. Reyes, J. Teruya, A. Jain (United States)
- PB503 Ir-CPI: An Original Inhibitor of Thrombosis and Thrombosis-associated with Cancer**
R. Darbousset, V. Pireaux, L. Crescence, S. Demoulin, L. Panicot-Dubois, E. Godfroid, C. Dubois (Belgium)

POSTERS

- PB504 The Relation between Coagulant and Vascular Function in Adult Survivors of Childhood Cancer**
M. Panova-Noeva, B. Wagner, M. Nagler, S. Eckerle, H. Spronk, M.-A. Neu, H. Merzenich, N. Arnold, J. Prochaska, A. Schneider, K. Lackner, H. ten Cate, T. Münzel, J. Faber, P. Wild (Germany)
- PB505 Effectiveness and Safety of Rivaroxaban versus Low Molecular-weight Heparin for Treatment of Cancer-associated Thromboembolism**
C.I. Coleman, T.J. Bunz, C.G. Kohn, J. Beyer-Westendorf (United States)
- PB506 Optimizing Therapy for Venous Thromboembolism in Multiple Myeloma: A Systematic Review**
S. Abegunde, I. Ajayi (Nigeria)
- PB507 Low Molecular Weight Heparin Dose in the Long-term Management of Cancer Associated Thrombosis: Single Centre Experience**
A. AL Zaki, R. Schmidt, N. Desilet, N. Ratnaweera, E. Peterson, A.Y.Y. Lee (Canada)
- PB508 Comparative Efficacy and Safety of Anticoagulation for the Treatment of Cancer-associated Thrombosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials**
C.I. Coleman, K. Sasiela, E. Smith, S.E. Trexler, K. Jackman, W.L. Baker (United States)
- PB509 A Monoclonal Antibody to Human Podoplanin Inhibits Human Platelet Aggregation Induced by Tumor Cells**
Y. Zhao (China)
- PB510 D-dimer Levels for Prediction of Symptomatic Central Venous Catheter-related Thrombosis in Breast Cancer Patients**
I. Benzidia, C. Frère, A. Hij, M. Espié, J. Gligorov, A. Elias, P.F. Dupré, S. Villiers, S. Giacchetti, P. Debourdeau, D. Farge (France)
- PB511 Hypercoagulation Screening as Tool for Cancer Diagnosis: An Update on Tumor Incidence and Risk Factors in the HYPERCAN Study**
S. Gamba, D. Raffaeli, M. Marchetti, L. Russo, C.J. Tartari, C. Giaccherini, C. Verzeroli, S. Brevi, V. Milesi, G. Sampietro, P. Malighetti, D. Spinelli, A. Falanga (Italy)
- PB512 Patients Experience of Living with Cancer Associated Thrombosis in New Zealand (PELICANZ)**
T. Woulfe, K. Mann, D. Pollack, A. Nelson, H. Prout, P. Gee, S. Noble (United Kingdom)
- PB513 Cost-effectiveness of Edoxaban versus Dalteparin for Treatment of Cancer-associated Thrombosis**
N. Connell, J. Connors (United States)
- PB514 Non-phosphorylated and Phosphorylated Signal Transduction Peptide (STP) of Tissue Factor (TF) in Urine Are Potential Biomarkers for Bladder and Colon Cancer**
R. Greenfield, T. Herd, K. Date, A. O’Kane, A. Maraveyas (United Kingdom)



- PB516** **Leucocyte and Platelet Activation in Patients with BCR-ABL Negative Myeloproliferative Disorders**
C. Portelli, M.C. Cini, P. Brincat, K. Vella, N. Calleja, A. Gatt (Malta)
- PB517** **Estimation of Risk Factors for PICC Catheter Related Thrombosis in Patients with Hematologic Malignancies**
Z. Weiwei, F. Yun (China)
- PB518** **Optimisation of Thrombin Generation as a Predictive Biomarker for Venous Thromboembolism in Gynaecological Malignancies**
M.P. Ward, F. Abu Saadeh, S.A. O'Toole, Z. Machocki, N. Gleeson, L.A. Norris (Ireland)
- PB519** **Evaluation of Risk Factors and Assessment Models for Predicting Venous Thromboembolism in Lung Cancer Patients**
J. Rupa-Matysek, M. Lembicz, E. Rogowska, L. Gil, M. Komarnicki, H. Batura-Gabryel (Poland)
- PB520** **Splanchnic Thrombosis Associated to Myeloproliferative Neoplasms: A Cohort of 233 Tunisian Patients**
I. Ghachem, H. Abbassi, S. Hadhri, L. Chaouch, H. Skouri (Tunisia)
- PB521** **The Effect of Hydroxyurea on Blood Coagulation in Sickle Cell Disease**
M. Borhany, M. Abid, N. Fatima, T. Shamsi (Pakistan)
- PB522** **The Effect of Inflammatory Cytokines IL-6, IL-10, IL-1b and TNFa on Thromboelastography Parameters in Pediatric Patients with Acute Lymphoblastic Leukemia**
S. Prasca, E. Orgel, J.H. Parmentier, S. Mittelman, G. Young (United States)
- PB524** **Clinical and Global Hemostatic Parameters in Patients with JAK2 V617F Mutation Myeloproliferative Neoplasms (MPNs)**
A. Sasakul, P. Chanrathammachart, S. Chuncharunee, A. Ungkanont, P. Angchaisuksiri, P. Niparuck, S. Pukiat, S. Phusanti (Thailand)
- PB525** **Generation of Neo-epitopes on Hypochlorous Acid-modified Human Antithrombin: An Immunological Study**
P. Ahmad, I.Q. Tantry, M.M. Rizwee, A. Ali, M.A. Jairajpuri (India)
- PB526** **Polymorphism of Folate Protein Genes Metabolism as a Predictor of Thrombosis in Patients with Proliferative Disease and Breast Cancer**
A. Markovsky (Russian Federation)
- PB527** **The Usefulness of Standard and Derived ROTEM Parameters for DIC Prediction in Septic Patients**
E. Scarlatescu, D.R. Tomescu (Romania)

POSTERS

- PB528** **Recombinant A2 Domain of von Willebrand Factor Attenuates Microthrombi Formation, Organ Injuries and D-dimer Levels in a Porcine Model of Methicillin-resistant Staphylococcus Aureus (MRSA) Sepsis-induced Disseminated Intravascular Coagulation (DIC)**
M. Cruz, J. Marini, B. Guillory, M. Martnez-Vargas, C. Valladolid, D. Cohen, F. Lam, S. Cirlos, Q. Da, B. Stoll, Y. Yuan, S. Kaplan, M. Desai, V. Vijayan, T. Nguyen (United States)
- PB529** **The Expression of Tissue Factor between Monocyte Subsets: A Role in Sepsis-associated Coagulopathy?**
K.M. Musgrave, M.-H. Ruchaud-Sparagano, J. Scott, A.J. Rostron, A.J. Simpson (United Kingdom)
- PB530** **Added Value of the DIC Score and of D-dimer to Predict Outcome after Successfully Resuscitated Out-of-Hospital Cardiac Arrest**
N. Buchtele, C. Schörghofer, A. Schober, B. Jilma, M. Schwameis (Austria)
- PB531** **Neutrophil Fluorescence: A New Indicator of Cell Activation during Septic Shock-induced Disseminated Intravascular Coagulation that Could Reflect NETosis**
L. Stiel, X. Delabranche, R. Clere-Jehl, C. Mayeur-Rousse, F. Zobairi, F. Toti, F. Meziani, L. Mauvieux, J. Helms (France)
- PB532** **Evaluation of the Effectiveness of AT III Concentrate in Acute DIC-syndrome**
N. Vorobyeva, A. Vorobyeva (Russian Federation)
- PB533** **von Willebrand Factor Interactions with Platelets and Leukocytes is Critical for Obesity-mediated Venous Thrombosis**
A. Michels, L.L. Swystun, C. Dwyer, K. Nesbitt, C. Kawecki, P. Lenting, D. Lillicrap (Canada)
- PB534** **Iron Deficiency Increases Platelet Procoagulant Capacity in a Ferric Chloride Model of Arterial Thrombosis**
K. Jimenez, G. Scharbert, A. Leitner, P. Schwabl, F. Leitner, R. Evstatiev, V. Khare, C. Gasche (Austria)
- PB535** **Dabigatran Enhances the Antibiotic Efficacy and Reduces Sepsis Induced Thrombosis in Severe Staphylococcus aureus Aortic Endocarditis**
C.J. Lerche, L.J. Christophersen, P.Ø. Jensen, J.P. Gøtze, P.R. Nielsen, K. Thomsen, N. Høiby, H. Bundgaard, C. Moser (Denmark)
- PB536** **Development of an Easily Reproducible and Inexpensive Experimental Rabbit Carotid Model of Atherothrombotic Occlusion with Morphological Similarities to the Human Disease: Monitored by Color Doppler Ultrasonography and Histopathology**
H. Mehrad, L. Zeinalizad, A. Arshadi, S. Sarabi, Z. Pishezari, M. Haji Sagati, M. Farhoudi (Iran)
- PB537** **Effect of Cooling Environment in the State of Haemostasis System in Rats**
N. Lycheva (Russian Federation)
- PB538** **Comparative Characteristics of the Hemostasis System State in Rats during Hypothermic and Early Reactive Periods of General Cold Trauma**
N. Lycheva (Russian Federation)



- PB539** **A Comparative Characteristic of the State of the Hemostasis System in Rats under the Action of a Single Immersion Hypothermia Immediately and a Day after they Reached an Super Deep Degree of Hypothermia**
N. Lycheva (Russian Federation)
- PB540** **Dynamics of Indicators of the Hemostasis System in Rats as the Core Temperature Decreases**
N. Lycheva (Russian Federation)
- PB541** **A Highly Efficient and Adhesive Antibacterial Dextran Derivative for Rapid Hemostasis with Wound Healing**
C. Liu, X. Liu, G. Sun, W. Qiao (China)
- PB542** **Rapid Detection and Classification of Direct-acting Oral Anticoagulants (DOACs) with a Novel Point-of-Care Thromboelastography DOAC Cartridge and Algorithm**
J.D. Dias, C. Lopez-Espina, J. Ippolito, H. Hsiao, F. Zaman, B. Mathew, A. Muresan, M. Walsh, B. Thurston, R. Artang, K. Bliden, P. Gurbel, J. Hartmann, H.E. Achneck (United States)
- PB543** **Normal to High Anti-Xa Levels in High Body Weight Patients Using Apixaban and Rivaroxaban**
Z. Mahir, T. Dowling, V. Collings, G.W. Moore, M.P. Crowley, K. Breen, B.J. Hunt, A.T. Cohen (United Kingdom)
- PB544** **Global Coagulation Assay Changes in Patients with Chronic Renal Impairment**
H.Y. Lim, M. Munnings, D. Barit, H. Nansurkar, P. Ho (Australia)
- PB545** **Assessment of the Agreement between the International Normalised Ratio (INR) Values Obtained by Applying Two Different Reagent/Instrument Combinations**
A.N. Blanco, L. Remotti, M.F. Ingrassi, S.H. Grosso, M.L. Romero, M.G. Agazzoni, M.P. Vera Morandini, A. Sánchez-Luceros (Argentina)
- PB547** **The Coagulation System State in Patients with Philadelphia-negative Myeloproliferative Neoplasms**
N. Silina, O. Matvienko, N. Korsakova, O. Golovina, S. Voloshin, V. Shuvaev, E. Efremova, M. Fominykh (Russian Federation)
- PB548** **Thromboelastographic Changes in Patients with BCR-ABL Negative Myeloproliferative Disorders**
M.C. Cini, C. Portelli, K. Vella, P. Brincat, P. Gatt, N. Calleja, A. Gatt (Malta)
- PB549** **The Impact of Age, Ethnicity and Gender on Global Coagulation Assays**
H.Y. Lim, C. Ng, J. Rigano, H. Nandurkar, P. Ho (Australia)
- PB551** **Identification of Protein C System-associated Thrombophilia using an Endothelial Cell-based Thrombin Generation Assay**
E. Coll, A. Amirkhosravi, M. Brodie, P. Martins, H. Desai, L. Robles-Carrillo, E. Spruill, J. Francis (United States)

POSTERS

- PB553** **Development of a New Point-of-care Test for the Detection of Direct Oral Anticoagulants (DOACs)**
G. Frydman, F. Ellett, N. Davis, J. Jorgensen, D. Hayden, E. Van Cott, H. Dalzell, D. Padmanabhan, M. Majmudar, C. Vanderburg, M. Toner, J. Fox, R. Tompkins (United States)
- PB554** **A Rapid Fully-automated Chemiluminescent Immunoassay for the Early Quantification of ADAMTS13 Activity in TTP Diagnosis**
C. Valsecchi, M. Maribet Perez, S. Faraudo, S. Blanch, F. Peyvandi (Italy)
- PB555** **Urgent Laboratory Investigation of HIT Syndrome with an Automated Immunoassay in Cardiovascular Patients**
G. Soufla, E. Iliopoulou, T. Kanellopoulou, S. Georgantis, M. Katafygioti, T. Kostelidou (Greece)
- PB556** **Platelet Hyporeactivity Combined with Enhanced Coagulation in Healthy Term and Preterm Newborns During First Days of Life**
E. Koltsova, E. Balashova, A. Ignatova, A. Poletaev, D. Polokhov, A. Kuprash, O. Ionov, A. Kirtbaya, A. Lenyushkina, L. Timofeeva, V. Zubkov, D. Degtyarev, G. Sukhikh, F. Ataulakhanov, M. Panteleev, A. Balandina (Russian Federation)
- PB557** **Von Willebrand Factor Antigen Levels Predict Major Adverse Cardiovascular Events in Patients with Asymptomatic Carotid Stenosis**
K. D. Kovacevic, F. J. Mayer, B. Jilma, C. J. Binder, A. D Blann, E. Minar, M. Schillinger, M. Hoke (Austria)
- PB558** **Thrombin Generation in Real-world Patients Treated with Two Different Doses of Apixaban**
M.D.L. Herrera, S. Pons, A. Grinson, S. Aguirre, V. Monserrat, A. Brodsky, A.S. Scaziota (Argentina)
- PB559** **Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran**
F. Härtig, I. Birschmann, A. Peter, M. Ebner, C. Spencer, M. Gramlich, H. Richter, J. Kuhn, R. Lehmann, C.S. Zuern, U. Ziemann, S. Poli (Germany)
- PB560** **Active von Willebrand Factor Levels in Kidney Disease Are Associated with Disease Severity and Type of Dialysis**
L.N. van der Vorm, R. Visser, D. Huskens, A. Veninga, J.A. Remijn, H.C. Hemker, P.L. Rensma, R. van Horsen, B. de Laat (the Netherlands)
- PB561** **Role of Thromboelastography to Assess Thrombin Generation in Acute Coronary Syndrome (ACS)**
Q. Lu, X. Wang (China)
- PB562** **Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of Direct Oral Anticoagulants on Several Thrombophilia Screening Tests**
J. Favresse, B. Lardinois, L. Sabor, B. Devalet, J. Vandepapeliere, M. Braibant, S. Lessire, B. Chatelain, H. Jacquemin, J. Douxfils, F. Mullier (Belgium)
- PB563** **Laboratory Assessment of Dabigatran Levels and Anti-Xa Anticoagulant Levels**
I. Paskaleva, D. Dineva, E. Doncheva (Bulgaria)



- PB564** **Monitoring Treatments by Unfractionated Heparin. Stability of Plasma Anti-Xa Activity for up to 4 Hours in Citrated Tubes**
P. Toulon, F. Fischer, A. Appert-Flory, S. Buvat, D. Jambou, M.-H. Mahagne (France)
- PB565** **Utility of PF4/IgG ELISA Optical Density Values as an Indicator of Positivity of the Heparin Induced Platelet Activation Test in Laboratory Testing for Heparin Induced Thrombocytopenia (HIT)**
M. Byrne, S. Lawlor, C. Haran, C. Gannon, B. White, K. Ryan, J. O'Donnell, N. O'Connell (Ireland)
- PB566** **Natural Anticoagulant Deficiencies in Thais: A Population-based Study**
P. Rojnuckarin, R. Settapiboon, B. Akkawat, N. Uaprasert, T. Intragumtornchai (Thailand)
- PB567** **Changes in Tissue Factor Concentration and APTT in Haemolysed and Non-haemolysed Paired Citrate Samples**
K. Hickey, A. Woolley, S. Kitchen (United Kingdom)
- PB568** **Antithrombin Deficiency Has Lower Prognostic Value in Comparison with INR in Critically ill Patients with SIRS**
E. Neporada, A. Travkov, S. Astrakov (Russian Federation)
- PB569** **DOAC Filter Effect on Thrombin Generation: Pre-analytical Considerations and Analytical Perspectives**
C. Bouvy, J. Evrard, R. Siriez, F. Mullier, J. Douxfils, D. Gheldof (Belgium)
- PB570** **Heparin-induced Thrombocytopenia: An International Assessment of the Quality of Laboratory Testing**
Z. Liederman, E.M. Van Cott, K. Smock, P. Meijer, R. Selby (Canada)
- PB571** **A Comparison of Two Point-of-Care Testing Platforms (CoaguChek® Pro II and CoaguChek® INRange) to Standard Laboratory Measurement of the International Normalised Ratio**
S.H. Yeang, E.J.S. See, Y.T. Shim, M.C. Kong, S.K. Koh, Y.F. Lai, C.X.Y. Liew, W.H. Wong, H. Kaur, H.M. Tay, C.W. Tan, H.J. Ng (Singapore)
- PB572** **Measurement of Coagulation Factors during Rivaroxaban and Apixaban Treatment: Results from Two Crossover Trials**
L.J.J. Scheres, W.M. Lijfering, S. Middeldorp, Y.W. Cheung, S. Barco, S.C. Cannegieter, M. Coppens (the Netherlands)
- PB573** **Stability of Thrombin Generation and Thrombin Dynamics in Healthy Individuals over a One-year Period**
J. Konings, D. Yin, R. Kremers, D. Huskens, S. Bloemen, B. De Laat, H. Kelchermans (the Netherlands)
- PB574** **The Association of Hereditary Thrombophilia with Clinically Relevant Hypercoagulation State and Free Flap Thrombosis in Microvascular Surgery**
K. Drizlionoka, J. Stepanovs, J. Krustiņš, A. Ozoliņa, L. Ņikitina- Zaķe, B. Mamaja (Latvia)

POSTERS

- PB575** **Use of a Liquid Recombinant Thromboplastin (DG-PT RecombiLIQ, Diagnostic Grifols) for Monitoring Vitamin K Antagonist Therapy**
A. Woolley, S. Kitchen (United Kingdom)
- PB576** **Heparin Anti-Xa Assay versus Activated Partial Thromboplastin Time to Monitor Unfractionated Heparin during Extracorporeal Membrane Oxygenation**
D. Jayakody Arachchillage, E. Dhillon, C. Vandenbriele, J. Dutton, N. Bhudia, M. Laffan (United Kingdom)
- PB577** **An Automated Modified Anti-Xa Assay for the Potency Assessment of Bemiparin in Pharmaceutical Formulations**
V. Monserrat, S. Aguirre, R. Raimondi, A. Scazzioia (Argentina)
- PB579** **The Impact of »in vitro« Added Idarucizumab on Thrombin Generation**
N. Vene, A. Mavri, M. Bozic Mijovski (Slovenia)
- PB580** **Limits to Sensitivity of 4T Score for Heparin Induced Thrombocytopenia**
D. Jayakody Arachchillage, F. Kamani, S. Fox, K. Patel, M. Laffan (United Kingdom)
- PB581** **External Quality Assessment of Point of Care Testing in Haemostasis**
S. Munroe-Peart, D. Kitchen, L. Brown, I. Jennings, S. Kitchen, T. Woods, I. Walker (United Kingdom)
- PB582** **Clot Waveform Analysis for Measuring and Quantifying Fibrin Clot Formation**
J. Evrard, R. Siriez, P. Themans, J. Laloy, F. Mullier, J.-M. Dogné, J. Douxfils (Belgium)
- PB583** **The Calibrated Automated Thrombography in Patients with Factor XII Deficiency**
O. Matvienko, N. Silina, O. Golovina, L. Papayan (Russian Federation)
- PB584** **Thrombin Generation Analysis with a New Automated System (ST-Genesia): Inter-series Performances during DRIVING Study and Comparison with CAT System**
V. Siguret, G. Foulon, J. Abdoul, A. Carlo, T. Lecompte, I. Gouin-Thibault (France)
- PB585** **Evaluation of Direct Oral Anticoagulants Assays in External Quality Control Surveys**
C. Bon, R. Meley, M. Lopez, C. Sotta, J.-C. Eynard, B. Poggi (France)
- PB586** **D-dimer Measurement: Lipid Interference Removal through High-speed Centrifugation**
F. Estève, M. Ramzi, N. Jonathan, S. Goulet-Cornilleau, A. Auby, A. Carlo, M. Grimaux (France)
- PB588** **Development of a HPLC-UV Method for the Measurement of Dabigatran from Plasma and its Application as Reference Method for the Evaluation of a Novel Chromogenic Dabigatran Assay**
A. Kurucz né Kern, M. Olajos, A. Kecán, J. Antal (Hungary)
- PB589** **Fibrinolysis System and Combined oral Contraceptives**
N. Vorobyeva, D. Gamyrkina (Russian Federation)



- PB590** **A Novel Prothrombin Time (PT) Assay - A Tool for Rapid Screening of All Non-Vitamin K-Dependent Oral Anticoagulants (NOACs)**
M. Abelius, E. Theodorsson, M. Rånby, T.L. Lindahl (Sweden)
- PB591** **Reference Change Value for INR: A Simple Tool for Management of Patients on Oral Anticoagulation**
S. Aguirre, V. Monserrat, R. Raimondi, A. Scazzioa (Argentina)
- PB593** **Reproducibility of Rotem® Device**
E. Scalabrino, L. Padovan, V. Chantarangkul, M. Clerici, F. Peyvandi, A. Tripodi (Italy)
- PB594** **Taipan Snake Venom Time Detects the Lupus Anticoagulants in Anticoagulated, Triple-positive Antiphospholipid Syndrome Patients**
G.W. Moore, R.A. Archer, E.S. Bromidge, A.P. Culhane, B.J. Hunt (United Kingdom)
- PB595** **Rotational Thromboelastometry (ROTEM) as an Alternative Method for Coagulation Assessment in Pediatric Patients Undergoing Invasive Intervention**
M. Durila, M. Durilova, M. Rygl, J. Skrivan, J. Jonas, T. Vymazal (Czech Republic)
- PB596** **Improving Lupus Anticoagulant Testing with 2 New APTT and dRVVT Reagents**
C. Frere, M. Kurdi, M. Peyrafitte, A. Permal, C. Dunois, I. Martin-Toutain (France)
- PB597** **Performance Verification of the ZL 6000i Cone Plate Rotational Viscometer**
D.W. Yoo, I.-S. Kim (Korea)
- PB598** **Validation of an Automated Algorithm for Interpretation of Lupus Anticoagulant Testing on Stago STA-R Max**
L. Florin, K.M.J. Devreese (Belgium)
- PB599** **Thrombin Generation Test in Detection of Prothrombotic Phenotype in Asymptomatic Carriers of the FV G1691A or/and FII G20210A Mutations**
S. Karpich, V. Shmeleva, S. Kapustin, O. Golovina, O. Smirnova, L. Papayan, O. Matvienko (Russian Federation)
- PB600** **Management of Direct Oral Anticoagulants for Low-bleeding Risk Surgery: The Example of Cataract Surgery**
A. Godier, A.-C. Martin, S. Lessire, F. Mullier, A. Radu, M. Vasse, I. Leblanc, I. Gouin-Thibault (France)
- PB601** **Using Drug Levels to Guide Peri-operative Management of Direct Oral Anticoagulants Prior to Emergency Orthopaedic Surgery; Experience from a Large Teaching Hospital within the UK**
E. Millen, L. Sanders, R. Gooding, L. Athanatos, D. Morfey (United Kingdom)
- PB603** **Antithrombin Levels Less than 60% Lead to Reduced Anti-Xa Levels**
C. Pillion, M. Riordan, I. Regan (Ireland)

POSTERS

- PB604** **Direct Oral Anticoagulants (DOACs) for the Management of Venous Thromboembolism in Patients Aged Less than 18 Years**
U. Faruqi, J. Alamelu, M. Pelidis, V. Collings, Z. Mahir, E. Williams, N. Husain, T. Dowling, K. Breen, B. Hunt, M. Crowley (United Kingdom)
- PB605** **Inpatient to Outpatient Transition of Care for Pediatric Patients with Venous Thromboembolism**
J. Munn, M. Rajpurkar, K. Patel, J. Journeycake, A. Sharathkumar, M. Wang, C. Watson, E. McCarthy, D. Cheng, M. DeSancho, J. Jaffray (United States)
- PB606** **Cerebral Sinovenous Thrombosis (CSVT) in Children: 25 Years Single-center Prospective Pediatric Cohort in Argentina**
G. Sciuccati, C. Cervio, M. Hepner, G. Pieroni, E. Annetta, J.P. Frontrouth, R. Romina, C. Pepe, A. Feliú Torres, M. Bonduel (Argentina)
- PB607** **Significance of GPIIb α -5T>C, GPIIb α VNTR, GPVI T13254C Polymorphisms and HPA-2 in the Etiology of Pediatric Arterial Ischemic Stroke**
A. Ceri, D. Coen Herak, D. Herak, R. Zrinski-Topic, J. Lenicek Krleza, I. Horvat, V. Djuranovic, N. Barisic, R. Zadro (Croatia)
- PB610** **D Dimer Levels and Thrombosis in Children with Systemic Lupus Erythematosus**
S. Thakur, J. Ahluwalia, N. Kumar, S. Singh, A. Jindal, R. Pilania (India)
- PB611** **Anti-factor H Autoantibody-associated Hemolytic Uremic Syndrome in an Argentinean Pediatric Cohort**
C. Dos Santos, N. Mogollon Molina, M.F. Alberto, M.L. Romero, A. Sanchez-Luceros (Argentina)
- PB613** **Prosthetic Valve Thrombosis in Children**
P. Mugaba, B.-J. Martin, P. Kewada, D. Ross, M. Bauman, M.P. Massicotte, A. Mackie, P. Kawada (Canada)
- PB614** **Towards a Consensus for Standardized Assessment of Pediatric Patients with Vascular Malformations (VM) at Risk for Coagulopathy**
M.L. Avila, C.M. Lumia, M.I. Montoya, C.C. Trenor, D. Adams, F. Blei, B. Feldman, L. Brandao, on behalf of the Special Interest Group on Vascular Anomalies for the American Society of Pediatric Hematology Oncology (Canada)
- PB615** **Otogenic Lateral Sinus Thrombosis in Children: Are There Prognostic and Predictor Factors? Experience of 25 Cases and a Proposal of a Management Protocol**
M. Luciani, A. Scorpecci, S. Giannantonio, M. Massoud, P. Zangari, S. Foligno, G. Di Felice, A. Minozzi, P. Marsella (Italy)
- PB616** **Dosing, Safety and Efficacy of Therapeutic and Prophylactic Low Molecular Weight Heparin in the Pediatric Population: A Systematic Review**
I.L.M. Klaassen, J.J. Sol, M.H. Suijker, K. Fijnvandraat, M.D. van de Wetering, C.H. van Ommen (the Netherlands)



- PB617** **Exploring Adolescent's Perceptions and Emotional Reaction to Thrombosis and Anti-coagulant Therapy: A Qualitative Study**
T. Biss, R. Struthers, V. Araujo-Soares, B. Arnott (United Kingdom)
- PB618** **Peripheral Gangrene in a Child: An Uncommon Initial Presentation of Pediatric Lupus**
S. Singh, A. Singh, J. Ahluwalia (India)
- PB620** **Long-term Protein C Prophylaxis in Conjunction with Dabigatran Etxilate Treatment in a Case with Late Onset Homozygous Protein C Deficiency**
S. Aytac, G. Skretting, I. Eker, F. Gümrük, M. Çetin (Turkey)
- PB621** **How do Adolescents Experience Anticoagulant Adherence? A Qualitative Exploration of the Barriers and Facilitators**
K.A. Rooney, T. Biss, B. Arnott, V. Araújo-Soares (United Kingdom)
- PB622** **IgG4 Related Disorder: A Clinical Possibility in Children with Peripheral Gangrene**
S. Singh, A. Singh, J. Ahluwalia (India)
- PB623** **Deep Venous Thrombosis with Osteomyelitis in a Child - A Rare Presentation**
S. Singh, A. Singh, J. Ahluwalia (India)
- PB624** **Spontaneous Thrombosis in a Patient With Factor XI Deficiency Homozygous for the p.Cys398Tyr Mutation**
U. Aygüneş, S. Caki Kilic, E. Berber (Turkey)
- PB625** **Plasminogen Activator Inhibitor-1 and Thrombosis at Childhood**
H. Kizilocak, G. Dikme, B. Koc, T. Celkan (Turkey)
- PB626** **The Joint Effect between Different Types of Combined Oral Contraceptives and Genetic Risk Factors on Venous Thrombosis Risk: Results from the MEGA Case-control Study**
D. Khialani, Clinical Epidemiology (the Netherlands)
- PB627** **Risk of Recurrent Venous Thromboembolism in Pregnancy and Postpartum Period: Results from the MEGA Follow-up Study**
L.J.J. Scheres, C.W. van Klaveren, B. Nemeth, S. Middeldorp, S.C. Cannegieter (the Netherlands)
- PB628** **Misuse of Low Molecular Heparin in Pregnancy**
J. Samonikov Tosevska, T. Makarovska Bojadzieva, M. Blagoevska, I. Nikoloska (Macedonia)
- PB629** **Written Alert System Improves Thromboprophylaxis Compliance in Caesarean Women**
L. Maggiari, I. Morales, J. Ojeda, B. Perez, I. Perez, V. Ribero, S. Grille, C. Guillermo (Uruguay)
- PB631** **Management of Venous Thromboembolism (VTE) during Pregnancy and Post-partum: Findings from the Indian Subset of an International, Observational Study (SAVE)**
R.M. Tiwari, J. Aoun, J.-C. Gris (India)

POSTERS

- PB632** **Thrombin Generation and Adverse Pregnancy Outcomes**
I. Gribkova, N. Koroleva, M. Davydovskaya, A. Murashko (Russian Federation)
- PB633** **The Management of Pregnancy and Successful Delivery of a Patient with Bland-White-Garland Syndrome and a Prosthesis Mitral Valve**
A. Makatsariya, J. Khizroeva, V. Bitsadze, M. Arslanbekova (Russian Federation)
- PB634** **Reduced Protein C Global Assay Level in Infertile Women with IVF Failure: A Pilot Study**
H. Azzam, S. El Masry, H. Youssef, M. Othman, M. Awad (Egypt)
- PB635** **Hereditary Thrombophilia Assessment in Pregnancy**
M. Blagoevska, J. Samonikov Tosevska, T. Makarovska Bojadzieva, A. Hristova Dimceva, L. Gorcaj (Macedonia)
- PB636** **Localization and Massiveness of Thrombosis in Women with Pregnancy Related Thrombosis Compared to Women with Unprovoked Venous Thromboembolism**
J. Bodrozic, P. Miljic, D. Lekovic, D. Vasic, M. Gonic (Serbia)
- PB637** **Prospective Study of Changes in Haemostasis in High-risk Pregnancy**
L. Stanciakova, M. Dobrotova, P. Holly, Z. Jedinakova, I. Skornova, J. Zolkova, L. Vadelova, J. Danko, J. Stasko, P. Kubisz (Slovakia)
- PB638** **Risk Assessment of Venous Thromboembolism (VTE) during Pregnancy and Post-partum: Findings from the Indian Subset of an International, Observational Study (SAVE)**
R. Tiwari, J. Aoun, J.-C. Gris (India)
- PB639** **Genetic Risk Factors of Endothelial Dysfunction in Pregnant Women**
N. Korsakova, S. Kapustin, N. Silina, O. Matvienko, O. Golovina, A. Nikolaeva, L. Papayan (Russian Federation)
- PB640** **Characterization and Outcomes of aTTP Patients with Initial or Recurrent Disease: Experience from the Phase III HERCULES Trial of Caplacizumab**
M. Scully, S. Cataland, F. Peyvandi, P. Coppo, P. Knöbl, J.A. Kremer Hovinga, A. Metjian, J. de la Rubia, K. Pavenski, F. Callewaert, D. Biswas, H. De Winter, R.K. Zeldin (Belgium)
- PB641** **Efficacy and Safety of Open-label Caplacizumab in Patients with Exacerbations of Acquired Thrombotic Thrombocytopenic Purpura during the Phase III HERCULES Study**
M. Scully, S. Cataland, F. Peyvandi, P. Coppo, P. Knöbl, J.A. Kremer Hovinga, A. Metjian, J. de la Rubia, K. Pavenski, F. Callewaert, D. Biswas, H. De Winter, R.K. Zeldin (Belgium)
- PB642** **Treatment of Acquired TTP with the Anti-vWF Nanobody, Caplacizumab, Results in a Significant Reduction in Healthcare Resource Utilization – Data from the Phase III HERCULES Trial**
M. Scully, S. Cataland, F. Peyvandi, P. Coppo, P. Knöbl, J.A. Kremer Hovinga, A. Metjian, J. de la Rubia, K. Pavenski, F. Callewaert, D. Biswas, H. De Winter, R.K. Zeldin (Belgium)
- PB643** **Targeted Thrombolytics for Thrombotic Thrombocytopenic Purpura**
C. Clark, M. Waning, A. Barendrecht, P. Lenting, C. Maas, S. de Maat (the Netherlands)



- PB644** **Initial Clinical Presentation of Thrombotic Thrombocytopenic Purpura with Focal Stroke: A Series of Patients from the French National Reference Center Registry for Thrombotic Microangiopathies**
M. Delrue, A. Wynckel, L. Galicier, E. Mariotte, P. Poullin, S. Canet, A. Veyradier, P. Coppo, A. Stépanian (France)
- PB645** **Provision of an External Quality Assessment for ADAMTS13**
I. Jennings, S. Kitchen, D. Kitchen, S. Munroe-Peart, L. Brown, T. Woods, I. Walker (United Kingdom)
- PB646** **Evaluation of the Fully Automated HemosIL® Acustar ADAMTS13 Activity Assay**
J. Favresse, B. Lardinois, B. Chatelain, H. Jacqmin, F. Mullier (Belgium)
- PB647** **Pre-test Likelihood of ADAMTS13 Severe Deficiency in the Context of Thrombotic Microangiopathies: Validation of the PLASMIC Score in a Southern Italy Hospital**
G. Tiscia, F. Cappucci, P. Scalzulli, C. Battista, F. Aucella, A. Antonio, C. Buquicchio, M. Brigante, G. D'Andrea, G. Giordano, B. Infante, P. Ranieri, L. Tullo, A. Ostuni, E. Grandone (Italy)
- PB648** **“How we Treat”: Recurrent TTP Patients Undergoing Elective Surgery**
S. Arcudi, B. Ferrari, S. Pontiggia, I. Mancini, F. Peyvandi (Italy)
- PB649** **On the Edge of Thrombotic Thrombocytopenic Purpura: Pathogenic ADAMTS13 Mutations in a Patient with HELLP Syndrome**
G. Sinkovits, D. Csuka, Á. Szilágyi, A. Molvarec, M. Réti, Z. Prohászka (Hungary)
- PB650** **Plasmic Score for the Initial Evaluation of Patients with Microangiopathic Hemolytic Anemia and Thrombocytopenia**
E. Umit, H. Goze, M. Baysal, M. Demir (Turkey)
- PB651** **Patient Experiences with Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Conceptual Model**
A.O. Oladapo, D. Ito, C. Hibbard, R.N. Krupnick, T.M. Hare, B.M. Ewenstein (United States)
- PB652** **Identification of Novel ADAMTS13 Gene Mutation in a Patient with Congenital Thrombotic Thrombocytopenic Purpura**
A. Rashid, K. D Friedman, N. Mushtaq (Pakistan)
- PB654** **Evaluation of Hospital Readmissions among Patients Hospitalized for Acute Medical Illness and at Risk for Venous Thromboembolism in the US**
A. Amin, R. Neuman, M. Lingohr-Smith, B. Menges, J. Lin (United States)
- PB655** **Comparison of the Risk of Recurrence in Patients with Venous Thromboembolism (VTE) Provoked by Major and Minor Surgery and Trauma**
T. Gregorio, M. Santos, L. Pagliani, R. Providencia, C. Buzea, A. Katholing, J. Weitz, C. Martinez, A. Cohen (Portugal)
- PB656** **Comparative Thrombosis Risk of Vascular Access Devices among Critically Ill Medical Patients**
S.M. Stevens, D. White, S.C. Woller, D.S. Collingridge, V. Chopra, G.V. Fontaine (United States)

POSTERS

- PB657** **Cost-effectiveness of Betrixaban Compared with Enoxaparin for Primary Venous Thromboembolism Prophylaxis in Hospitalised Acute Medically Ill Patients in the United States**
V. Laskier, H. Guy, M. Fisher, A. Hafeman, R. Neuman, S. Deitelzweig, A. Cohen (United States)
- PB658** **Venous Thromboembolism Clinical Risk Assessment Model for Patients with a Lower Limb Trauma Requiring Immobilization: The TIP Score**
D. Douillet, A. Penalzoa, T. Moumneh, P.-M. Roy (France)
- PB659** **Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer**
M. Giustozzi, A. Curcio, S. Sudikas, B. Weijs, T. Field, A. Katholing, C. Wallenhorst, J.I. Weitz, C. Martinez, A.T. Cohen (Italy)
- PB660** **A Single Center Analysis of Pre-, Intra- and Post-operative Thrombotic Events in a Cohort of 470 Orthotopic Whole Liver Transplantations**
N. Riva, A. Gatt, R.K. Pruthi, W.L. Nichols, J.Y. Findlay, C.B. Rosen, P.S. Kamath, A.A. Ashrani (Malta)
- PB661** **miRNA Expression Profile in Venous Thrombosis Disease: Results from the Genetic Analysis of Idiopathic Thrombophilia Project**
A. Rodriguez-Rius, S. Lopez, A. Martinez-Perez, M. Sabater-Lleal, C. Muñoz, A. Hamsten, J.C. Souto, J.M. Soria (Spain)
- PB662** **Clinical Characteristics and Outcome of Patients with Subsegmental Pulmonary Embolism**
C. Fernandez-Capitan, D. Jimenez, O. Madridano, M. Ciammaichella, E. Usandizaga, R. Otero, A. Bura-Rivière, F.J. Vazquez, F. Moustafa, M. Monreal, RIETE Investigators (France)
- PB663** **Assessment of General Awareness of Thrombosis and How Best to Communicate this Information**
A.M. O'Neill, K. Collins, S. Bourke (Ireland)
- PB664** **Postoperative Venous Thromboembolism Prophylaxis in Perioperative Trials of Tranexamic Acid: A Systematic Review and Meta-analysis**
J. Taylor, I. Perelman, J. Yates, S. Khair, J. Lampron, A. Tinmouth, A. Davis, E. Saidenberg (Canada)
- PB665** **Testosterone Therapy and Venous Thromboembolism: A Systematic Review and Meta-analysis**
D.E. Houghton, M. Alsawas, L.J. Prokop, P. Barrioneuvo, B. Beuschel, W. Farah, M. Tello, J.B. Layton, M.H. Murad, S. Moll (United States)
- PB666** **Homozygotes in FXI rs 2289252 and ABO rs 8176719 Have a Low Risk of VTE Recurrence**
J. Kvasnicka, P. Bobcikova, J. Hajkova, Z. Krska, M. Sevcik, T. Kvasnicka (Czech Republic)
- PB667** **Risk of Pulmonary Embolism after Surgical Resection of Meningioma**
A. Artoni, M. Abbattista, G. Carrabba, M. Capecci, P. Bucciarelli, F. Gianniello, A. Lecchi, M. Castellani, F. Peyvandi, I. Martinelli (Italy)
- PB668** **Lower-leg Injury Leads to a Procoagulant State**
C.E. Touw, B. Nemeth, I.B. Schipper, R.G.H.H. Nelissen, S.C. Cannegieter (the Netherlands)



- PB669** **Evaluation of Inter-rater Agreement of a Risk Assessment Model for Thromboprophylaxis in Medical Hospitalised Patients: Preliminary Results of a Cohort Study**
C. Ferreira, R. Avelino Mancini, M. Monique Lana Diniz, S. Miriam Paulinelli G Alves, M. de Bastos, S. Meireles Rezende (Brazil)
- PB670** **The Effect of Alpha-2 Plasmin Inhibitor Activity and Antigen Levels and p.Arg6Trp Polymorphism on the Risk of Venous Thromboembolism**
É. Katona, R. Bogáti, T. Miklós, R. Gindele, M. Speker, V. Fedoriska, A. Teráz-Orosz, Z. Mezei, Z. Bereczky (Hungary)
- PB671** **Risk Stratification for Prevention of Venous Thromboembolism in Hospitalized Medical Patients: Can Thromboprophylaxis in Hospitalized Medical Patients Be Safely Restricted to Reduce Costs?**
A.M. Bond, S.E. Walker, A. Diamantouros, W.H. Geerts (Canada)
- PB672** **Predictors of Venous Thromboembolism in Patients Undergoing Neurosurgery for Glioma**
M. Capecchi, P. Bucciarelli, A. Artoni, M. Abbattista, F. Gianniello, A. Lecchi, G. Carrabba, M. Castellani, F. Peyvandi, I. Martinelli (Italy)
- PB673** **VSS Safety Zone Protocol vs Padua Score in the Prevention of Thromboembolic Disease in Medical Patients: A Comparative Prospective Study**
J. Serrano, B. Rodriguez, M.C. Chindamo (Venezuela)
- PB675** **Prophylaxis of Venous Thromboembolism in an Internal Medicine Department**
M. Calçada, I. Neto, A.R. Freitas, M. Santos, C. Bastos (Portugal)
- PB676** **Clinical Profile of Acutely-ill Medical Hospitalized Patients: Preliminary Results of a Cohort Study on Thromboprophylaxis**
M.M. Lana Diniz, R.A. Mancini, C. Rodrigues Lima Ferreira, S.M. Paulinelli Garcia Alves, M. de Bastos, S. Meireles Rezende (Brazil)
- PB680** **25mmHg vs. 35 mmHg Graduated Elastic Compression Stockings to Treat Acute Symptoms of Deep-Vein Thrombosis: The CELEST Double-blind Trial**
J.-P. Galanaud, S. Blaise, C. Vermorel, C. Rolland, F. Verriere, I. Bertaina, H. Guenneguez, J.L. Bosson (Canada)
- PB681** **Individualized Prediction Model for Risk of First DVT Using Clinical Assessment and D-dimer**
S. Parpia, L.-A. Linkins, J. Julian, G.-J. Geersing, K. de Wit, C. Kearon (Canada)
- PB682** **Long-term Risk of Post-thrombotic Syndrome after Symptomatic Distal Deep-vein Thrombosis: The CACTUS-PTS Study**
J.-P. Galanaud, M. Righini, L. Lecollen, A. Douillard, H. Robert-Ebadi, D. Pontal, D. Morrison, M. Carrier, I. Quééré, S.R. Kahn (France)
- PB683** **Age-adjusted versus Clinical Probability-adjusted D-dimer to Exclude Pulmonary Embolism**
S.M. Stevens, S. Takach Lapner, S.C. Woller, G. Snow, C. Kearon (United States)

POSTERS

- PB684 Vena Caval Filters in Patients Presenting with Major Bleeding during Anticoagulation for Venous Thromboembolism**
M. Mellado, J. Trujillo-Santos, B. Bikdeli, D. Jimenez, M.J. Nunez, M. Ellis, P.J. Marchena, J.R. Vela, A. Clara, F. Moustafa, M. Monreal, RIETE Investigators (France)
- PB685 Whole Leg Ultrasound for the Diagnosis of Deep Vein Thrombosis Recurrence**
M. Sartori, E. Favaretto, L. Valdrè, G. Guazzaloca, A. Amato, B. Cosmi (Italy)
- PB686 Polymorphisms in PARK2 and MRPL37 Are Associated with Higher Risk of Recurrent Venous Thromboembolism in a Sex-specific Manner**
K. Sundquist, A. Ahmad, P.J. Svensson, B. Zoller, J. Sundquist, A. Memon (Sweden)
- PB687 The safety of Low Molecular Weight Heparin, Direct Oral Anticoagulants, & Warfarin in Patients with Chronic Liver Disease; Analysis of 932 Patients from the RIETE Database**
J. Shatzel, R. Chandran, S. Gardiner, V. Rosa, A. Lorenzo, L. Mazzolai, A. Villalobos, R. Quintavalla, P. Verhamme, M. Monreal, the RIETE Investigators (United States)
- PB688 Clinical Predictors of Right Ventricular Dysfunction in Acute Pulmonary Thromboembolism**
J. Bonorino, J. Bilbao, H. Fernandez, J. Santucci, J. Aboy, P. Alarcon, N. Torres, E. Martino, G. Moles, V. Martin Napoli, P. Colimodio, R. Melchiori, M.E. Aris Cancela, S. Baratta, A. Hita (Argentina)
- PB689 Individualized Thromboprophylaxis in Patients with Lower-leg Cast Immobilization - A Validation and Subgroup Analysis in the POT-CAST Trial**
B. Nemeth, S. le Cessie, S.C. Cannegieter, Pot-(k)cast Study Group (the Netherlands)
- PB690 Prevalence of Pulmonary Embolism in Patients Presenting to the Emergency Department with Syncope in an Integrated Healthcare System**
S.M. Stevens, J. Bledsoe, J. Jacobs, A. Frizell, J. Quinn (United States)
- PB692 Efficacy and Safety of Rivaroxaban in Morbid Obesity: A Retrospective Analysis of over 600 Patients with BMI ≥ 40**
D. Rao, S.S. Tolu, Y. Choi, J. Gao, H.H. Billett, M. Kushnir (United States)
- PB693 Assessment of D-dimer Value at First Venous Thromboembolism and Risk of Recurrence**
R. Vidal, D. Velasco-Rodríguez, A. Penedo, A. García-Raso, J.M. Alonso-Domínguez, P. Llamas Sillero (Spain)
- PB694 Patients Experience of Living with Cancer Associated Thrombosis in Canada (PELICANADA)**
S. Noble, A. Nelson, J. Scott, A. Berger, K. Schmidt, H. Prout, P. Gee, A. Lee (United Kingdom)
- PB695 A Systematic Review to Determine Patient Preferences to Receive Thromboprophylaxis to Prevent Deep Vein Thrombosis and Pulmonary Embolism**
N. Dembrey, M. Grainge (United Kingdom)
- PB696 Efficacy and Safety of Rivaroxaban and Apixaban in Relation to Low Molecular Heparin and Vitamin K Antagonists in Acute Venous Thromboembolism - A Single Center Prospective Study**
W. Wysokinski, D. Bott-Kitslaar, A. Casanegra, D. Froehling, M. Bartlett, C. Lenz, D. Houghton, D. Hodge, E. Vargas, R. McBane (United States)



- PB697** **Circulating Endothelial Cells as a New and Early Candidate Biomarker of Residual Pulmonary Vascular Obstruction after Pulmonary Embolism**
B. Planquette, N. Gendron, J. Peron, A. Roche, M. Barritault, P. Gaussem, O. Sanchez, D.M. Smadja (France)
- PB698** **Thrombophlebitis Post Varicose Vein Surgery: To Treat or Not to Treat?**
H.Y. Lim, I. Bayat, P. Ho, F. Hong (Australia)
- PB699** **Comparison of Risk Assessment Methods to Prevent Venous Thromboembolism (VTE) in Surgical Patients with Short Length of Hospital Stay**
M.C. Chindamo, G.G. Sardinha, D. Mousinho, W. Schiavini, A.B. Nunes (Brazil)
- PB700** **Peripherally Inserted Central Catheter Associated Upper Extremity Thrombosis (PICC-UET): A Single Centre Retrospective Study**
C. Delaney, S. Kelliher, K. Saeed, B. Kevane, A. Fortune, M. Fay, F. Ni Ainle (Ireland)
- PB701** **Effectiveness and Safety of Outpatient Rivaroxaban versus Warfarin in Patients with Provoked Acute Venous Thromboembolism**
C.I. Coleman, T.J. Bunz, J. Jan Beyer-Westendorf (United States)
- PB702** **Rivaroxaban and Apixaban for Treatment of Acute Isolated Calf Deep Vein Thrombosis - A Single Center Prospective Study**
R. McBane, D. Bott-Kitslaar, A. Casanegra, D. Froehling, M. Bartlett, C. Lenz, D. Houghton, D. Hodge, E. Vargas, W. Wysokinski (United States)
- PB703** **Simulation in VTE Treatment: Improving the Use of Guideline-directed Care**
J. Spyropoulos, M. Warters, D. Blevins (United States)
- PB704** **The Relationship between Neutrophil Lymphocyte Ratio and Deep Vein Thrombosis in Unilateral Limb Edema in Suspected Deep Vein Thrombosis Patients**
I. Rinaldi, R. Hamonangan, R. Cahyanur, M.S. Azizi, A.I. Fatya, F. Wirawan (Indonesia)
- PB705** **Application of an Explanatory Model for Emergency Physician Pulmonary Embolism Testing in a National Cohort**
K. de Wit, S. Zarabi, M. Mercuri, T. Chan (Canada)
- PB706** **Deep Dive into DVTs: A 3 Year Retrospective Review of Patients with Deep Vein Thrombosis (DVT) on an Ambulatory Integrated Care Pathway (ICP)**
V. Graham, B. White, K. Ryan, J.S. O'Donnell, M. Lavin, M.P. Colgan, G. McMahon, N. O'Connell (Ireland)
- PB707** **The Association of Characteristics of Central Venous Catheters with Venous Thrombotic Events in Pediatric Patients Undergoing Fontan Surgery**
V. Kovalik, A. Hussain, T. MacDonald, K. Kulkarni (Canada)
- PB708** **Implementation of an Acute DVT Ambulatory Care Pathway in a Large Urban Centre: Current Challenges and Future Opportunities**
S. Kelliher, B. Kevane, D. Dinu, F. NiAinle, T. Breslin (Ireland)

POSTERS

- PB709 Treatment Satisfaction with Rivaroxaban for the Management of Venous Thromboembolism (VTE) - Early Results from the 'Follow-up in Rivaroxaban Patients in Setting of Thromboembolism' (FIRST) Registry**
V. Speed, V. Auyeung, J. Patel, T. Jones, J. Samuel, L. Roberts, R. Patel, R. Arya (United Kingdom)
- PB710 Elevated Levels of Resistin and Visfatin Are Associated with Platelet Activation and Blood Coagulation in Type 2 Diabetic Patients with Venous Thromboembolism**
O. Korzh, E. Lavrova, S. Krasnokutskiy (Ukraine)
- PB711 Evaluation of an Educational Video for Patients Taking Warfarin**
J.M. Costa, R.C.d.S. Groia, E.I.d.F. Campos, M.A. Parreiras Martins, A.M.M. Reis (Brazil)
- PB712 Subsegmental Pulmonary Embolism: An Innocent Bystander?**
M.C. Gerritsen, F.A. Mohamed Hoessein, P.A. de Jong, K.A.H. Kaasjager, M. Nijkeuter (the Netherlands)
- PB713 Evaluation of Unmet Clinical Needs in Prophylaxis and Treatment of Venous Thromboembolism in High-risk Patient Groups**
B. Brenner, J. Beyer-Westendorf, I. Elalamy, R. Hull, D. Imberti, R. Arya (Israel)
- PB714 Outpatient Management of Deep Vein Thrombosis using Direct Oral Anticoagulants is Safe and Cost-effective**
P. Lambros, S. Savage, V. Chellaram, P. Ho, H.Y. Lim (Australia)
- PB715 Knowledge Derived from a Hospitalar Thromboprophylaxis Program**
M.C. Chindamo, G.G. Sardinha, W. Schiavini, D. Mousinho, A.B. Nunes (Brazil)
- PB716 Quality Assessment of Oral Anticoagulation by Time in Therapeutic Range in Patients with Venous Thromboembolism**
H.-G. Hwang, S.-M. Koo, S.-T. Uh, Y.-K. Kim (Korea)

PUBLICATION ONLY

Publication Only Abstracts will be published online as a supplement issue of the *Research and Practice in Thrombosis and Haemostasis (RPTH) Journal*.

- PO001 Study of the Hemostatic System in Children in the Republic of Uzbekistan**
I. Berger, A. Makhmudova (Uzbekistan)
- PO002 Total Knee Arthroplasty after Knee Fusion in Severe Hemophilia A**
P. Beurrier, N. Stieltjes, Y. Ronzi, M. Hamadouche, P. Bizot (France)
- PO003 Autoimmune Acquired von Willebrand Syndrome with Short von Willebrand Factor Half-life**
E. Salazar, L. Rice (United States)



- PO004** **Spectrum of Mutations: An Identified Locus of Point Missense Mutation in Fibrinogen Gene Alpha of Inherited Factor 1 Deficiency Patients**
T. Khan, A. Naz, A. Biswas, A. Goodeve, N. Ahmed, S. Ahmed, T. Shamsi, J. Oldenburg (Pakistan)
- PO005** **Response to Recombinant FVIII Therapy in a Young Haemophilia A Patient with Spiral Fracture of the Left Femur**
W. Shokunbi, T. Akingbola, K. Shonde-Adebola, T. Adeoye (Nigeria)
- PO008** **A Study of the Peculiarities of Hematomeseenchymal Dysplasia in Patients with Hemophilia**
A. Makhmudova, I. Berger, M. Makhmudova, M. Nabieva (Uzbekistan)
- PO009** **Near-fatal Acquired Inhibitor of Human Thrombin**
E. Salazar, L. Rice (United States)
- PO010** **The Radiologist: A Key Member in the Diagnose of a Patient with Hemophilia A**
J. Restrepo-Avenia, J. Echeverri, J. Duque-Gil, J. Ramirez-Varela (Colombia)
- PO011** **A Multinational Prospective, Non-interventional, Post-marketing Surveillance Study to Observe the Real-world Use of Recombinant Factor IX Albumin Fusion Protein (rIX-FP) in Patients with Hemophilia B**
G. Castaman, J. Oldenburg, B. Pan-Peteschn, V. Jiménez-Yuste (Italy)
- PO012** **A Clinical Audit of Low Dose Prophylaxis Programme for Nigerian Children with Haemophilia**
T. Nwagha, T. Adeyemo, C. Udo, S. Yuguda, K. Korubo, H. Okoye, Nigeria Low Dose Prophylaxis Programme (Nigeria)
- PO013** **Which Is the Best Coagulometer on the Market?**
D. Sánchez Argüello, C. De Brabandere, M. Sarasa Valdes, L. Guerrero Fernandez, C. Fernandez Canal, S. Sánchez Matías, J. Torres Varona, P. Chamorro Chamorro, A. Fernandez Gonzalez, V. Robles Marinas (Spain)
- PO015** **The FORMA-07 Study: A Post-marketing, Phase IV, Observational Study Evaluating the Safety and Efficacy of a New Human Fibrinogen Concentrate in Congenital Fibrinogen Deficiency**
C. Solomon, F. Peyvandi, B. Schwartz (Switzerland)
- PO016** **Severe Acquired von Willebrand Syndrome (Type 3-like) in a Patient Affected with Systemic Lupus Erythematosus (SLE)**
F. Stufano, L. Baronciani, E. Biguzzi, G. Cozzi, P. Colpani, M. Chisini, F. Peyvandi (Italy)
- PO017** **Successful Excision of Limb Pseudotumor in a Severe Hemophilia Patient Treated with Low-dose Radiotherapy Prior to Combined Bolus and Continuous Intravenous Factor Replacement: A Case Experience**
J.A. de Castro, P.R. Mancio, P. Caguioa, F. Hernandez, M.L. Bangcoy, J.K. Jacinto (Philippines)
- PO018** **Real-world Use of BAY 81-8973 for Routine Prophylaxis in Colombia: A Preliminary Report**
G.E. Mora Figueroa, A. Plata García, R. Camacho Grimaldos (Colombia)

PUBLICATION ONLY

- PO019** **The First Clinical Use of a von Willebrand Factor Concentrate with a Low FVIII Content for the Long-term Prophylaxis of Severe von Willebrand Disease in Slovakia**
T. Simurda, M. Dobrotova, J. Sokol, J. Stasko, P. Kubisz (Slovakia)
- PO021** **Outcomes of Splenectomy in Patients with Non-Hodgkin Lymphomas Complicated by Immune Thrombocytopenia**
Y. Yevstakhevych, I. Yevstakhevych, Y. Vyhovska, M. Semerak, O. Petronchak, V. Loginsky (Ukraine)
- PO023** **Deficiency Acquired in Factor X Revealing an AL Amyloidosis**
Y. Ouahlent, H. Hamza (Algeria)
- PO024** **An Audit of Acquired Clotting Defects in Hematology Clinics in Karachi**
A. Naz, F. Ahmed, T.S. Shamsi (Pakistan)
- PO025** **A Rare Case of Factor II Deficiency Overlooked due to Anaemia in Hematology Clinic**
A. Naz, T. Shamsi (Pakistan)
- PO027** **Challenges and Key Learnings in the Design and Implementation of an International Hemophilia Registry with Pharmaceutical Industry Support**
C.R.M. Hay, M. Shima, M. Makris, V. Jiménez-Yuste, J. Oldenburg, K. Fischer, A. Iorio, M.W. Skinner, E. Santagostino, S. von Mackensen, N. Church, S. Rauchensteiner, P. Mathew, S. Krassova, C.M. Kessler (United Kingdom)
- PO028** **Hereditary Afibrinogenemia in Children: A Single Center Experience**
M. Söker, H. Uzel, K. Öncel, S. Söker (Turkey)
- PO029** **Paradoxical Thrombotic Events in Bleeding Disorders**
L. Stanciakova, M. Dobrotova, P. Holly, J. Ivankova, M. Samos, T. Bolek, P. Kubisz, J. Stasko (Slovakia)
- PO030** **Study the Polymorphism of Tumor Necrosis Factor Alpha (TNF-) Gene and the Risk of Development of FVIII Inhibitors in Egyptian Hemophilia A Patients: A Single Center Experience**
D. El Demerdash, A. Ayad, D. Mohamed, M. Mattar, H. Sadek (Egypt)
- PO031** **Assessment of Some Markers of Thrombosis in a Nigerian Population of Normal Pregnant Women**
H. Okoye, T. Nwagha, A. Ugwu, L. Eweputanna, V. Ugwu (Nigeria)
- PO032** **Evaluation of Morbidity and Mortality among Patients with Hereditary Bleeding Disorders in Southern Iran**
M. Karimi, A. Farjami, S. Hagpanah, S. Parand (Iran)
- PO033** **Acquired Deficit in Coagulation Factors and Head Trauma**
Y. Ouahlent, H. Hamza (Algeria)
- PO034** **Methods of Preparation of Blood Coagulation Factor VIII Concentrate**
N. Shurko, T. Danysh, V. Novak (Ukraine)



- P0035 Experience in our Center of Anticoagulant Therapy with Tinzaparina Sodique in Patients with Cancer, Renal Insufficiency and / or Intolerance to Antivitamin K**
M.A. Garcia Ruiz, E. Morente Constantin, P. Romero Garcia, M. Rivas Luque, P. Garrido Collado, M.D. Fernandez Jimenez, M. Jurado Chacón (Spain)
- P0036 Diagnosis of a Transient Ischemic Attack (TIA) from Elevated Coagulation Inhibitors (A Case Report)**
E. Vagdatli, M. Issa, K. Bani, K. Tsioni, K. Karantani, A. Diamantopoulou (Greece)
- P0039 Platelet Transfusion Triggers in Thrombocytopenic Patients in a Tertiary Care Hospital**
R. Akbar, A. Ahmad, N. Akbar, S. Yunis (Pakistan)
- P0043 Association of Pregnancy Loss with Some Thrombogenic Markers**
H. Okoye, J. Chinawa, E. Aniwada, L. Eweputanna, T. Nwagha, U. Nwagha (Nigeria)
- P0044 Transition of Care for Adult Patients with Venous Thromboembolism**
M. DeSancho, M. Malone, C. Holmes, H. Billett, T.-F. Wang, D. Cheng, E. McCarthy, C. Watson, M. Rajpurkar (United States)
- P0046 Awareness Session for Pharmacist on World Thrombosis Day 13th October 2017 in Hospital of Developing Country Karachi, Pakistan**
S. Khan, S.S. Raza, U. Rani (Pakistan)
- P0047 A Quality Audit on Appropriate Dosing of Rivaroxaban in Acute Care Hospital**
S. Khan, B. Moiz, A. Khalil, A. Bilal (Pakistan)
- P0048 Platelet Count and Mean Platelet Volume of Diabetic Clients Attending Nigeria Navy Hospital Calabar, Nigeria**
D.C. Okpokam, C.O. Opara, O.E. Okpokam, A.O. Emeribe (Nigeria)
- P0049 Management of Thrombophilia in Pregnancy - Case Report**
V. Emilija, V. Dejanova-Ilijevska, V. Neceva, T. Makarovska-Bojadzieva, M. Sorova, T. Uzunovska, I. Nikoloska (Macedonia)
- P0050 When to Test for Thrombophilia**
F. Martins Pereira, A. Brito, A.P. Amaral, F. Lobo, M. Costa (Portugal)
- P0051 Dramatic Deep Vein Thrombosis Presentation in Young and Healthy Patients: A Report of 3 Cases**
C.E. García Einschlag, M.M. Szlagowski, M. Giusti, F. Giachello, J.H. Milone, D. Aguerre (Argentina)
- P0053 Effectiveness of Direct Oral Anticoagulants (DOAC) in Patients Submitted to Digestive Surgery. Case Report**
D. Sánchez Argüello, C. De Brabandere, M. Sarasa Valdes, P. Chamorro Chamorro, L. Guerrero Fernández, C. Fernandez Canal, S. Sánchez Matías, J. Torres Varona, S. Ortiz saez, V. Robles Marinas (Spain)
- P0054 Analysis of the Causes of Bleeding during Therapy with Anticoagulants**
N. Vorobyeva, A. Schapkov, L. Melnichuk (Russian Federation)

PUBLICATION ONLY

- PO055 Antithrombotic and Thrombolytic Effects of Heparinoid from the Pion**
L. Lyapina, M. Lyapina, M. Kalugina (Russian Federation)
- PO056 Simple Method for Removal of Doacs from Plasma Samples**
T. Exner, N. Michalopoulos, J. Pearce, R. Xavier, M. Ahuja (Australia)
- PO058 Thromboprophylaxis in Hereditary Thrombophilia - A Case Report**
T. Makarovska Bojadzieva, M. Blagoevska, J. Samonikov Tosevska, I. Nikoloska, R. Apostolovska (Macedonia)
- PO059 Comparison of Two Thromboplastin Reagents for Prothrombin Time (PT) Measurement**
R. Perez Montes, E. Martin Martin, F. Depasse (Spain)
- PO061 Thrombophilia in Children and Adolescent: Phenotype - Genotype Relationship**
U. El Safy, M. Fathy, M. Zakria, M. Besheer, T. Hassan, N. Rafaat, S. Aush (Egypt)
- PO062 Two Novel Variants in ADAMTS13 Gene and Clinical Relation between Phenotype/Genotype in Congenital Thrombotic Thrombocytopenia Purpura (TTP)**
J. Paiva, A.C. Kempfer, A.I. Woods, M.M. Casinelli, A. Sánchez-Luceros, M.A. Lazzari (Argentina)
- PO063 False Hypercoagulability Possibly Induced by the in vitro Accidental Presence of Tissue Factor**
C. Delianu, C. Tuchilus, L. Foia (Romania)




isth JULY 18-21
2018 ♦
SSC DUBLIN
Education, Innovation, Collaboration

**GENERAL MEETING
INFORMATION**

Convention Centre Floorplans
General Meeting Information

GENERAL MEETING INFORMATION

CONVENTION CENTRE FLOORPLANS



Levels 3-5

- Auditorium**
- Plenary Session
- SSC Sessions
- Educations Sessions
- Internet Stations
- Partner Resource Center

Level 2

- Wicklow Rooms**
- SSC Sessions
- Supported Symposia
- Speaker Ready Room
- Poster Pick-Up Booth
- Corporate Meeting Suites

Level 1

- Liffey Rooms**
- Poster Sessions
- SSC Sessions
- Supported Symposia
- Master Classes
- Education Sessions
- Trainee Sessions
- ISTH Booth
- Ancillary Meeting Rooms


Ground Level

- Forum Rooms**
- Registration
- Exhibition Hall
- Main Entrance
- Charging Lockers
- Lost and Found




GENERAL MEETING INFORMATION

Levels 3-5




Level 2




GENERAL MEETING INFORMATION

Level 1



Ground Level





GENERAL MEETING INFORMATION

Abstracts

The ISTH SSC 2018 abstracts will be available as an online supplement (only) to *Research and Practice in Thrombosis and Haemostasis (RPTH) Journal*.

Ancillary Meeting Rooms

Ancillary Meeting Rooms are pre-arranged by related organizations or partners for internal meetings on the occasion of the ISTH SSC 2018 Meeting. The locations of these meeting rooms are on level 1 of the Convention Centre Dublin (CCD). Please check with organizers of your meetings for the exact location.

ATM/Cash Machines

ATMs are widespread and found in most banks, hotels and shopping centers. The Convention Centre Dublin does not have an ATM. The closest ATM is in the Fresh convenience store on Mayor Street Lower.

Badges

Participants receive their name badges when collecting their meeting documents onsite. Participants are required to wear a name badge during all meeting events, including the Networking Evening (if applicable). Please note that admission to scientific sessions and the exhibition is restricted to participants wearing badges.

PLEASE NOTE: Exhibitor badges do not give access to the general scientific programming.

The charge for a replacement badge is €10.

Business Center

There is no business center located within the CCD. Attendees in need of facilities for printing, copying and faxing can go to SNAP Printing located in Mayor Square, a 5-minute walk from the CCD.

Certificate of Attendance

Certificates of Attendance will be available for printing on-site Friday, July 20 and Saturday, July 21 in the registration area, or via email after the meeting. Questions after the meeting should be directed to registration@isth.org

Charging Lockers

Mobile devices can be safely secured and charged using Charging Lockers **located on the ground/entrance level of the CCD**. Lockers offer several plug variations to charge your mobile device quickly.

Cloakroom and Luggage

The CCD cloak room is located on the ground level near the registration area.

■ Wednesday, July 18	06:00 – 19:00
■ Thursday, July 19	06:30 – 19:00
■ Friday, July 20	06:30 – 19:45
■ Saturday, July 21	06:30 – 13:30

CME

The **64th Annual Scientific and Standardization Committee (SSC) Meeting, Dublin, Ireland, 18/07/2018 – 21/07/2018**, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 8 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

GENERAL MEETING INFORMATION

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

NOTE: Badges will be scanned for CME credit outside the session room. If you intend to claim CME credit, you must be scanned by ISTH SSC 2018 meeting staff upon entering the session.

Conference Capture

Plenary and Education Lectures of ISTH SSC 2018 will be recorded and available online 24 hours after the presentation to both meeting attendees and ISTH members.

These lectures can be accessed on the ISTH Academy at academy.isth.org or by downloading the **ISTH Academy Mobile App** (*search Apple Store or Google Play for ISTH Academy*).

Use your ISTH login credentials to access the Academy. If you have not created a login before, use your registration email address and password “**ssc2018**” to access meeting content. Contact membership@isth.org for any login issues.

Currency, Banks, and Foreign Exchange Offices

The Euro is the unit of currency in Ireland, which comes in bills and coins.

Only major banks exchange foreign currency. Banking hours are 09:00 – 16:00.

Delegate Bags

The ISTH SSC 2018 delegate bag, including all delegate materials, is distributed to registered participants at the SSC Meeting bag desk in the registration area. **Please note that there are no replacements for lost bags.**

Duplicating/Recording

Any form of duplication (recording, audio taping, photography and/or video) of sessions is prohibited without expressed written consent of the author and meeting organizer. Please do not use your mobile device to duplicate or record any sessions.

We kindly ask that attendees DO NOT photograph, record, film, or use a cellphone to capture images of presentations at any time during the meeting, as well as on the poster and exhibit floors. **Please note that you may be photographed, videotaped and/or recorded during your visit by the official ISTH SSC 2018 photography/video team.**

By entering the ISTH SSC 2018 Meeting, you agree to each of the following:

- 1) You consent to be photographed, filmed and/or otherwise recorded in connection with, or as part of ISTH 2018 journalistic, advertising, marketing, promotional, archival and/or security activities;
- 2) You consent to such photography, filming and/or recording and to any use, in any and all media throughout the world in perpetuity, without compensation to you, of your appearance, voice and/or name for the above noted purposes;
- 3) You understand that all photography, filming and/ or recording will be done in reliance on these consents given by you by entering the meeting;
- 4) To protect, among other things, the personal information of our attendees, you agree not to reproduce, perform, display or upload any photographs of sessions/presentations.

If you do not wish to be photographed or filmed via the official SSC Meeting photography and video team, kindly inform representatives of your preference.

Emergency Numbers

For Emergency outside the Convention Centre Dublin dial 112 or 999 for all emergencies (police, fire, medical). Callers will then be placed through to the appropriate emergency service.

For Emergencies within the CCD, please contact the nearest staff person.



GENERAL MEETING INFORMATION

Exhibition Hours

The ISTH SSC 2018 Industry Exhibition is located in **The Forum on the ground/entrance level** at the following times:

- **Wednesday, July 18** **09:45 – 15:15**
- **Thursday, July 19** **09:45 – 15:15**
- **Friday, July 20** **09:45 – 15:15**

Insurance and Liability

It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. ISTH and Conference Partners International (CPI) as organizers cannot accept responsibility for personal injuries, or loss of, or damage to private property belonging to the meeting participants and accompanying persons.

Internet Stations

The ISTH SSC 2018 Internet Stations are located on the **Level 3 Foyer of the CCD**. Attendees can use the Internet Stations to check email and search the internet.

Language

The official language of the meeting is English. There is no simultaneous translation service provided.

Lost and Found

Lost and found is located at the ISTH registration desk. Anything that is still left in the evening when registration closes will be taken to the **Security Command Centre at the CCD**.

Lunches and Coffee Breaks

Lunch is provided as part of the registration fee for the meeting. Lunch vouchers are provided with your delegate badge.

From Wednesday, July 18 to Friday, July 20, lunch and coffee breaks will be available in the catering areas of the **Exhibition Hall (The Forum) on the ground/entrance level**. On Saturday, July 21, coffee will be available in the Foyers of the CCD.

Master Classes

The SSC 2018 Master Classes will be held each morning, Thursday, July 19 – Saturday, July 21, from 07:00 – 08:00 at the CCD. Continental breakfast will be provided.

Attendance must be pre-booked.

Please be sure to arrive on-time as to not disrupt the session. If you have not arrived to the session by 10 minutes after the start, your seat may be given up. There will be no admittance to the room after 20 minutes.

Meeting Hashtag

#ISTHSSC18

To get the latest updates throughout the meeting, follow ISTH online via the following links:

www.facebook.com/internationalsocietythrombosisandhaemostasis

www.facebook.com/worldthrombosisday

www.twitter.com/isth

www.twitter.com/jthjournal

www.twitter.com/rpthjournal

www.twitter.com/thrombosisday

www.linkedin.com/company/2253026/

www.linkedin.com/groups/7025460

www.instagram.com/isthofficeteam/

www.instagram.com/worldthrombosisday/

www.youtube.com/user/IntlSocThrombHemo

GENERAL MEETING INFORMATION

Mobile App

Use your mobile device to navigate the ISTH SSC 2018 Meeting by downloading the **free ISTH SSC 2018 Meeting Mobile App** (Apple Store or Google Play)!

It conveniently provides iPhone/iPad, Windows and Android smartphone or tablet users with on-the-go access to the SSC 2018's most important information and interactive features, such as program overviews, speaker and abstract information, general meeting and exhibitor information, venue and city maps and tips.



Meeting Venue

The Convention Centre Dublin (CCD)

Spencer Dock
North Wall Quay
Dublin 1 D01 T1W6 Ireland
Phone: +353 1 8560000
Email: info@theccd.ie

Mobile Telephones

As a courtesy to speakers and other participants, all mobile phones and pagers must be switched off when attending sessions or symposia. We kindly ask that you DO NOT record / film any sessions with your mobile telephone. Those who violate this policy may be asked to leave the room.

Opening Hours

Cloakroom

■ Wednesday, July 18	06:00 – 19:00
■ Thursday, July 19	06:30 – 19:00
■ Friday, July 20	06:30 – 19:45
■ Saturday, July 21	06:30 – 13:30

Exhibition Hours

■ Wednesday, July 18	09:45 – 15:15
■ Thursday, July 19	09:45 – 15:15
■ Friday, July 20	09:45 – 15:15

Poster Pick-up Hours

■ Wednesday, July 18	07:00 – 17:30
■ Thursday, July 19	07:00 – 17:30
■ Friday, July 20	07:00 – 09:00

Registration Hours

■ Tuesday, July 17	15:00 – 19:00
■ Wednesday, July 18	06:00 – 18:00
■ Thursday, July 19	06:30 – 18:00
■ Friday, July 20	06:30 – 19:00
■ Saturday, July 21	06:30 – 14:00

Speaker Ready Room Hours

■ Tuesday, July 17	15:00 – 19:00
■ Wednesday, July 18	06:00 – 18:00
■ Thursday, July 19	06:30 – 18:00
■ Friday, July 20	06:30 – 19:00
■ Saturday, July 21	06:30 – 14:00

Partner Resource Center

Partner organizations who would like to promote their upcoming meetings and/or programs are invited to display materials at the Partner Resource Center. Participants are encouraged to visit the Partner Resource Center to learn about upcoming scientific events in the field. The Partner Resource Center is located on the right hand side of the **Level 3 Foyer**.

Pocket Program

A pocket program is provided to participants upon registration. It is a handy reference and contains a program-at-a-glance, venue and meeting information, and maps.



GENERAL MEETING INFORMATION

Poster Pick-up Booth

Accepted poster presenters were offered the opportunity to have their posters professionally printed and delivered to the meeting at no cost. If you have opted to take advantage of this service, kindly note that you can pick up your poster(s) at the Poster Pick-up Booth located in the **Wicklow Foyer on Level 2** during the following times:

Date	Hours
■ Wednesday, July 18	07:00 – 17:30
■ Thursday, July 19	07:00 – 17:30
■ Friday, July 20	07:00 – 09:00

Poster Sessions

Posters will be presented during two poster sessions as follows:

Poster Session 1

- Wednesday, July 18 from 13:15 to Thursday, July 19 at 12:00

Poster Session 2

- Thursday, July 19 from 13:15 to Friday, July 20 at 12:00

Posters can be picked up at the Poster Pick-up Booth located in the **Wicklow Foyer on Level 2**. Posters will be displayed in Liffey B. Posters can be hung beginning at 13:15 the day of your poster session and should be dismantled by 12:00 the next day. **NOTE: All posters that have not been taken down by 12:00 will be dismantled and destroyed.**

We ask that poster presenters be present at their poster during the formal Poster Networking for the appropriate poster session to which they have been assigned.

Poster Session 1 Networking

- Wednesday, July 18 17:00 – 18:30

Poster Session 2 Networking

- Thursday, July 19 17:00 – 18:30

Mounting material (Velcro) will be provided to hang your poster.

As an added-value service, all presenters who gave permission will have their poster added to the ISTH Academy. By having posters included in the ISTH Academy it will prolong the poster session experience and increase the visibility of posters for long after the meeting has finished. You can also exchange ideas and ask questions to presenters. Scan the QR code below to access the ISTH Academy website or visit academy.isth.org.



Print Program

In an effort to be environmentally conscious, copies of the print program are distributed to attendees who opted to have the print version when they registered. There are a limited number of extra programs available. The full program, as well as additional information and interactive features can be found on the ISTH SSC 2018 Mobile App.

Registration Hours

Registration will start Tuesday, July 17 in the afternoon. The registration area is located on the **main entrance level** of the Convention Centre Dublin and is open during the following hours:

- Tuesday, July 17 15:00 – 19:00
- Wednesday, July 18 06:00 – 18:00
- Thursday, July 19 06:30 – 18:00
- Friday, July 20 06:30 – 19:00
- Saturday, July 21 06:30 – 14:00

GENERAL MEETING INFORMATION

Restaurants

Dublin has a growing 'foodie' scene and has a variety of cuisines to choose from when dining out. Reservations are recommended, particularly on Thursday, Friday and Saturday nights.

Meal prices at restaurants include VAT at the rate of 13.5%. Many restaurants include the tip as a service charge added automatically to the bill (it's usually listed at the bottom, just before the bill's total). It usually ranges from 10% to 15%. When no service charge is added, tip around 12% or so, depending on the quality of the service.

Smoking

Please note that this is a non-smoking meeting. Smoking is neither permitted in or outside the meeting halls nor in the exhibition area.

Social Media

ISTH SSC 2018 encourages use of social media, such as Twitter, Facebook, LinkedIn, Instagram and other social media platforms at the meeting as a way to summarize, highlight, excerpt, review or promote the presented materials of the meeting in general, provided that:

- **Copyright law is observed;**
- **verbatim information is limited to a few quotes;**
- **and the author or speaker is referenced and cited appropriately.**

Speaker Ready Room

The Speaker Ready Room is located in **Wicklow Meeting Room 1 (Level 2)**. Speakers are asked to upload their formatted presentations (PowerPoint presentations) at the Speaker Ready Room at least 2 hours before their session or the day before for an early morning presentation. All conference rooms feature state-of-the-art technical equipment. Audiovisual material will be available for your presentation.

Speaker Ready Room Hours

- | | |
|-----------------------------|----------------------|
| ■ Tuesday, July 17 | 15:00 – 19:00 |
| ■ Wednesday, July 18 | 06:00 – 18:00 |
| ■ Thursday, July 19 | 06:30 – 18:00 |
| ■ Friday, July 20 | 06:30 – 19:00 |
| ■ Saturday, July 21 | 06:30 – 14:00 |

Taxes

In Ireland, the standard Value Added Tax (VAT) rate is 23% of the net price and are applied to almost every product you purchase, with the exceptions of food, children's clothing, medical services and purchases from non-profit organizations. Non-EU residents may qualify for a refund of some of the VAT they have paid during their visit in Ireland.

Tipping

Tips and Value Added Tax (VAT) are officially included in all prices. For exceptional service, an extra tip is recommended. When tipping at a restaurant, tips should be handed to the waiter/waitress and not left on the table.

- **Taxis**
A tip is not expected, but is appreciated. A good rule of thumb is to round up to the nearest euro for a short trip and to the nearest 10 euro for a longer ride.
- **Restaurants**
10% – 15%. Sometimes already included in your bill, so be sure to check the bill first.
- **Porters**
€ 1 - 2 per item
- **Room maids**
€ 1 - 2 per day
- **Hairdressers**
10%



GENERAL MEETING INFORMATION

Transit

Conveniently located in Dublin's Docklands, the business hub of the city, The Convention Centre Dublin can be accessed via a network of public transport options.

■ Rail and DART

The CCD is less than 10 minutes on the Luas Red Line from Dublin's two main railway stations, Connolly and Heuston. Operated by Irish Rail, these stations serve all the major towns and cities in Ireland.

The DART (Dublin Area Rapid Transit) rail network runs along the coast of Dublin, from Malahide and Howth, to Bray and Graystones, providing transport from the city centre to suburban areas. Connolly, Pearse Street and Tara Street DART stations are all located about 10 minutes' walk from The CCD.

■ Tram (Luas)

Luas is Dublin's light rail transit system. There are two lines, the Green Line and the Red Line. The CCD is on the Red Line, conveniently linking to downtown Dublin and Connolly and Heuston rail stations. Major Square and Spencer Dock are the closest stops. Switch between the Red and Green lines at Abbey Street / O'Connell – GPO / Marlborough stops.

■ Bus

Dublin Bus offers a high frequency, easy-to-use and accessible service across all of the city centre and surrounding areas. These services include city bus services, Airlink, Nitelink and DART feeder buses. Exact change, weekly tickets or top up Leapcards must be used.

Busáras is the central bus station in Dublin for intercity and regional bus services operated by Bus Éireann. Busáras is just 5 minutes from The CCD on the Luas Red Line and is located beside Connolly railway station.

Travel Awards

Travel award recipients can go to the specific "Travel Award" desk in the registration area on the main entrance level of the CCD to receive their grant. Grants can be collected from 06:30 – 18:00 on Wednesday, July 18 through Friday, July 20.

Virtual Delegate Bag

Consult the ISTH SSC 2018 Virtual Delegate Bag to take advantage of a new and innovative service. Receive exclusive and valuable information from the ISTH and its partner organizations, as well as supporters and exhibitors.

Conveniently accessible via the ISTH SSC 2018 Mobile App or via: <http://goveb.co/eb/214780>, the Virtual Delegate Bag is always with you, without having to carry it around!



Wireless Internet

Wi-fi is available throughout the convention center.

■ **Wifi name: ISTHSSC2018**

■ **Password: Roche2018**



JULY 18-21
ISTH 2018 ♦
SSC DUBLIN
Education, Innovation, Collaboration

EXHIBITS & SUPPORTED SYMPOSIA

ISTH SSC 2018 Supporters
Supported Symposia
Exhibition Floorplan
Exhibitor List
Exhibitor Profiles
Corporate Meeting Suites

together we can change haemophilia



CARL LYONS
Carl has haemophilia A
and lives in Denmark

“We must help one another, and accept that it is ok to ask for help too”

Sine Lyons
Mother of Carl, who has haemophilia A
Denmark

Changing Haemophilia® was established to help people living with haemophilia to live a life with as few limitations as possible.

We are working in close collaboration with global patient organisations such as the World Federation of Haemophilia (WFH) and European Haemophilia Consortium (EHC), supporting their projects through sponsorships and donations as well as aligning with their strategic goals to achieve better haemophilia care together. We also work actively to identify advocacy projects together with Novo Nordisk affiliates on local and regional levels.

Together, we aim to change perceptions and behaviours by raising awareness, and supporting projects so that people with haemophilia can experience the freedom to live life to the fullest.

Learn more at novonordisk.com/changinghaemophilia

changing
haemophilia®



Changing Haemophilia® and the Apis bull logo are registered trademarks of Novo Nordisk A/S. H0MMA/CH/1717/0198a



CHRIS BOMBARDIER
Chris has haemophilia B
and lives in the US

ISTH SSC 2018
Novo Nordisk satellite symposium

Improving patient outcomes with innovative approaches to haemophilia management

Symposium agenda

Thursday 19 July 2018, 13.15–14.30, Liffey Hall A

Welcome & introduction

Chair: Pratima Chowdary (UK)

Raising FIX activity levels in haemophilia B patients: the PK profile of N9-GP

Carmen Escuriola (DE)

Clinical experience with N8-GP in haemophilia A: the pathfinder™ programme

Pratima Chowdary (UK)

Treatment convenience built on the legacy of factor replacement: development of N8-GP for subcutaneous administration

Kasper Almholt (DK)

Re-balancing the coagulation system with concizumab: an alternative approach to treating haemophilia

Johannes Oldenburg (DE)

Q&A, discussion and final remarks

All

**changing
haemophilia**®

N9-GP (nonacog beta pegol) has been authorised by EMA and FDA, but is currently not available in Ireland. N8-GP (turoctocog alfa pegol) has been submitted for marketing authorisation to EMA and FDA, but is currently not approved. Concizumab is a product in development.


novo nordisk®

Changing Haemophilia® and the Apis bull logo are registered trademarks of Novo Nordisk A/S. HQMM/CH/0318/0069

ISTH SSC 2018 SUPPORTERS

The ISTH and the SSC 2018 Local Organizing Committee would like to thank the following companies for their support of the 64th Annual SSC Meeting of the ISTH.

Platinum Supporters



Gold Supporters



Silver Supporters





Wednesday, July 18

13:15 – 14:30

Liffey A (Level 1)

Managing Thrombosis Risk with Precision: Anticoagulation in the NOAC Era

Supported by Bayer AG



Chairs: Ajay Kakkar, *United Kingdom*, Rupert Bauersachs, *Germany*

- 13:15 – 13:20** **Opening Remarks**
Ajay Kakkar, *United Kingdom*
- 13:20 – 13:30** **Evolution of CAT Treatment. What is the NOAC Clinical Perspective After the Latest Trials?**
Alok Khorana, *United States*
- 13:30 – 13:40** **NOAC Outcomes in CAT. What is the Evidence from Real-World Studies?**
Jan Beyer-Westendorf, *Germany*
- 13:40 – 13:50** **VTE Recurrence. How the Latest Studies Reopen the Discussion of who is at Risk?**
Paolo Prandoni, *Italy*
- 13:50 – 14:00** **Extended VTE Treatment in the NOAC Era. How to Choose the Dosing Regimen?**
Peter Verhamme, *Belgium*
- 14:00 – 14:10** **NOACs in Arterial Thrombosis. Which Patient Will Benefit Most?**
Rupert Bauersachs, *Germany*
- 14:10 – 14:25** **Panel Discussion**
- 14:25 – 14:30** **Closing Remarks**
Ajay Kakkar, *United Kingdom*

Liffey Hall 2 (Level 1)

The Role of the Core Lab and Point-of-Care Testing in Managing Bleeding Disorders Benefits and Challenges

Supported by Stago



Chair: Martin Besser, *United Kingdom*

- 13:15 – 13:25** **Welcome and Introduction: What is the Point of Care?**
Martin Besser, *United Kingdom*
- 13:25 – 13:50** **Experience of Managing Critical Bleeding at Point of Care: Recent Developments and Limitations**
Bruce Spiess, *United States*

SUPPORTED SYMPOSIA

SUPPORTED SYMPOSIA

- 13:50 – 14:15** **Contribution of the Core Lab in the Management of Bleeding Disorders**
Alberto Tosetto, *Italy*
- 14:15 – 14:25** **Q&A**
- 14:25 – 14:30** **Conclusion**
Martin Besser, *United Kingdom*

Wicklow Hall 1 (Level 2)

Overview of Adeno-Associated Virus Vector-Based Gene Therapy with Potential Application in Haemophilia

Supported by Spark Therapeutics, Inc.



Chair: Leonard A. Valentino, *United States*

- 13:15 – 13:20** **Introduction**
Leonard A. Valentino, *United States*
- 13:20 – 13:55** **Current Haemophilia Care: Where We Are and Where We Need To Be**
Leonard A. Valentino, *United States*
- 13:55 – 14:30** **AAV: Potential as a Transformative Biotechnology for Gene Replacement**
Margaret Ragni, *United States*

Wicklow Hall 2 (Level 2)

Management of Haemophilia – Today and in the Future

Supported by CSL Behring

CSL Behring

Chair: Ingrid Pabinger, *Austria*

- 13:15 – 13:20** **Welcome and Introduction**
Ingrid Pabinger, *Austria*
- 13:20 – 13:40** **rIX-FP: Bridging Clinical Trials to Real World Experience**
Elena Santagostino, *Italy*
- 13:40 – 13:55** **Extending the Evidence for rVIII-SingleChain**
Vinod Balasa, *United States*
- 13:55 – 14:10** **A Multifactorial Role for Factor VIII**
Jason A Taylor, *United States*
- 14:10 – 14:20** **Individualizing Prophylaxis with rIX-FP and rVIII-SingleChain: The WAPPS-Hemo Project**
Alfonso Iorio, *Canada*
- 14:20 – 14:30** **Q&A Session and Closing Remarks**
Ingrid Pabinger, *Austria*



Thursday, July 19

13:15 – 14:30

Liffey A (Level 1)

Improving Patient Outcomes with Innovative Approaches to Haemophilia Management

Supported by Novo Nordisk Healthcare AG



Chair: Pratima Chowdary, *United Kingdom*

- 13:15 – 13:25** **Welcome & Introduction**
Pratima Chowdary, *United Kingdom*
- 13:25 – 13:40** **Raising FIX Activity Levels in Haemophilia B Patients:
The PK Profile of N9-GP**
Carmen Escuriola-Ettingshausen, *Germany*
- 13:40 – 13:55** **Clinical Experience with N8-GP in Haemophilia A:
The pathfinder™ Programme**
Pratima Chowdary, *United Kingdom*
- 13:55 – 14:05** **Treatment Convenience Built on the Legacy of Factor Replacement:
Development of N8-GP for Subcutaneous Administration**
Kasper Almholt, *Denmark*
- 14:05 – 14:20** **Re-balancing the Coagulation System with Concizumab: An Alternative
Approach to Treating Haemophilia**
Johannes Oldenburg, *Germany*
- 14:20 – 14:30** **Q&A, Discussion and Final Remarks**

Liffey Hall 2 (Level 1)

Venous Thromboembolism (VTE): Pervasive, Persistent, Preventable The Unmet Need in Acutely Ill Medical Patients

Supported by Portola Pharmaceuticals



Chair: Alexander Cohen, *United Kingdom*

- 13:15 – 14:30** **Venous Thromboembolism (VTE): Pervasive, Persistent, Preventable
The Unmet Need in Acutely Ill Medical Patients**
Alexander Cohen, *United Kingdom*

SUPPORTED SYMPOSIA

SUPPORTED SYMPOSIA

Wicklow Hall 1 (Level 2)

New Challenges in the Diagnosis of Coagulation and Thrombotic Disorders and the Impact on Clinical Treatment Decisions

Supported by Roche Diagnostics



Chair: Stephen MacDonald, *United Kingdom*

-
- | | |
|---------------|--|
| 13:15 – 13:20 | General Introduction on Challenges of Coagulation Diagnostics
Stephen MacDonald, <i>United Kingdom</i> |
| 13:20 – 13:40 | The Role of the Lab in the Management of Patients Treated With Direct Oral Anticoagulants
Sophie Testa, <i>Italy</i> |
| 13:40 – 14:00 | Clinical Data Generation on a New Coagulation Platform: Results of a Comparison Study on Accuracy and Precision
Steve Kitchen, <i>United Kingdom</i> |
| 14:00 – 14:20 | The Future Needs of the Specialist Haemostasis Laboratory
Gary Moore, <i>United Kingdom</i> |
| 14:20 – 14:30 | Question & Answer Session and Session Close
Stephen MacDonald, <i>United Kingdom</i> |

Wicklow Hall 2 (Level 2)

Protection in Haemophilia: The Evolving Science and Long-Term Outcomes of Fc Fusion Factors

Supported by Sobi™ | Bioverativ, a Sanofi company



Chairs: Stefan Lethagen, *Sweden*, Nisha Jain, *United States*

-
- | | |
|---------------|---|
| 13:15 – 13:25 | Welcome and Introduction
Nisha Jain, <i>United States</i> , Stefan Lethagen, <i>Sweden</i> |
| 13:25 – 13:40 | New Insights Into the Mechanism of Fc-Driven Tempering of the Immune Response to FVIII
Katalin Kis-Toth, <i>United States</i> |
| 13:40 – 14:00 | The Secrets of FIX Biology: Does Extravascular FIX Distribution Matter in the Treatment of Haemophilia B?
K. John Pasi, <i>United Kingdom</i> |
| 14:00 – 14:20 | Raising Expectations in Haemophilia Management: Long-Term Outcomes Beyond Low ABRs
Roshni Kulkarni, <i>United States</i> |
| 14:20 – 14:30 | Questions and Answers, Closing Remarks
Nisha Jain, <i>United States</i> , Stefan Lethagen, <i>Sweden</i> |



Friday, July 20

07:00 – 07:45

Liffey Hall 2 (Level 1)

New Strategies to Prevent CV Events After Hospital Discharge

Supported by Medscape Education

Partner: NATF (North American Thrombosis Forum)

Supported by an independent educational grant from Portola Pharmaceuticals, Inc.



Chair: Samuel Z. Goldhaber, *United States*

- 07:00 – 07:05** **Welcome and Introductions**
Samuel Z. Goldhaber, *United States*
- 07:05 – 07:15** **Crisis and Unmet Need in Medically Ill Hospitalized Patients**
Steven B. Deitelzweig, *United States*
- 07:15 – 07:30** **Prevention of VTE, Stroke, and Rehospitalization for Medically Ill Hospitalized Patients**
Samuel Z. Goldhaber, *United States*
- 07:30 – 07:40** **Management of Major Bleeding Among Patients Taking DOACs: State-of-the-Art**
Samuel A. Berkman, *United States*
- 07:40 – 07:45** **Q&A, Concluding Remarks**
Samuel Z. Goldhaber, *United States*

Friday, July 20

13:15 – 14:30

Liffey Hall 1 (Level 1)

Reducing Mortality in aTTP – Faster Diagnosis, Improved Treatment, Better Follow-up

Supported by Ablynx NV



Chair: J. Evan Sadler, *United States*

- 13:15 – 13:25** **Welcome and Introductions – Entering a new era in aTTP**
J. Evan Sadler, *United States*
- 13:25 – 13:40** **Reducing Mortality in aTTP – Faster Diagnosis**
Spero Cataland, *United States*
- 13:40 – 13:55** **Reducing Mortality in aTTP – Improved Treatment**
Flora Peyvandi, *Italy*

SUPPORTED SYMPOSIA

SUPPORTED SYMPOSIA

13:55 – 14:10 **Reducing Mortality in aTTP – Better Follow-up**
Marie Scully, *United Kingdom*

14:10 – 14:30 **Questions & Answers**

Liffey Hall 2 (Level 1)

Monitoring Needs in Hemophilia and von Willebrand Disease

Supported by Shire



Chair: Peter L. Turecek, *Austria*

13:15 – 13:20 **Welcome**
Peter L. Turecek, *Austria*

13:20 – 13:35 **Laboratory and Clinical Monitoring of FVIII: One-Stage and Chromogenic Assays**
Steven Pipe, *United States*

13:35 – 13:45 **Monitoring in Acquired Hemophilia**
Alice Ma, *United States*

13:45 – 13:55 **Monitoring BPAs: Role of Global Assays**
Yesim Dargaud, *France*

13:55 – 14:10 **Monitoring in von Willebrand Disease**
Agnès Veyradier, *France*

14:10 – 14:30 **Panel Discussion**
Peter L. Turecek, *Austria*

Wicklow Hall 1 (Level 2)

AAV-Mediated Gene Therapy for Haemophilia: A Closer Look

Supported by BioMarin Pharmaceutical



Chair: K. John Pasi, *United Kingdom*

13:15 – 13:35 **Deep Dive into the Science of AAV-Mediated Gene Therapy**
David Lillicrap, *Canada*

13:35 – 13:55 **A Clinician's Guide to Evaluating Trial Data**
Johnny Mahlangu, *South Africa*

13:55 – 14:15 **"Surrogate" Endpoints in Hemophilia Trials: Factor Levels or Bleeding Rates?**
Margareth Ozelo, *Brazil*

14:15 – 14:30 **Q&A**



Wicklow Hall 2 (Level 2)

**From Molecule Design to Monitoring:
The Science Behind Extended Half Life rFVIII Products**

Supported by Bayer AG




Chair: Johannes Oldenburg, *Germany*

-
- | | |
|----------------------|---|
| 13:15 – 13:20 | Welcome and Introduction
Johannes Oldenburg, <i>Germany</i> |
| 13:20 – 13:40 | Examining EHL Molecules: Common Strategies for Prolonging Protection
Elena Santagostino, <i>Italy</i> |
| 13:40 – 14:00 | Investigating the Impact of EHL Technologies: The Pharmacokinetic Perspective
Alfonso Iorio, <i>Canada</i> |
| 14:00 – 14:20 | Considering the Current and Future Challenges of Monitoring Treatment in the Changing Clinical Landscape
Steve Kitchen, <i>United Kingdom</i> |
| 14:20 – 14:30 | Panel Discussion & Q&A
Johannes Oldenburg, <i>Germany</i> |

SUPPORTED SYMPOSIA

EXHIBITION FLOOR PLAN





H3	5-Diagnostics	NP6	INVENT - VTE
B5	Ablynx	NP2	ITAC-CME
F3	Affinity Biologicals, Inc.	NP1	<i>Journal of Thrombosis and Haemostasis (JTH)</i>
D2 & E1	Bayer AG	A5	Labtech International Ltd
B2	Bio Products Laboratory (BPL)	B1a	Lepu Medical
C1	BioMarin Pharmaceutical	G8	LumiraDx Care Solutions
F2	BioMedica Diagnostics	G2	Nordic Biomarker
D1	BMS Pfizer Alliance	C4	Portola Pharmaceuticals
G4	Cardinal Health	G1	Precision BioLogic
D5	CSL Behring	NP1	<i>Research and Practice in Thrombosis and Haemostasis (RPTH)</i>
B1	Diagon	E5	Roche Diagnostics
H2	DOASENSE	A1	Sanofi Genzyme
G5	DSM Pentapharm	A2	Sebia
H4	Enzyme Research / r2 Diagnostics, Inc.	C5	Shire
NP5	European Haemophilia Consortium (EHC)	A4	Sinnova Medical Science & Technology Co., Ltd
G7	George King Bio-Medical, Inc.	F4	Sobi
B3	Haematologic Technologies, Inc.	G6	Spark Therapeutics, Inc.
NP4	Haematologica Journal	H1	Stago
B4	Haemonetics	F5	Sysmex Corporation & Siemens Healthineers
A3	HYPHEN BioMed	F6	Technoclone
G3	iLine Microsystems	NP7	Thrombosis UK
F1	Instrumentation Laboratory	NP3	World Federation of Hemophilia
NP1	International Society on Thrombosis and Haemostasis (ISTH) (Not pictured, in Level 1 Foyer)	NP1	World Thrombosis Day

EXHIBITOR PROFILES

5-Diagnostics

Stand H3



Contact Email	info@5-diagnostics.com
Website	www.5-diagnostics.com
Phone Number	+41 61 588 07 84

5-Diagnostics employs a global network of dedicated hemostasis representatives and product specialists, each of whom have years of proven expertise in meeting the needs of a wide range of customers including clinical, research and industry-based groups. We are determined to bring innovation to the diagnostic technician and scientist by sourcing and manufacturing the very best research and clinical products available worldwide. Our commitment to high quality is reflected in our rapidly expanding portfolio of unique and specialized assays and components.

Ablynx

Stand B5



Contact Name	Daphné Benichou
Contact Email	daphne.benichou@ablynx.com
Website	www.ablynx.com
Phone Number	+32 9 262 00 00

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc; Merck KGaA; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium.

Affinity Biologicals, Inc.

Stand F3



Contact Name	Greg Fullerton
Contact Email	greg.fullerton@affinitybiologicals.com
Website	www.affinitybiologicals.com
Phone Number	+1 905 304 9896

Affinity Biologicals, Inc. is a primary manufacturer of products used worldwide in thrombosis and haemostasis research and medical diagnostics. Products include an extensive line of antibodies, conjugates, antibody pairs for immunoassay of human and animal analytes, the VisuLize™ line of complete ELISA kits, full line of immuno-depleted human plasma products, VisuCal™ Calibrator Plasma, VisuCon™ Normal, Abnormal and Low Fibrinogen Control Plasmas and VisuDep™ Factor Deficient Plasmas. Services include protein purification, antibody production, assay development, custom lyophilization and custom plasma production.



Bayer AG

Stand D2 & E1



Company Name	Bayer AG
Contact	Email info@bayer.com
Website	www.bayer.com
Phone Number	+49 30 468 1111

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. For more information, go to www.bayer.com

BioMarin Pharmaceutical

Stand C1



Contact Name	Jessica Anderson
Contact Email	jessica.anderson@bmrn.com
Website	www.biomin.com
Phone Number	+1 415 506 6700

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. Approved products include the first and only medications for PKU and LEMS, and the first and only enzyme replacement therapies for MPS I, MPS VI and Morquio A syndrome. Visit www.biomin.com to learn more.

BioMedica Diagnostics

Stand F2



Contact Name	Paul Phillips
Contact Email	pPhillips@biomedicadiagnostics.com
Website	www.biomedicadiagnostics.com
Phone Number	+1 902 798 5105

Focusing on thrombosis & haemostasis diagnostic solutions for human and animal health, BioMedica offers a complete line of diagnostic and research products, recently strengthened by an acquisition of specialty coagulation products and technologies. Our line-up includes high quality kits, controls, reagents and calibrators that are designed for use in routine and specialty coagulation and are also widely used in research and industry spaces. Many BioMedica products are Health Canada Registered, FDA 510(k) cleared and/or CE marked.

EXHIBITOR PROFILES

Bio Products Laboratory (BPL)

Stand B2



Bio Products Laboratory

Company Name	Bio Products Laboratory (BPL)
Contact Name	Nikki St Paul
Contact Email	nikki.stpaul@bpl.co.uk
Website	www.bplgroup.com
Phone Number	020 8957 2678

Bio Products Laboratory (BPL), headquartered in Hertfordshire, England, is a global operation that provides high quality plasma products and technical support to over 45 markets worldwide. Our products include a wide range of plasma products for patients with rare blood disorders. BPL contains two operating divisions – BPL Plasma and BPL Therapeutics.

BMS Pfizer Alliance

Stand D1



Bristol-Myers Squibb



Contact Email	info@pfizer.com
Website	www.pfizer.com
Phone Number	+44 1304 616161

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer's global scale and expertise in this field.

Cardinal Health

Stand G4



CardinalHealth
Essential to care™

Contact Name	Gianluca Magrone
Contact Email	giacchinoluca.magrone@cardinalhealth.com
Website	www.cardinalhealth.com
Phone Number	+39 335 5609947

Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically proven medical products, pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. To help combat prescription drug abuse, the company created a national drug education and awareness program. Cardinal Health ranks #14 on the Fortune 500.



CSL Behring

Stand D5

CSL Behring

Contact Name	Anastasia Walsh
Contact Email	Anastasia.Walsh@cslbehring.com
Website	CSLBehring.co.uk
Phone Number	+1 610 517 5820

A century ago, CSL Behring made a promise to serve the needs of patients with serious medical conditions. Today that same promise has never been stronger. A global leader in the biotherapeutics industry, CSL Behring is passionate about improving the quality of patients' lives and remains committed to the global bleeding disorders community. The company manufactures and markets a range of recombinant and plasma-derived products for treating Hemophilia, von Willebrand's disease and other bleeding disorders.

Daiichi Sankyo Co., Ltd.

Supporter



Daiichi-Sankyo

Contact Name	Hideyuki Otsuki
Contact Email	otsuki.hideyuki.au@daiichisankyo.co.jp
Website	www.daiichisankyo.com/
Phone Number	+81 70 1398 8192

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services to address diversified, unmet medical needs in more than 20 countries around the world. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.

Diagon

Stand B1



Contact Name	Marco van der Looij, PhD MBA
Contact Email	sales@diagon.com
Website	www.diagon.com/en/
Phone Number	+36 1 369 6500

Diagon – established in 1989 – is a leading clinical diagnostic manufacturing company, with 100% Hungarian ownership. The company develops and manufactures reagents for a wide range of coagulometers and haematology analyzers. Diagon, as a system provider offers its own line of reagents, instruments and control materials in both coagulation and haematology. The Coag Line features laboratory and point-of-care instruments as well. Today, Diagon is a recognized leader in the field of coagulation and haematology.

EXHIBITOR PROFILES

DOASENSE

Stand H2



Contact Name	Dr. Frieder Loesel
Contact Email	f.loesel@doasense.de
Website	www.doasense.de
Phone Number	+49 6221 825 9785

DOASENSE presents a new generation of devices for point-of-care testing for Direct Oral Anticoagulants (DOACs): DOAC testing – now fast and easy as with creatinine. Our proprietary technologies for assessing DOACs in urine provide crucial data to healthcare professionals, all in a swift and easy assessment process. *When every minute counts ... fast DOAC testing really matters.*

DSM Pentapharm

Stand G5



Contact Name	Daniela Tschanz
Contact Email	daniela.tschanz@pentapharm.com
Website	www.pentapharm.com
Phone Number	+41 61 706 48 48

PENTAPHARM is an innovative and reliable supplier of active ingredients for the pharmaceutical, diagnostic and cosmetic industries. Our roots as researchers, developers and manufacturers of state-of-the-art products reach back to 1948. Pentapharm is recognized as a high-quality Swiss manufacturer of coagulation diagnostics products such as:

- Haemostasis kits
- Customized development and production of semi finished kit components or finished kits under OEM
- A wide range of various substrates
- Protein stabilizer Prionex®
- Inhibitors for serine proteinases (Pefabloc® SC)
- Highly purified snake venom enzymes (Protac®, Ecarin, Batroxobin...)

Enzyme Research / r2 Diagnostics, Inc.

Stand H4



Contact Name	Kimberly Martz
Contact Email	info@enzymeresearch.com info@r2diagnostics.com
Websites	www.enzymeresearch.com www.r2diagnostics.com
Phone Numbers	+1 574 288 2268 +1 574 288 4377

Enzyme Research Laboratories provides coagulation and fibrinolytic proteins from human plasma, other source plasmas and platelets. Additionally, we offer monoclonal and polyclonal antibodies, immunodepleted plasmas and ELISA reagents. Custom purifications and contract services are also available.

r2 Diagnostics, Inc strives to provide high quality, innovative and economical products for the hemostasis market. We place major emphasis on the production of optimized and versatile products for the detection of thrombophilia. We offer clot-based kits for quantitation of PS and Lupus Anticoagulants.



European Haemophilia Consortium (EHC)

Stand NP5



Contact Name	Raia Mihaylova
Contact Email	raia.mihaylova@ehc.eu
Website	www.ehc.eu/
Phone Number	+32 2 893 24 70

The European Haemophilia Consortium (EHC) is an international non-profit organisation that works to improve the quality of life for people with haemophilia, von Willebrand Disease (VWD) and other rare bleeding disorders in Europe. It is an umbrella organisation that represents and actively supports 45 national patient organisations from 27 Member States of the European Union and most Member States of the Council of Europe.

George King Bio-Medical, Inc.

Stand G7



Contact Name	Katie Wilkes
Contact Email	plasma@kingbiomed.com
Website	www.kingbiomed.com
Phone Number	+1 913 469 5464

George King Bio-Medical, Inc. is proud to be a global leader in diagnostic coagulation and thrombosis since 1973; celebrating 45 years this year! Our valued customers include clinical laboratories at many distinguished and renowned hospitals, pharmaceutical companies and research facilities worldwide.

Our product line includes congenital factor deficient plasmas, coagulation and specialty control plasmas, and convenience plasma kits. We look forward to serving your laboratory.

Grifols

Supporter



Contact Name	Leire Reverte
Contact Email	leire.reverte@grifols.com
Website	www.grifols.com
Phone Number	+ 34 670 920 481

Grifols is a global healthcare company with more than 75-years legacy focused on improving people's health and well-being by offering high-quality plasma-derived protein therapies, innovative diagnostic tools and essential hospital services. In the field of hemostasis we are committed to offering complete disease management comprising a clear and precise diagnosis and plasma-derived therapies with outstanding records of efficacy and safety, to treat patients with coagulation disorders and improve life expectancy.

EXHIBITOR PROFILES

Haematologic Technologies, Inc.

Stand B3



Contact Email	hti@haemtech.com
Website	www.haemtech.com
Phone Number	+1 802 878 1777

Haematologic Technologies, Inc. (HTI) is a primary manufacturer of plasma proteins and other products used in blood coagulation and fibrinolysis research. Our product line consists of highly purified coagulation factors, antibodies, deficient plasmas and customized blood collection tubes for clinical studies. cGMP services available include: stability, release and other QC testing for biopharmaceuticals, ADA development and IVIG analytical testing.

Haematologica Journal

Stand NP4



Contact Name	Simona Giri
Contact Email	simona.giri@haematologica.org
Website	www.haematologica.org
Phone Number	+39 382 27129

Haematologica was founded in 1920 by Adolfo Ferrata and is owned and published by the Ferrata Storti Foundation (Italy).

The scope of the journal is to report the results of research studies that:

- have an important impact on our understanding of hematology;
- provide new insights in the development of hematology diseases;
- contribute significantly to improve diagnosis or treatment of hematology disease.

Haematologica ranks 4th out of all hematology related journals.

2016 Impact Factor: 7.702

Haemonetics

Stand B4



Contact Name	Olivia Baliguet
Contact Email	Olivia.baliguet@haemonetics.com
Website	www.haemonetics.com
Phone Number	+41 791 269 656

Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Our devices, consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. To learn more about Haemonetics, visit our web site at <http://www.haemonetics.com>.



HYPHEN BioMed

Stand A3



A Company of Sysmex Group

Contact Name	Ms. Sayo Riviere
Contact Email	info@hyphen-biomed.com
Website	www.hyphen-biomed.com
Phone Number	+33 1 34 40 65 10

HYPHEN BioMed is highly specialized for developing, manufacturing and distributing in-vitro diagnostic and research reagents in thrombosis and hemostasis, for multiplatform applications. Being expert in the field, the company provides innovative and value-adding solutions to hospital laboratories (e.g., DOACs, HIT, Hemophilia), research institutions and pharmaceutical industry (customized solution). Our unique offer of high quality reagents is available worldwide through an extensive distributor network in all major markets: Find your local distributor on our web site.

iLine Microsystems

Stand G3



Contact Name	Elisabete Lasuen
Contact Email	elasuen@ilinemicrosystems.com
Website	www.ilinemicrosystems.com
Phone Number	+34 688 605 170

iLine Microsystems was founded in 2007 with the aim to meet the needs of current and future healthcare models, improving the efficiency of healthcare professionals and patient's quality of life in the field of hemostasis and coagulation.

In 2011 the company obtained the CE marking for its first product, the microINR System, and initiated its commercial launch.

In the meantime, the microINR System has obtained the clearance by the most stringent Health Authorities such as México, Brazil, Australia, and China, among others.

Instrumentation Laboratory

Stand F1



A Werfen Company

Contact Name	Jennifer Gannon
Contact Email	jgannon@ilww.com
Website	www.instrumentationlaboratory.com
Phone Number	+1 800 955 9525

Instrumentation Laboratory (IL) delivers innovative IVD solutions for a range of Hemostasis testing needs. Our booth features: ACL TOP® Family 50 Series Systems, HemoCell™ Specialized Lab Automation, HemoHub™ Intelligent Data Manager, ACL AcuStar™ System, ACL Elite® Systems and HemosIL® assays. And, for whole blood Hemostasis testing at the point of care, ROTEM® viscoelastic testing systems, Hemochron® Signature Elite systems and VerifyNow™ platelet-reactivity systems. IL is a Werfen Company.

EXHIBITOR PROFILES

INVENT – VTE

Stand NP6



Contact Name	Marc Rodger
Contact Email	mrodger@toh.ca
Website	www.invent-vte.com
Phone Number	+1 613 862 0055

INVENT is an independent, not-for-profit network that exists to promote international collaboration between academic research networks conducting venous thromboembolism (VTE) related clinical research, and to enhance the profile, science, and impact of investigator-led VTE clinical research.

International Society on Thrombosis and Haemostasis (ISTH) Stand NP1 (Foyer Level 1)



Contact Name	Louise St. Germain Director of Marketing and Membership
Contact Email	Louise_StGermain@isth.org
Website	www.isth.org
Phone Number	+1 919 929 3807

The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The Society is dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals wherever they may live.

ISTH 2019

Stand NP1 (Foyer Level 1)



Contact Name	Louise St. Germain Director of Marketing and Membership
Contact Email	Louise_StGermain@isth.org
Website	www.isth2019.org
Phone Number	+1 919 929 3807

The ISTH invites you to attend the next ISTH Congress in Melbourne, Australia! Save the dates of July 6-10, 2019 and plan to join thousands of the world's experts in thrombosis, hemostasis and vascular biology. This meeting has the greatest impact on the future of basic science and clinical practice, and your attendance and contribution is essential to the advancement of the field of thrombosis and hemostasis. Learn more at ISTH2019.org.



ITAC-CME Stand NP2



Contact Name	Dominique Farge
Contact Email	groupe.gftc@gmail.com
Website	www.itaccme.com

The International Initiative on Thrombosis and Cancer-Continuous Medical Education (ITAC-CME) is the international section of the Groupe Francophone Thrombose et Cancer (GFTC), a not-for-profit clinical research organization that developed and published the 2013 international clinical practice guidelines, endorsed by ISTH and updated in 2016 plus the ITAC-CME web-based mobile application freely accessible at www.itaccme.com. The mandate of ITAC-CME multidisciplinary working group is to reinforce to improve patient with cancer and thrombosis outcomes globally.

Journal of Thrombosis and Haemostasis (JTH) Stand NP1 (Foyer Level 1)



Contact Name	Louise St. Germain Director of Marketing and Membership
Contact Email	Louise_StGermain@isth.org
Website	jth.isth.org
Phone Number:	+1 919 929 3807

The Journal of Thrombosis and Haemostasis (JTH) is the flagship journal of the ISTH and is the leading medical journal in the fields of thrombosis and haemostasis. Through the diffusion and exchange of information and ideas within the international research community, *JTH* strives to advance science related to the important medical problems of thrombosis, bleeding disorders, and vascular biology. It publishes high quality, original research reports; state-of-the-art reviews; letters and announcements; and invited commentary and debate on timely topics. Submit your research at jth.isth.org.

Labtech International Ltd Stand A5



Contact Name	Dr Andrew Ridley
Contact Email	a.ridley@labtech.com
Website	www.labtech.com
Phone Number	+44 1435 517 000

Labtech International is a UK supplier and service provider of a technology driven product portfolio. This includes the Fluxion BioFlux 1000z system that offer a fully-integrated solution for automated, high throughput shear flow assays for investigating platelet aggregation and adhesion, thrombosis, migration/invasion and atherosclerosis models.

Labtech supports this portfolio, with a highly qualified team of application specialists. In this way, Labtech not only provides state of the art tools to vascular biologists, but also provides high-level application and service support.

EXHIBITOR PROFILES

Lepu Medical

Stand B1a



Contact Name	Ryan Huang
Contact Email	ryanhuang@lepu-medical.com
Website	en.lepumedical.com
Phone Number	+86 13510369225

Lepu Medical was established in 1999. It is specialized in developing, manufacturing and marketing the high-tech medical devices and equipment. Today, Lepu Medical has grown into a global leading group company in the fields of cardiovascular interventions, structural heart diseases, cardiac rhythm management, anesthesia and critical care, in vitro diagnostics, and general surgeries. In 2009, Lepu Medical successfully went public, and listed on ChiNext Shenzhen Stock Exchange Market (stock code: 300003).

LumiraDx Care Solutions

Stand G8



Contact Name	Stephanie Neemann
Contact Email	stephanie.neemann@lumiradx.com
Website	lumiradxcaresolutions.com
Phone Number	+44 1209 710999

For twenty years we've helped healthcare professionals in over 2,700 locations across the UK to improve anticoagulation management with INRstar, our decision support software.

Our continuous innovation alongside clinicians and patients has allowed us to develop a new model of care for the management of anticoagulation therapy.

Our unrivalled technology joins up data across fragmented clinical systems, patient apps and monitoring devices for seamless data flow with no additional workload for busy care teams.

Medscape Education

Supporter



Company Name	Medscape Education
Contact Email	MedscapeEducation@medscape.net
Website	www.medscape.org
Phone Number	+1 212 301 6700

Medscape is the leading online global destination for physicians and healthcare professionals worldwide, offering the latest medical news and expert perspectives; essential point-of-care drug and disease information; and relevant professional education and CME. The North American Thrombosis Forum (NATF) is a nonprofit organization that focuses on unmet needs and issues related to thrombosis and cardiovascular diseases such as deep vein thrombosis, pulmonary embolism, myocardial infarction, peripheral arterial occlusive disease, and stroke.



Nordic Biomarker

Stand G2



**NORDIC
BIOMARKER**

Contact Name	Rikard Rodén, CEO
Contact Email	info@nordicbiomarker.com
Website	www.nordicbiomarker.com
Phone Number	+46 90 71 86 01

Nordic Biomarker is a Swedish original manufacturer of latex reagents for coagulation and clinical chemistry analyzers, who is especially focused on development and manufacturing of latex immunoassays, for example reagents for testing of D-dimer, FDP and Free Protein S. We are collaborating closely with OEM-clients around the world to deliver customized solutions together with technical support.

Novo Nordisk Healthcare AG

Supporter



Company Name	Novo Nordisk Healthcare AG
Contact Name	Corinne Landolt
Contact Email	cnld@novonordisk.com
Website	www.novonordisk.com
Phone Number	+41 43 222 43 00

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, and “novonordisk” on Facebook, Twitter and LinkedIn.

Portola Pharmaceuticals

Stand C4



Contact Name	Melissa Beard
Contact Email	mbeard@portola.com
Website	www.portola.com
Phone Number	+1 650 246 7000

Portola Pharmaceuticals develops products in the fields of thrombosis and other hematologic diseases. Approved in the US: Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor anticoagulant. In development: AndexXa® (andexanet alfa), a recombinant protein to reverse the anticoagulant effects of oral or injectable Factor Xa inhibitors; and cerdulatinib, a Syk/JAK inhibitor to treat hematologic cancers.

EXHIBITOR PROFILES

Precision BioLogic

Stand G1



Contact Name	Kayla Dent
Contact Email	customer@precisionbiologic.com
Website	www.precisionbiologic.com
Phone Number	+1 800 267 2796

In 1992, we launched our first cryocheck™ product: a normal control for PTs and APTTs.

The benefits of frozen products quickly caught on and CRYOcheck grew from a single product to an integrated line of frozen controls, calibrators, reagents, and diagnostic kits that have become synonymous with quality in coagulation labs around the globe.

Today, with our laboratory, biotech and pharmaceutical partners, we're developing new products to address current and future challenges in the diagnosis and therapeutic monitoring of disease.

Research and Practice in Thrombosis and Haemostasis (RPTH)

Stand NP1
(Foyer Level 1)



Contact Name	Louise St. Germain Director of Marketing and Membership
Contact Email	Louise_StGermain@isth.org
Website	rpth.isth.org
Phone Number	+1 919 929 3807

Research and Practice in Thrombosis and Haemostasis (RPTH) is the official open-access journal of the ISTH. *RPTH* serves as a catalyst for global discussion and connects scientists and clinicians with the non-scientist public to discuss the latest findings and research in the field. Submit your upcoming research to *RPTH*. All articles are freely and immediately available to read, download, and share. Get started at rpth.isth.org.

Roche Diagnostics International Ltd

Stand E5



Contact Name	Alexandros Fistouris International Product Manager
Contact Email	alexandros.fistouris@roche.com
Website	www.cobas.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in *in vitro* diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.



Sanofi Genzyme

Stand A1



Website www.sanofigenzyme.com
Phone Number +1 617 252 7500

Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.

SEBIA

Stand A2



Contact Email sebia@sebia.com
Website www.sebia.com
Phone Number +33 1 69 89 80 80

SEBIA, world leader in protein electrophoresis, develops, manufactures and commercializes IVD tests and analyzers dedicated to the in vitro diagnosis of cancer, inflammatory diseases, and diabetes and hemoglobin disorders. Sebia's focus on both, gel and capillary electrophoresis techniques enables it to maintain a sustained R&D program, providing access to real innovations in any lab. Sebia recently introduced the Von Willebrand Multimers assay, to address the diagnostics unmet needs of this coagulation disorders.

Shire

Stand C5



Contact Name Garrett Alexander
Contact Email garrett.alexander@shire.com
Website www.shire.com
Phone Number +1 617 349 0200

Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas, supplemented by diversified capabilities in highly specialized conditions. We feel a strong sense of urgency to address the high unmet medical needs of these patient communities.

EXHIBITOR PROFILES

Siemens Healthineers

Stand F5



Contact Name	Eva-Maria Landmann
Contact Email	eva-maria.landmann@siemens-healthineers.com
Website	www.siemens.com/hemostasis
Phone Number	+49 172 6770624

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. Further information is available at www.siemens-healthineers.com.

Sysmex Corporation

Stand F5



Contact Name	Jean-Christophe Daniel
Contact Email	JeanChristophe.Daniel@sysmex.co.jp
Website	www.sysmex.co.jp/en
Phone Number	+33 6 6478 0649

Sysmex Corporation is an integrated supplier of instruments, reagents and software that are essential to testing processes performed during health checkups, treatment and ongoing disease management. Sysmex products are used by medical institutions in more than 190 countries and Sysmex holds the top share of the global market in the field of haematology. We are expanding our operations, augmenting our traditional strength in haematology with non-haematology fields such as immunochemistry, haemostasis, and life science field.

Sinnowa Medical Science & Technology Co., Ltd

Stand A4



Contact Name	Tim Shen
Contact Email	skt@sinnowa.com; info@sinnowa.com
Website	www.sinnowa.com/en
Phone Number	+86 25 84127188

SINNOWA is one of the leading manufacturers in Clinical lab device since 2002.

Main devices are including: PL Platelet Function Analyzer, Biochemistry Analyzer, Hematology Analyzer etc, all devices have passed ISO 13485 quality control system along with CE approval. By 15 years marketing, we have built business cooperation relationships by OEM & Distribution with customers from more than 80 countries, including USA, Ireland, Belgium, Spain, Italy etc.



Sobi

Stand F4



Contact Name	Charlotte af Klercker
Contact Email	Charlotte.afKlercker@sobi.com
Website	www.sobi.com
Phone Number	+46 70 729 73 27

Sobi is a pioneer in rare diseases with a 50 years heritage in haemophilia. Providing people with haemophilia treatment choices that will help them live the lives they want, with a continued intent to make the treatments accessible to all.

Please visit: www.sobihaemophilia.com

Spark Therapeutics, Inc.

Stand G6



Contact Name	Michael Kahn
Contact Email	michael.kahn@sparktx.com
Website	sparktx.com/

One of the areas of research at Spark Therapeutics is hemophilia A and B, inherited bleeding disorders caused by mutations in the genes that encode the clotting factors. These factors are normally synthesized in the liver. Led by researchers and clinicians with long-standing commitment to the hemophilia community, we recognize the essential need to understand and gain important perspectives from patients, caregivers and leaders in the community.

Stago

Stand H1



Contact Name	Pascal Boulanger
Contact Email	webmaster@stago.com
Website	www.stago.com
Phone Number	+33 46 88 20 20

Stago, created in 1945, is an IVD Company which develops and markets reagents and automated systems for the investigation of blood coagulation disorders. Stago is a leading player in Haemostasis. Headquarters, as well as R&D, manufacturing and logistics activities are located mainly in the Paris area (France). Its products are also available in more than 110 countries throughout the world through a network of 15 affiliates and 95 distributors. In 2016, Stago has more than 2,350 employees worldwide.

EXHIBITOR PROFILES

Technoclone

Stand F6



Contact Name	Marijn Tor (Head of customer service)
Contact Email	marijn.tor@technoclone.com, sales@technoclone.com
Website	www.technoclone.com
Phone Number	+43 1 86373 0

Technoclone is a world-leading producer of diagnostics tests, equipments and research products in the area of blood clotting. It offers global as well as speciality coagulation tests. With the fully automated coagulation analyzer the Ceveron® alpha and the semi-automated Ceveron®'s the portfolio was completed. Ceveron® alpha TGA offers the unique feature of fully automated thrombin generation in the routine. A complete range for ADAMTS-13 testing, as well as for new anticoagulants is offered.

Thrombosis UK

Stand NP7



Contact Name	Jo Jerome, CEO
Contact Email	jo@thrombosisuk.org
Website	www.thrombosisuk.org
Phone Number	+44 300 772 9603

Thrombosis UK is a UK registered UK charity dedicated to promoting awareness, care and research of venous thromboembolism (VTE). A leader in identifying, informing and partnering, we collaborate with the NHS, healthcare providers, like minded organisations and individuals to work to improve prevention of VTE and the management and care of unavoidable VTE events.

Our priority is for everyone to know the risks, signs and symptoms of VTE and to support research to extend understanding into the prevention and best management of VTE.

World Federation of Hemophilia

Stand NP3



Contact Name	Vanessa Herrick
Contact Email	vherrick@wfh.org
Website	www.wfh.org
Phone Number	+1 514 875 7944

WORLD FEDERATION OF HEMOPHILIA

For over 50 years, the World Federation of Hemophilia (WFH), an international not-for-profit organization, has worked to improve the lives of people with hemophilia and other inherited bleeding disorders. Established in 1963, it is a global network of patient organizations in 140 countries and has official recognition from the World Health Organization. Visit WFH online at www.wfh.org.



World Thrombosis Day

Stand NP1 (Foyer Level 1)



WORLD THROMBOSIS DAY
13 OCTOBER

Contact Name	Louise St. Germain Director of Marketing and Membership
Contact Email	Louise_StGermain@isth.org
Website	www.worldthrombosisday.org
Phone Number:	+1 919 929 3807

Recognized on 13 October, World Thrombosis Day (WTD) focuses attention on the often overlooked and misunderstood condition of thrombosis. With thousands of educational events in countries around the world, WTD and its partners place a global spotlight on thrombosis as an urgent and growing health problem. Learn more at worldthrombosisday.org.

CORPORATE MEETING SUITES



Bayer AG

Wicklow Meeting Room 2
Level 2



BioMarin Pharmaceutical

Liffey Meeting Room 4
Level 1

CSL Behring

CSL Behring

Liffey Meeting Room 5
Level 1



Novo Nordisk Healthcare AG

Wicklow Meeting Room 3
Level 2



Portola Pharmaceuticals

Wicklow Meeting Room 5
Level 2



Sobi

Wicklow Meeting Room 4
Level 2

CONFLICT OF INTEREST DISCLOSURE INFORMATION

'Local Organizing Committee

Marian Brennan	Receipt of grants/research support: Enterprise Ireland, Science Foundation, Ireland, Daiichi Sankyo
Dermot Cox	Receipt of grants/research support: Daiichi Sankyo, Sinnowa
Olwen Foley	No potential conflict of interest to report
Dermot Kenny	No potential conflict of interest to report
Steven Kerrigan	No potential conflict of interest to report
Michelle Lavin	Receipt of grants/research support: Shire Receipt of honoraria or consultation fees: Shire
Patricia Maguire	No potential conflict of interest to report
Tony McHale	No potential conflict of interest to report
Niamh Moran	No potential conflict of interest to report
Fionnuala Ní Áinle	Receipt of grants/research support: LEC Pharma, Actelion, Bayer Receipt of honoraria or consultation fees: BMS/Pfizer, Bayer, Daiichi Sankyo, Boehringer
Beatrice Nolan	Trial of Investigational Medical Product: Bayer, CSL Behring, Bioverativ
Niamh O'Connell	Receipt of grants/research support: Baxter Receipt of honoraria or consultation fees: Bayer, Baxter, Sobi, Bristol Myers Squibb, Pfizer, Freeline
James O'Donnell	Receipt of grants/research support: Pfizer, Shire, Bayer Receipt of honoraria or consultation fees: Leopharma, Shire, LFB
Brian O'Mahony	No potential conflict of interest to report
Roger Preston	Receipt of grants/research support: Bayer, Shire
Albert Smolenski	No potential conflict of interest to report
Rebecca Watkin	No potential conflict of interest to report



64th Annual Meeting of the Scientific and Standardization Committee (SSC) of the ISTH
CONFLICT OF INTEREST DISCLOSURE INFORMATION

CONFLICT OF INTEREST DISCLOSURE

SSC Chairmen Who Contributed to the Education Program

Walter Ageno	Receipt of grants/research supports: Bayer Receipt of honoraria or consultation fees: Bayer, Boehringer, BMS/Pfizer, Portola, Aspen, Sanofi, Daiichi Sankyo, Stago, CSL Behring
Donald Arnold	Receipt of grants/research supports: Novartis Receipt of honoraria or consultation fees: Amgen, Novartis, UCB, Rigel
James Douketis	Receipt of honoraria or consultation fees: Bayer, Boehringer- Ingelheilm, Janssen
Sabine Eichinger	Receipt of honoraria or consultation fees: Bayer, Boehringer-Ingelheilm Participation in a company sponsored speaker's bureau: Daiichi-Sankyo, BMS/Pfizer
Paolo Gresele	No potential conflict of interest to report
Joost C.M. Meijers	Receipt of honoraria or consultation fees: Bayer, Daiichi-Sankyo
Nicola Mutch	No potential conflict of interest to report
Charles Marc Samama	No potential conflict of interest to report
Jecko Thachil	Receipt of honoraria or consultation fees: Bayer, Boehringer-Ingelheilm, Amgen, Novartis Participation in a company sponsored speaker's bureau: Daiichi-Sankyo, BMS/Pfizer, Octapharma
Guy Young	Receipt of honoraria or consultation fees: Alnylam, Bioverativ, Bayer, CSL Behring, Kedrrion, Novo Nordisk, Roche/Genetech, Shire

NEW STRATEGIES TO PREVENT CV EVENTS AFTER HOSPITAL DISCHARGE CME

FRIDAY, JULY 20, 2018

BREAKFAST AND REGISTRATION: 06:30 – 07:00 | **PROGRAM:** 07:00 – 07:45
VENUE: THE CONVENTION CENTRE DUBLIN, SPENCER DOCK, NORTH WALL QUAY
ROOM: LIFFEY HALL 2 | **LIVE BREAKFAST SYMPOSIUM**

Medscape®
LIVE!

This activity is supported by an independent educational grant from Portola Pharmaceuticals, Inc.

To register, please visit: www.medscape.org/townhall/vte-stroke-prevention-registration

CHAIR



Samuel Z. Goldhaber, MD

Professor of Medicine
Harvard Medical School
Interim Chief, Division of Cardiovascular Medicine
Section Head, Vascular Medicine
Director, Thrombosis Research Group
Brigham and Women's Hospital
Boston, Massachusetts



Steven B. Deitelzweig, MD, MMM, SFHM, FACP, FACC

Professor of Medicine
University of Queensland
Regional Business Development
System Chairman
Department of Hospital Medicine
Ochsner Health System
New Orleans, Louisiana

FACULTY



Samuel A. Berkman, MD

Clinical Professor of Medicine
Division of Hematology/Oncology
The University of California, Los Angeles
Private Practice
Internal Medicine/Hematology
Cedars Sinai Medical Center
Los Angeles, California



Held at the 64th annual Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and Haemostasis (ISTH) in 2018

Developed through a collaboration between NATF and Medscape Education



Medscape
EDUCATION



PORTOLA®
PHARMACEUTICALS

EXIT

Visit
Booth
C4

Out of the hospital, but not out of the woods

Venous thromboembolism (VTE) risk for acutely ill medical patients
is highest in the first 30 days, starting with hospital admission¹

Learn more about why your acutely ill medical patients aren't fully
out of the woods after discharge

Visit VTEriskfacts.com

Reference: 1. Amin AN, Varker H, Princic N, Lin J, Thompson S, Johnston S. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. *J Hosp Med.* 2012;7(3):231-238.

© 2018 Portola Pharmaceuticals, Inc. All rights reserved. PP-NA-IE-0001